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Chapter I Introduction 
I.1 Vascular function  
Blood flow to different organs and tissues is continuously adapted according to their 
metabolic needs. This is ensured by the pumping heart, which creates an appropriate blood 
pressure at the entrance of the tissues. Subsequently, local blood flow within the tissues is 
regulated by intrinsic contractile and relaxing factors that originate from the blood vessel 
itself or from surrounding tissues. Intrinsic factors include myogenic (i.e. changes in 
transmural pressure), neurogenic and metabolic (i.e. changes in the concentration of local 
metabolites) mechanisms. Ultimately these mechanisms will regulate the tone of the 
vascular smooth muscle cells, mainly by interfering with the intracellular Ca2+ levels. 
Impaired regulation of the vascular tone is an important factor in the pathogenesis of 
vascular diseases such as hypertension, atherosclerosis, erectile dysfunction and others.  
I.1.1 Mechanism of vasoconstriction (Fig. I.1) 
Several stimuli can evoke contraction of vascular smooth muscle cells. Regardless of the 
stimulus, smooth muscle cells use cross-bridge cycling between actin and myosin to develop 
force which is initiated by an increase in intracellular Ca2+ concentration.  
In the smooth muscle, stimuli can increase intracellular Ca2+ concentration and thus elicit 
contraction through two processes. The first process is called ‘electromechanical coupling’ 
and refers to stimuli (for example KCl or cell stretch) that elicit a contraction by directly 
initiating depolarization of the smooth muscle membrane. This membrane depolarization 
leads to opening of voltage-dependent Ca2+ channels (VOCs), allowing Ca2+ to diffuse into 
the cell down its concentration gradient. The second process by which intracellular Ca2+ 
concentration can be elevated is called ‘pharmacomechanical coupling’. Here, instead of 
evoking contraction by changing the membrane potential, contractions are induced by the 
binding of an agonist to a membrane receptor. Subsequently, intracellular molecules or 
second messengers are produced which elicit the release of Ca2+ [1, 2].  
Vascular contractile tone is mainly regulated by sympathetic neurons that innervate the 
arterial wall. One of the key pathways modulating vessel tone is the release of 
norepinephrine (NOR) from these nerve endings. Upon arrival of the action potential at the 
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terminal axon, the open probability of plasma membrane Ca2+ channels increases resulting in 
elevated intraneuronal Ca2+ concentration [3]. This in turn will trigger the release of NOR, 
which will diffuse across the neuromuscular junction and will bind predominantly to α1-
adrenergic receptors on the smooth muscle membrane. Binding of the α1-receptors, which 
are coupled to a heterotrimeric G protein, stimulates the activity of phospholipase C (PLC). 
This enzyme is specific for the membrane phospholipid phosphatidyl-inositol-4,5-
biphosphate (PIP2) which catalyzes the formation of two potent second messengers: inositol 
triphosphate (IP3) and diacylglycerol (DAG). The binding of IP3 to IP3 receptors on the 
sarcoplasmatic reticulum stimulates the release of Ca2+ into the cytosol. DAG also increase 
intracellular Ca2+ content by activating protein kinase C (PKC), which phosphorylates specific 
target proteins such as VOCs or other proteins that regulate cross-bridge cycling [1, 2, 4-6]. 
Besides NOR, other agonists such as endothelins, prostaglandins, neuropeptide Y and 
angiotensin II can also elicit vascular contraction through the aforementioned PIP2 pathway 
when binding to their respective G-protein coupled receptors [4, 7]. 
Elevation of free intracellular Ca2+ does not directly stimulate smooth muscle cell 
contraction. Instead Ca2+ acts indirectly by binding to a cytoplasmatic protein, calmodulin, to 
form a Ca2+/calmodulin complex (CaM). This complex then activates the myosin light chain 
kinase (MLCK) to phosphorylate the light chains on the myosin heads. This phosphorylation 
enables the molecular interaction of myosin with actin. In addition, actin activates myosin’s 
magnesium-dependent ATPase activity. This ATPase cleaves high-energy phosphate bonds in 
ATP thus providing the energy needed for the actin-myosin cross-bridge cycling that 
shortens the muscle cell and produces force [1, 2, 4-6].  
Initially smooth muscle contraction is thus induced by the elevation of intracellular Ca2+. This 
results in a phasic (rapid) contraction. However, contractile responses also involve a tonic 
(slow) contraction phase allowing further force generation and is independent of a rise in 
intracellular Ca2+ levels [2, 5, 6, 8-10]. This pathway, called the Ca2+ sensitization mechanism, 
allows vascular smooth muscle cells to maintain contractile force for a longer period of time 
at a low cost of energy [2, 5, 6, 8-10]. The Ca2+ sensitizing pathway is dependent on the 
activation of the small G-protein RhoA and its downstream target, Rho kinase. RhoA is a 
small GTPase that acts as a switch by cycling between an active (guanosine triphosphate 
(GTP)-bound) and an inactive (guanosine diphosphate (GDP)-bound) conformation. The 
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activity of RhoA is tightly regulated by three proteins; RhoA guanosine exchange factor 
(RhoGEF), RhoA GTPase activating proteins (RhoGAP) and RhoA guanosine dissociation 
inhibitor (RhoGDI) [8, 10-14]. In resting cells, RhoA-GDP is generally trapped in the cytosol by 
GDIs, which binds to RhoA-GDP and extracts it from the membrane to the cytosol. Activation 
of RhoGEF, by binding of various agonists to their G-protein coupled receptors, promotes the 
exchange of GTP for GDP on RhoA and the dissociation from RhoGDI. The activated RhoA-
GTP is than able to translocate from the cytosol to the plasma membrane, where it can 
initiate signal transduction by interacting with Rho kinase. RhoA is inactivated by RhoGAP, 
which enhances the intrinsic GTPase activity of RhoA, leading to the hydrolysis of GTP to 
GDP and subsequent inactivation of RhoA. RhoA then re-associates with RhoGDI and 
relocates to the cytosol [8, 10-14]. In addition inhibition of RhoA-mediated functions can 
also occur by phosphorylation of RhoA which increases its association with GDIs [15]. Binding 
of RhoA-GTP with Rho kinase, a serine/threonine kinase, induces a conformational change 
leading to activation of Rho kinase towards specific substrates. In smooth muscle cells, Rho 
kinase induces vasoconstriction through the phosphorylation and subsequent inhibition of 
myosin light chain phosphatase (MLCP), an enzyme that dephosphorylates the myosin light 
chains and thus promotes smooth muscle relaxation. Due to the Rho kinase inhibition of 
MLCP, myosin light chains remain phosphorylated and interaction between actin and myosin 
is favored [16, 17]. In addition, Rho kinase has been shown to directly phosphorylate the 
myosin light chains [18], allowing interaction with actin. Taken together, the RhoA-Rho 
kinase pathway results in MLC phosphorylation to promote smooth muscle contraction 
independent of changes in intracellular Ca2+ concentration or MLCK activity but by increasing 
Ca2+ sensitivity. 
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Figure I.1 Regulation of smooth muscle contraction. Various agonists bind to their specific receptors to initiate 
smooth muscle contraction. Activation of these G protein-coupled receptors increases PLC activity which 
catalyzes the hydrolysis of PIP2 to produce two potent second messengers: DAG and IP3. IP3 binds to specific 
receptors on the sarcoplasmatic reticulum, yielding the release of Ca
2+
. DAG together with Ca
2+
 activates PKC, 
which phosphorylates different target proteins in order to further sustain the increase in intracellular Ca
2+
 
levels. Free Ca
2+
 binds to calmodulin, resulting in the activation of MLC kinase and subsequent 
phosphorylation of the light chain of myosin. Subsequently cross-bridge cycling between actin and myosin 
occurs and the shortening of the smooth muscle cell is initiated. As the elevation in Ca
2+
 levels within the cell is 
transient, contractile response is maintained by a Ca
2+
 sensitizing mechanism. This Ca
2+
-sensitizing mechanism 
is initiated at the same time that PLC is activated, and it involves the activation of the small GTP-binding 
protein RhoA by RhoGEF. Upon activation RhoA enhances Rho kinase activity. This will lead to phosphorylation 
and inhibition of MLCP, favoring the maintenance of phosphorylated myosin light chain. (Webb et al. [6].) 
 
I.1.2 Mechanism of vasorelaxation (Fig. I.2) 
Smooth muscle relaxation occurs when the contractile stimulus is removed or by direct 
action of a substance that inhibits the contractile mechanism. In all cases, the process of 
relaxation requires a decrease in intracellular Ca2+ concentration and/or increased MLCP 
activity.  
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There are several ways to lower intracellular Ca2+ concentrations and thus elicit 
vasorelaxation. The first way is removal of the stimulus that is responsible for the increased 
intracellular Ca2+ levels. For example, if the stimulus for contraction is an agonist that binds 
to its specific membrane receptor, such as NOR, then dissociation of the agonist will end the 
production of second messengers such as IP3 and DAG that led to increased intracellular Ca
2+ 
levels [1, 2, 4, 6]. If contraction is initiated by an agonist that induces membrane 
depolarization, such as elevated extracellular K+ levels, then removal of this agonist will 
result in membrane repolarization. As this repolarization is accompanied with the closure of 
VOCs, influx of extracellular Ca2+ will stop. Similarly hyperpolarization of the smooth muscle 
membrane, due to activation of K+ channels and subsequent K+ efflux, results in the closure 
 
 
 
 
 
 
 
 
 
 
 
 
Figure I.2 Regulation of smooth muscle relaxation. Removal of the contractile stimulus or direct action of a 
substance stimulates inhibition of the contractile mechanism elicit vasorelaxation. A decrease in intracellular 
Ca
2+
 levels and/or increased MLCP activity is needed to initiate the relaxation process. Ca,Mg-ATPases in the 
sarcoplasmatic reticulum and the plasma membrane and Na
+
/ Ca
2+
 exchangers in the plasma membrane all 
reduce intracellular Ca
2+ 
levels by removing Ca
2+ 
from the cytosol. Receptor- and voltage-operated Ca
2+
 
channels in plasma membrane close during relaxation, leading to a decreased Ca
2+
 entry into the cell. (Webb et 
al.[6]) 
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of VOCs and thus reduced Ca2+ influx. As a consequence both repolarization and 
hyperpolarization of the smooth muscle membrane are associated with vascular smooth 
muscle relaxation [2]. 
Another way to lower intracellular Ca2+ concentrations involves activation of ATP-dependent 
Ca2+ pumps which are located in the membrane of sarcoplasmatic reticulum as well as in the 
plasma membrane. In both cases, the pump has an ATPase activity providing the energy 
needed for moving Ca2+ against a concentration gradient. When phosphorylated the Ca,Mg-
ATPase in the sarcoplasmatic reticulum (SERCA), binds two Ca2+ ions, which are then 
translocated to the luminal side of the sarcoplasmatic reticulum where they are stored until 
they are released again. Mg2+ is required for the activity of the ATPases as it binds to the 
catalytic site of ATPase to mediate the reaction. This Ca2+ uptake into the sarcoplasmic 
reticulum is reversibly inhibited by phospholamban. Phosphorylation of phospholamban 
relieves its inhibitory effect, therefore increasing SERCA activity and the rate of Ca2+ uptake 
[2, 4, 9]. The plasma membrane also contains Ca,Mg-ATPases (PMCA) which provide an 
additional way to reduce the intracellular Ca2+ levels as it will transport Ca2+ out of the cell. 
This Ca,Mg-ATPase differs from the ATPase in the sarcoplasmatic reticulum in that it has an 
autoinhibitory domain that can be bound by calmodulin, causing stimulation of the plasma 
membrane Ca2+ pump. In addition, Na+/Ca2+ exchangers (NCX) are also located on the 
plasma membrane. This exchanger transports one Ca2+ ion out of the cell in exchange for 
two sodium ions brought into the cell [1, 2, 4, 6]. 
A third way by which smooth muscle relaxation can occur is by elevation of levels of the 
second messengers, cyclic adenosine monophosphate (cAMP) or cyclic guanosine 
monophosphate (cGMP) within the smooth muscle cell. cAMP is synthesized from 
intracellular ATP by adenylyl cyclase (AC), which can be activated by several agonists that 
bind to their G-protein-coupled receptor. cGMP may be synthesized in the vascular smooth 
muscle cells from GTP by a particulate guanylyl cyclase (pGC), located at the plasma 
membrane and activated by natriuretic peptides, or by soluble guanylyl cyclase (sGC), 
located in the cytosol and mainly activated by NO and NO donors [1, 19] (Fig. I.3). Upon 
formation, cAMP activates cAMP-dependent protein kinase (PKA), while cGMP activates 
cGMP-dependent protein kinase (PKG). However each cyclic nucleotide can activate both 
protein kinases. For instance, cAMP can also activate PKG, but it requires nearly a 10-fold 
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higher cAMP concentration compared to the cGMP levels that activate this kinase [1, 2, 19]. 
The signals evoked by cAMP and cGMP are mainly ceased and controlled by 
phosphodiesterases (PDEs). These enzymes catalyze the hydrolysis of cAMP and cGMP to 
their inactive metabolites adenosine monophosphate (AMP) and guanosine monophosphate 
(GMP) respectively [1, 19].  
 
 
 
 
 
 
 
Figure I.3 Regulation of levels of cyclic nucleotides and activation of kinases. Green arrows indicate 
stimulation. (Morgado et al. [1]) 
 
Both PKA and PKG will phosphorylate numbers of targets which all lead to a decrease in 
intracellular Ca2+ concentrations and thus smooth muscle relaxation (Fig. I.4). Several targets 
for PKA and PKG have been suggested, including K+ channels, different types of Ca2+ channels 
(such as those located on the sarcoplasmatic reticulum and VOCs), SERCA, PMCA, NCX, 
phospholamban, IP3, RhoA and many others. The net result of all of these PKA- and PKG-
mediated effects is a decrease of intracellular Ca2+ concentration, leading to a decrease in 
MLCK activity and/or increase in the MLCP activity through inhibition of RhoA. Subsequently 
dephosphorylation of the myosin light chains is favored and thus smooth muscle relaxation 
occurs [1, 4, 19].  
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Nitric oxide 
Although many endogenous vasodilators have been shown to exert relaxant effects on 
different vascular beds, nitric oxide (NO) is believed to be the principal mediator of vascular 
relaxation. NO is a gaseous messenger molecule with a short life-time, that is enzymatically 
formed together with L-citrulline from L-arginine, molecular oxygen and reduced 
nicotinamide adenine dinucleotide phosphate (NADPH) by NO synthases (NOS) [20, 21]. 
Constitutive NOS enzymes are present in endothelial cells (eNOS) and in non-adrenergic non-
cholinergic (NANC) neurons (nNOS). In addition, an inducible NOS (iNOS) isoform exists, 
which is up-regulated in response to various stimuli [21]. eNOS and nNOS are activated in 
response to receptor stimulation (e.g. acetylcholine) causing intracellular Ca2+ increase and 
subsequent formation of CaM complexes, which will activate eNOS or nNOS. Subsequent 
increase in blood flow causes shear stress, which further stimulates eNOS through 
phosphorylation at the serine 1177 residue, resulting in sustained activation of eNOS [20, 
21]. Upon release, from neurons and endothelial cells, NO diffuses to the smooth muscle cell 
and activates sGC, resulting in an increase of cGMP concentration and thus smooth muscle 
relaxation. Apart from NO, other vasodilators such as vasoactive intestinal peptide, 
prostaglandin E1, prostaglandin I2 (prostacyclin), substance P, calcitonin gene related 
 
 
 
 
 
 
 
 
Figure I.4 Mechanisms involved in the decrease of intracellular Ca
2+
 concentrations induced by cyclic 
nucleotide-dependent protein kinases. Green arrows indicate stimulation, red arrows indicate inhibition. 
(Morgado et al. [1]) 
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peptide, H2S have been shown to influence smooth muscle tone [4, 22-27]. However their 
contribution in vessel tone regulation remains rather vague.  
I.2 Paracrine modulation of vascular tone 
Tissues or cells surrounding arteries can influence the contractile degree of the vascular 
smooth muscle cells through the release of vasoactive substances. These factors that are 
released by neighboring cells are often called ‘paracrine modulators’. The term ‘paracrine’ 
refers to a kind of hormone function in which the effects of the hormone are restricted to 
the local environment. Nowadays, besides the nervous system, the vascular endothelium is a 
well-known paracrine regulator of vascular smooth muscle tone. More recently it was 
discovered that also the perivascular adipose tissue (PVAT) functions as a paracrine organ in 
the regulation of vascular tone.  
I.2.1 Endothelium 
In the past the endothelium was believed to be just a simple semipermeable membrane 
lining the luminal surface of all blood vessels. However, from the 1980s it has become clear 
that the vascular endothelium is a fundamental regulator for the homeostasis of the 
underlying layer of smooth muscle cells by controlling the balance between vasoconstriction 
and vasorelaxation [28]. This is accomplished through the release of several relaxing and 
contracting factors under basal conditions and in response to many substances (drugs, 
circulating hormones and cytokines) as well as to physical and chemical stimuli (e.g. changes 
in pressure, shear stress and pH) [29]. Endothelium-derived factors with vasodilatory effects, 
collectively called ‘endothelium derived relaxing factors (EDRFs)’, include NO, prostacyclin 
and endothelium-derived hyperpolarizing factors (EDHF). These latter refer to molecules 
causing endothelium-dependent relaxations that are resistant to NOS and cyclooxygenase 
(COX) inhibitors and that result in endothelium-dependent hyperpolarization of the vascular 
smooth muscle cells [30, 31]. Hyperpolarization of the vascular smooth muscle cells leads to 
a decrease in intracellular Ca2+ concentration and in this way EDHF can promote 
vasorelaxation. The contribution of EDHF to endothelium-dependent relaxations appears to 
be inversely related to vessel diameter since EDHF seems to play a more prominent role in 
smaller (resistance) arteries compared to larger (conduit) arteries [32]. From its discovery in 
the late 1980s it has become clear that EDHF is likely not a single diffusible ‘factor’. 
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Numerous identified putative EDHFs have been reported and the acronym ‘EDHF’ has 
become an overall term applied to the various endothelium-derived mechanisms that 
mediate hyperpolarization and relaxation of the vascular smooth muscle cells [30, 31, 33]. Of 
the most frequently reported mechanisms underlying EDHF activity are that of K+-efflux from 
the endothelial cells, generation of diffusible epoxyeicosatrienoic acids, hydrogen peroxide 
and electrical coupling between endothelial cells and vascular smooth muscle cells through 
myoendothelial gap junctions [30, 31, 33].  
Endothelin-1 (ET-1), angiotensin II (AII), thromboxane A2 (TXA2) and reactive oxygen species 
(ROS) are among the factors that exert vasoconstrictor effects and are collectively known as 
‘endothelium-derived contracting factors (EDCFs)’[7, 29, 31, 33] (Fig. I.5). 
 
Figure I.5 Endothelial cells release various vasoactive factors and therefore maintain the balance between 
vasodilation and vasoconstriction. 
 
Endothelial dysfunction and oxidative stress 
Normal endothelial function regulates the balance between the release of EDRFs and EDCFs 
which is vital for maintaining vascular smooth muscle relaxation, blood pressure and blood 
flow. Disturbance of this tightly regulated balance leads to endothelial dysfunction [29, 34]. 
There is considerable evidence showing that endothelial dysfunction is an early event in the 
development of cardiovascular diseases such as diabetes, hypertension, 
hypercholesterolemia, atherosclerosis and heart failure [35-38]. Although the pathogenesis 
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of endothelial dysfunction is multifactorial, the hallmark seems to be impaired NO 
bioavailability which is functionally reflected in decreased endothelium-dependent 
relaxation [39, 40]. Impaired NO bioavailability can be the result of either decreased NO 
production or accelerated NO degradation. However in both cases oxidative stress seems to 
play a pivotal causative role, limiting NO to exert its effect [29]. Oxidative stress refers to a 
condition in which cells are exposed to excessive amounts of chemical oxygen derivatives, 
the so called ROS [41, 42]. ROS include free radicals such as superoxide anion (O2
•−), 
peroxynitrite (ONOO•−), and hydroxyl (OH•), and non-radicals such as hydrogen peroxide 
(H2O2). O2
•− is considered as the ‘primary’ ROS and is formed after addition of one electron 
to molecular oxygen (dioxygen) [43]. Within mammalian cells, several enzyme systems are 
capable of transferring electrons to molecular oxygen producing O2
•−, the four most 
important being nicotinamide-adenine-dinucleotide phosphate oxidases (NOX), the 
mitochondrial electron transport chain, xanthine oxidase (XO) and uncoupled NOS [41]. O2
•− 
can further interact with other molecules to generate ‘secondary’ ROS such as H2O2 and 
ONOO•−. O2
•− is rapidly converted into H2O2 either spontaneously or via the catalytic 
intervention of superoxide dismutase (SOD). OH• is generated from H2O2 in the presence of 
ferrous iron (Fe2+) by the Fenton reaction, but is also formed by the interaction between O2
•− 
and H2O2 [41, 42] (Fig. I.6). 
Oxidative stress contributes markedly to endothelial dysfunction, primarily due to rapid 
oxidative inactivation of NO by excess O2
•− resulting in the highly reactive ONOO•− and 
thereby reducing NO bioavailability. In a second step, persisting oxidative stress renders 
eNOS dysfunctional (eNOS uncoupling), a process whereby eNOS switches from a NO-
producing enzyme to a O2
•−-generating molecule [44, 45]. Mechanistically, the major cause 
for eNOS uncoupling and endothelial dysfunction could be found in the oxidation of 
tetrahydrobiopterin (BH4, a critical eNOS cofactor) by ONOO
•− or O2
•− which makes BH4 
unavailable for eNOS generation of NO [20, 21, 41, 45, 46]. In addition depletion of the 
enzyme substrate L-arginine can also be implicated [20, 21, 41]. Thus uncoupled eNOS not 
only reduces NO production, but also potentiates the pre-existence of oxidative stress and 
endothelial dysfunction. 
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Figure I.6 Enzymes involved in the generation and inactivation of reactive oxygen species (ROS). The 
superoxide anion (O2
•−
) can be produced by NADPH oxidase (NOX), xanthine oxidase (XO), uncoupled 
endothelial nitric oxide synthase (eNOS) and the leakage of activated oxygen (O2) from mitochondria during 
respiration. O2
•− 
can be converted
 
to hydrogen peroxide H2O2 by the enzyme superoxide dismutase (SOD). 
H2O2 can undergo spontaneous conversion to the hydroxyl radical (OH
•
) via the Fenton reaction. H2O2 can be 
detoxified by glutathione (GSH) peroxidase and catalase to H2O and O2. (Adapted from Li et al. [41]) 
 
I.2.2 Perivascular adipose tissue 
Historically adipose tissue was thought to be simply lipid-rich connective tissue [47]. 
Similarly, perivascular adipose tissue (PVAT), which is the adipose tissue surrounding nearly 
all blood vessels, was long considered as a mechanical support and protection to the vessels 
during contraction of neighboring tissues [48]. Therefore PVAT was routinely removed for 
isolated blood vessel studies. Soltis and Cassis [49] demonstrated for the first time that PVAT 
decreases NOR-induced contractions of rat aorta. From then on, it became clear that besides 
structural support, PVAT also act as an active endocrine organ that releases various 
substances, called adipo(cyto)kines, which affect the underlying vascular cells[50-53]. Among 
the plethora of adipo(cyto)kines are pro- and anti-inflammatory cytokines and an adipocyte-
derived releasing factor (ADRF), which can influence vascular tone in a paracrine way. These 
are discussed in a review in chapter III (published in Curr Hypertens Rep 2012;14:270-278). 
Under physiological conditions, the release of these vasoactive adipo(cyto)kines results in a 
net beneficial anticontractile effect on vascular function and this is essential for the 
maintenance of vascular resistance [49, 54-57]. The anticontractile effect of PVAT is directly 
dependent on its amount [54, 57, 58]. Therefore it would be conceivable to assume that in 
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obesity, where the amount of PVAT is increased throughout the vasculature, the 
anticontractile effect of PVAT is increased. However, the opposite occurs and the 
anticontractile effect of PVAT is lost in obesity [54, 59-61] (Fig. I.7). Various explanations 
have been proposed for this surprisingly finding, mostly focusing on the fact that, besides 
structural changes, functional changes in PVAT are triggered in obesity, which render the 
adipose tissue dysfunctional. These functional changes imply a dysregulated synthesis of 
vasoactive adipo(cyto)kines by the adipose tissue in favor of harmful vasoconstrictor and 
pro-inflammatory substances [62]. Due to this imbalanced pro-inflammatory adipo(cyto)kine 
production, obesity is characterized as a state of chronic low-grade inflammation [63]. It has 
been proposed that hypoxia underlies this inflammatory response, as hypoxia occurs in 
areas of fat depots when the vascular oxygen supply is compromised due to tissue mass 
expansion [64]. Interestingly, adipose tissue dysfunction is not restricted to obesity, where 
PVAT mass and adipocyte size increase. In several hypertensive animals models, where PVAT 
mass and adipocyte size decreases, a similar ‘obesity-like’ impairment of PVAT function was 
reported [58, 65, 66] (Fig. I.7).  
Taken together, in addition to endothelial dysfunction, adipose tissue dysfunction might 
create an environment for the development of vascular inflammation and dysfunction [53, 
67-69]. 
 
Figure I.7 Alterations of PVAT structure and function during obesity and hypertension lead to decreased 
anticontractile effects of PVAT. (Adapted from [48]). 
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I.3 Erectile function  
I.3.1 Anatomy of the penis (Fig. I.8) 
The penis in man and in most other mammalian species consists of three corpora: dorsally 
paired corpora cavernosa, which comprise the erectile tissue and the ventral corpus 
spongiosum that surrounds the urethra and expands distally to form the glans penis. A thick 
fibrous sheath, the tunica albuginea, surrounds each of the corpora cavernosa and fuses in 
the midline to form a perforated septum.  
The corpora cavernosa resemble a sponge as it is composed of a meshwork of 
interconnected hollow cavernous spaces or sinusoids, which are lined with endothelial cells 
and are separated by trabeculae. The trabeculae contain bundles of smooth muscle cells in a 
framework of elastic fibers and connective tissue. The arterial blood supply is ensured by the 
resistance helicine arteries which branch from the deep penile cavernosal artery. Subtunical 
veins drain the sinusoidal spaces and pierce the tunica to drain into the circumflex veins, and 
then join the deep dorsal vein of the penis. The cavernosal arteries and the trabecular 
smooth muscles are under control of sympathetic and parasympathetic innervation [70, 71]. 
 
 
 
 
 
 
 
 
 
Figure I.8 Anatomy and hemodynamics of the corpora cavernosa. The figure is adapted from Kandeel et al. 
[71]. 
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I.3.2 Regulation of penile erection 
Penile erection is basically a spinal reflex that involves central nervous processing and 
integration of tactile, olfactory, auditory, and mental stimuli [72]. The generated nervous 
signals will influence the balance between the contracting and relaxing factors, which 
determine the contractile tone of the cavernosal and arterial smooth muscle cells and thus 
the functional state of the penis. As with vascular smooth muscle contraction and relaxation, 
penile smooth muscle tone is determined by the levels of intracellular free Ca2+ as well as by 
the Rho kinase pathway. 
 
Under basal conditions, NOR is released from adrenergic neurons and binds to α1 
adrenoceptors on the smooth muscle membrane eliciting contraction of arterial and 
cavernosal smooth muscle. In addition, the RhoA/RhoA kinase signaling pathway has been 
suggested to be involved in the maintenance of contraction of the cavernosal smooth 
muscle cells [70, 73, 74]. Subsequently only a small blood volume is delivered to the sinuses 
and this volume is readily drained out through subtunical veins. As a consequence 
intracavernosal pressure remains low and the penis maintains a flaccid state.  
Nowadays, NO is accepted as the key mediator of penile erection [75]. Upon sexual 
stimulation, NO is released directly from the parasympathetic NANC neurons which 
innervate the penis (Fig. I.9). The subsequent increase in blood flow-induced shear stress 
and the release of acetylcholine from the parasympathetic cholinergic nerve endings will 
activate eNOS and stimulate NO release from the arteriolar and sinusoidal endothelial cells 
[75-77] (Fig. I.9). Neurogenic-derived NO is believed to be responsible for the initiation and 
the majority of the smooth muscle relaxation, while NO originating from endothelial cells 
contributes to the maintenance of the erection [77, 78]. Like in vascular relaxation, NO 
release will result in relaxation of the arterial and cavernosal smooth muscle cells through 
the activation of the sGC/cGMP pathway. As a consequence increased arterial blood flow to 
and the expansion of the cavernosal sinusoids is allowed [70, 75, 76, 78, 79]. As the corpora 
cavernosa are surrounded by the tunica albuginea, which has a limiting stretching capability, 
the expansion of the cavernosal sinusoids will compress subtunical veins, causing a 
decreased venous outflow (veno-occlusion). The increased inflow and decreased outflow 
results in the high intracavernosal pressures which are characteristics of penile erection [70, 
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79]. Degradation of cGMP by PDE 5, the predominantly form present in penile tissue, is 
primarily responsible for detumescence and returning the penis to the flaccid state [71, 74, 
80]. 
 
Although NO/cGMP is considered the most important agent responsible for penile erection, 
other regulatory mechanisms such as VIP/cAMP may also be involved [70, 75, 76, 78, 79]. 
 
 
 
Figure I.9 Regulation of cavernosal smooth muscle relaxation by NO released from the non-adrenergic non-
cholinergic (NANC) nerves and sinusoidal endothelium. Stimulation of the NANC nerves and the endothelial 
cells in the penis cause Ca
2+
 influx which promotes the production of NO. Binding of NO on sGC in the 
cavernous smooth muscle catalyzes the conversion of GTP to cGMP. Due to activation of PKG and PKA, 
increased levels of cGMP and cAMP induce relaxation of the arterial and cavernosal smooth muscle cells by 
decreasing intracellular levels of Ca
2+
, which eventually results in the expansion of the cavernosal sinusoids 
and thus in penile erection (adapted from [81]).  
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I.3.3 Erectile dysfunction  
Normal erectile function is a complex neurovascular process which depends on a tightly 
regulated balance between vasoconstrictor agents, causing limited blood inflow, and 
vasodilators, allowing increased blood inflow and erection. Hence, alterations favoring 
contractile responses and/or impeding relaxant responses of the cavernosal smooth muscle 
may lead to erectile dysfunction (ED). ED is generally defined as the inability to achieve and 
maintain an erection sufficient to permit satisfactory sexual intercourse [82]. It is estimated 
that ED affects approximately 20 % of adult males over the age of 20 [83], and by 2025 it is 
thought that ED will affect 332 million men worldwide [84]. Although ED is not a life 
threatening dysfunction, it seriously affects man’s quality of life as well as interpersonal well-
being.  
The cause of ED can be psychological or organic (vascular, neurologic, hormonal, structural 
or drug-induced) or mixed psychological and organic. Vascular disease is however by far the 
most common cause of ED [72, 85]. Several conditions such as type II diabetes and 
hypertension as well as lifestyle factors such as tobacco use, obesity, frequency of exercise 
are highly associated with ED [86, 87]. The common characteristic of many of these vascular 
risk factors is the presence of (oxidative stress-induced) endothelial dysfunction [88, 89]. As 
the endothelium is a major source of NO, the main mediator of penile erection, impaired NO 
release and subsequent decreased corporal smooth muscle relaxation inevitably results in 
ED [85, 90]. However, besides NO several other mediators might also be involved in 
endothelial and erectile dysfunction. For instance, changes in prostaglandin synthesis and 
signaling may contribute to imbalanced penile eicosanoid homeostasis which can result in 
contraction of penile arteries and corporal smooth muscles. In addition, elevated levels of AII 
or ET-1 can further promote (vaso)constriction and thus ED [90]. 
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I.4 Polyphenols 
Hippocrates, the father of modern medicine, said many centuries ago: “let food be thy 
medicine”. Today this ancient quote still shows its value as the popular thought “you are 
what you eat” is nowadays a well-established fact. Indeed it is known that diet is one of the 
most important lifestyle risk factors and that it can strongly influence the incidence of 
cardiovascular disease [91, 92]. In search for understanding how increased intake of certain 
foods can lead to a better health, polyphenols have gained a lot of interest. Polyphenols are 
naturally occurring compounds found in diverse plant-derived foods that are synthesized as 
secondary metabolites as defensive responses against stress due to UV radiation, pathogens 
and physical damage [93, 94]. According to the number of phenolic rings and on the basis of 
the structural elements that bind these rings to one another, polyphenols are classified into 
four categories: phenolic acids, flavonoids, stilbenes and lignans (Table I.1). Flavonoids are 
further classified into six subclasses: flavonols, flavones, isoflavones, flavanones, 
anthocyanidins and flavanols [93].  
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Classes of polyphenols Chemical structure 
Phenolic acids (C6-C1 and C6-C3) 
 
Flavonoids (C6-C3-C6) 
  
Stilbenes (C6-C2-C6) 
 
Lignans (C6-C3-C3-C6) 
 
Table I.1. Chemical structures of the main classes of polyphenols 
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The diversity of the chemical structures of dietary polyphenols makes it difficult to estimate 
their total content in foods. A typical diet rich in fruits, vegetables and plant beverages has 
been estimated to provide about 1 g of polyphenols/day, with significant variations 
depending on the amount of consumption of drinks rich in polyphenols [95]. Fruits like 
grapes, apple, pear, cherries and berries contain up to 200-300 mg polyphenols per 100 
grams fresh weight [96]. The manufactured products of these fruits, also contain 
polyphenols in significant amounts. Typically a glass of red wine contains about 100 mg 
polyphenols [94].  
From some decades, these polyphenols have been the focal point of extensive research on 
their capacity to improve health. This research includes a wide variety of clinical and 
nutritional epidemiological studies that indicate that for instance populations who consume 
a diet rich in polyphenols are less susceptible to cardiovascular diseases and their 
complications [91, 97].  
 
I.4.1 Resveratrol and quercetin 
In 1992 the concept of the ‘French paradox’ was first introduced based on the observation 
that the French population had the lowest mortality and a low risk of cardiovascular disease 
despite a high consumption of saturated fat and prevalence of other risk factors [97]. 
Moderate red wine consumption was thought to explain this paradoxical finding [97]. 
Moreover, the polyphenolic content of red wine has been assumed to be responsible for 
cardiovascular benefits associated with moderate red wine consumption. The polyphenols 
present in red wine vary extremely due to differences in variety and grape sources as well as 
due to the grape processing. Red wine contains a higher concentration of polyphenols than 
white wine, because red wine is maturated with the skin and seeds during the wine-making 
process and these contain most of the polyphenols [98-100].  
The main polyphenols present in red wine are resveratrol (a stilbene) and to a lower extent 
quercetin (a flavonol) [100-103] (Fig. I.10). Concentrations of resveratrol in red wine vary 
depending upon grape variety and geographic cultivation sites but concentrations up to 9 
mg/L have been found, making red wine the major source of resveratrol in human diet [100, 
101, 103]. Besides the skin of grapes, resveratrol and quercetin are found in high abundance 
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in many fruits and vegetables that are components of the human diet such as mulberries, 
cranberries, blueberries, onions and peanuts [93, 102]. As a consequence daily intake of 
quercetin is in the range of <5 mg to about 40 mg quercetin/day [104-107]. However daily 
amounts of quercetin as 200-500 mg may be reached by high-end consumers of fruits and 
vegetables, notably when individuals ingest the peel of quercetin-rich fruits and vegetables 
such as apples and onions [108]. For resveratrol, daily intake, including safe wine drinking, is 
estimated between 6 and 8 mg resveratrol/day [109].  
 
 
 
 
 
 
 
 
 
 
 
Figure I.10 Chemical structure of resveratrol (left) and quercetin (right) 
 
Both polyphenols have gained a lot of attention for their plethora of beneficial effects 
against cardiovascular disease, neurodegenerative disease, obesity, diabetes and cancer 
[110-114]. The beneficial effects of resveratrol and quercetin on the cardiovascular system 
have been attributed to their ability to improve endothelial function as well as their ability to 
reduce vascular oxidative stress and their anti-inflammatory properties [110-112, 114-116] 
(Fig. I.11). 
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Figure I.11 Potential mechanism(s) in the cardiovascular effects of resveratrol and quercetin. 
Vascular activities 
Hypertension is one of the major risk factors of cardiovascular disease, which is associated 
with an increased risk of stroke, myocardial infarction, heart failure, etc. [117]. Adequate 
management of blood pressure helps to reduce the risk of cardiovascular disease. Several in 
vitro and in vivo studies in different animals suggested that resveratrol or quercetin may 
provide an alternative therapeutic option for managing blood pressure as both polyphenols 
have been demonstrated to exert acute and chronic effects on the cardiovascular system. 
First of all, resveratrol and quercetin acutely cause endothelium-dependent relaxations in 
different vascular beds [118-125]. It should however be noted that a part of the relaxant 
effect of resveratrol and quercetin occurs independently of the endothelium. Activation of 
different types of K+ channels may account for this endothelium-independent relaxing effect 
[119, 122, 123, 125]. 
Besides a direct relaxant effect, resveratrol ameliorates impaired endothelial function of 
aortic rings in different disease states. For instance improved vascular responses to 
acetylcholine were demonstrated after acute or chronic resveratrol administration in 
hypertensive rats [126-129] or in hypercholesterolemic rabbits [130]. Similarly acute or 
chronic quercetin treatment enhances endothelial-dependent responses to acetylcholine in 
various models of experimental hypertension [131-136]. Moreover, it was found that chronic 
treatment with resveratrol or quercetin lowers blood pressure in hypertensive animal 
models [126, 127, 133-137]. The improved endothelial function and the direct relaxant effect 
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of both polyphenols is largely attributed to enhanced NO production as treatment of 
isolated arteries with eNOS inhibitors decreases the relaxing influence of resveratrol and 
quercetin. These studies thus indicate that activation of the NO-pathway seems to be 
involved in their relaxing effect [118, 120, 121, 124].  
Resveratrol and quercetin are known to enhance NO bioactivity by acutely increasing 
enzymatic activity of eNOS. For instance both polyphenols have been found to stimulate 
eNOS phosphorylation in endothelial cells and thereby increasing eNOS activity [120, 138, 
139]. In addition to their acute effect on eNOS activity, which occurs within minutes, 
resveratrol and quercetin can also enhance eNOS expression (within hours) [136, 140]. At 
physiological relevant concentrations of 0.1 µM resveratrol and quercetin increase eNOS and 
mRNA expression in cultured endothelial cells [140-143]. It is thought that the effects of 
resveratrol on eNOS expression may be attributed to activation of protein deacetylase 
sirtuin 1 (SIRT 1). SIRT 1 activation results in deacetylation of eNOS at lysine residues, 
thereby stimulating eNOS activity [144]. It was demonstrated that pretreating human 
umbilical vein endothelial cells with resveratrol significantly reduced oxidant-induced 
decrease in SIRT 1 levels and eNOS acetylation. As a consequence NO production and 
endothelial function was enhanced [145]. Furthermore knock down of endogenous SIRT 1 by 
RNAi significantly limited resveratrol-induced increases in eNOS mRNA and protein 
expression [146] and reduced resveratrol-induced increases in NO levels [144].  
Besides activation of SIRT1, activation of estrogen receptors (ER) has been suggested to be 
involved in the vascular effects of resveratrol as it is structurally similar to a synthetic 
estrogen, diethylstilbestrol. Indeed, polyphenol extracts induced endothelium-dependent 
relaxations in wild type but not in ER alpha knockout mice, providing evidence that the 
vasorelaxant properties of polyphenols are exerted through ER alpha activation [147]. 
Moreover it has been shown that resveratrol is an agonist for ER alpha [148] and that wine 
polyphenols, including resveratrol are responsible for eNOS activation by acting on ERs 
[149]. Furthermore, it has been demonstrated that depletion of ER alpha by siRNA 
attenuated resveratrol eNOS phosphorylation [138].  
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Taken together, the ability of resveratrol and quercetin to improve NO production and thus 
endothelial function may contribute to a great extent to their protective effects in the 
cardiovascular system.  
Anti-oxidant effects  
Living organisms have developed several effective mechanisms to protect themselves from 
ROS-induced damage [41]. These antioxidant defense systems include enzymes such as 
superoxide dismutase, catalase and glutathione peroxidase but also non-enzymatic reactions 
with glutathione, ascorbic acid and alpha-tocopherol. However in several diseases the 
available antioxidant defense systems are exceeded by excessive formation of ROS resulting 
in an oxidative stress state [41]. The polyphenols resveratrol and quercetin may have an 
additive effect to the endogenous antioxidant defense mechanisms as they can interfere 
with several free radical producing systems. 
First, quercetin is reported to act as a potent direct scavenger of ROS. Quercetin is known to 
scavenge O2
•− [150, 151] and ONOO•− [150, 152, 153]. Moreover quercetin also acts as an 
indirect antioxidant through the inhibition of key ROS-producing enzymes such as XO [154] 
and NOX [136]. In in vitro systems resveratrol, at high concentrations (> 100 µM), is reported 
to directly scavenge a variety of oxidants such as O2
•− [155-157], H2O2 [158], OH
• [157] and 
ONOO•− [159]. However the direct antioxidant effects of resveratrol are rather weak 
compared to those of well-established antioxidants such as ascorbate and cysteine. Thus, 
the protective effects of resveratrol against ROS-induced damage are likely to be attributed 
to the upregulation of the endogenous cellular antioxidant systems or to inhibition of ROS 
forming enzymes rather than its direct ROS scavenging activity [160, 161]. Indeed, 
resveratrol regulates the expression and activity of ROS-producing or ROS-eliminating 
enzymes, such as SOD. SOD catalyzes the dismutation of O2
•− into H2O2, which is further 
inactivated by glutathione peroxidases (GPx) and catalase [162]. In human endothelial cells 
resveratrol increased mRNA and protein levels of SOD1, SOD2 and SOD3 [163-165]. In 
addition resveratrol also upregulates GPx1 and catalase in aortic segments or in cultured 
aortic smooth muscle [158]. Furthermore, treatment of apolipoprotein E (apoE) knockout 
mice, a model for oxidative stress, with resveratrol (30 – 100 mg/kg per d for 7 d) 
upregulated SOD1, SOD2, SOD3, GPx1 and catalase in the heart [166]. In addition resveratrol 
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is reported to decrease ROS by reducing NOX2 and NOX4 expression in the heart of apoE-
knockout mice [165] and NOX2 expression in the aorta of diabetic mice [129]. 
Due to the (direct) antioxidant properties of both polyphenols, enhanced ROS production 
and thus oxidative stress can be limited. Hence by reducing ROS levels, the phenomenon of 
‘eNOS uncoupling’ can be prevented. Resveratrol and quercetin have both been shown to 
prevent eNOS uncoupling in cardiovascular tissues [46, 165, 167]. Untreated apoE-knockout 
mice have an increased oxidation of BH4 [46] and ROS production in their aorta [46, 168] and 
heart [165]. As the NOS inhibitor, L-NAME, decreased O2
•− production in both the aorta and 
heart, eNOS is suggested to be in an uncoupled state and thus producing ROS in this 
pathological model. Treatment of the apoE-KO mice with resveratrol reduced cardiac O2
•− 
production and reversed eNOS uncoupling [165]. In addition, also quercetin seems to 
impede eNOS uncoupling as quercetin was found to prevent endothelial dysfunction by 
impeding ET 1–induced superoxide formation and eNOS uncoupling in aortic ring segments 
of male Wistar rats [167]. 
As previously mentioned, increased ROS production and subsequent oxidative stress causes 
decreased NO bioavailability and thus impairment of endothelial function. Therefore, the 
antioxidant capacity of resveratrol and quercetin can prevent oxidative stress-induced 
inactivation of NO and thus improve vascular function. 
Effects on adipose tissue 
Obesity, insulin resistance and type 2 diabetes are characterized by chronic state of 
‘inflammation’ which is the result of abnormal cytokine production and activation of a 
network of inflammatory signaling pathways [63, 169]. The primary source that triggers and 
where this inflammatory process which emerges in obesity is located, seems to be the 
adipose tissue [63]. Indeed, both in obese mice and human an imbalanced 
release/production of pro- and anti-inflammatory adipo(cyto)kines can be found [170-172]. 
Therefore, as polyphenols, including resveratrol and quercetin, are known to affect 
adipogenesis and have anti-inflammatory properties, these bioactive compounds could be 
beneficial in preventing or limiting obesity and its associated complications [173]. 
It has been shown that the differentiation of swine preadipocytes, mouse mesenchymal 
stem cells and 3T3/L1 fibroblasts into adipocytes was inhibited by resveratrol in a SIRT1-
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dependent manner [174-176]. In addition, resveratrol has been shown to reduce lipid 
accumulation by both inhibiting lipogenesis and promoting lipolysis [177, 178]. For instance, 
treatment of isolated rat adipocytes with 125 µM and 250 µM resveratrol reduced insulin 
activity, which induces lipogenesis (glucose to lipid conversion) in adipose tissue, by 16 % 
and 25 % respectively [178]. In addition to resveratrol, quercetin was found to inhibit 3T3/L1 
adipocyte differentiation and to induce apoptosis in mature adipocytes, suggesting that also 
quercetin can reduce mature adipocyte mass [179].  
The effect of both polyphenols on adipose tissue reaches beyond their anti-adipogenesis 
activities since resveratrol and quercetin are known to potently reduce adipose tissue 
inflammation by interfering with the adipo(cyto)kine expression/secretion [180]. Resveratrol 
ameliorates inflammation by modulating the adipo(cyto)kine expression and secretion 
profile in different adipocyte models: resveratrol treatment decreases the levels of pro-
inflammatory adipo(cyto)kines (such as TNFα, IL-6 and resistin) and increases the adiponectin 
expression/secretion [181-186]. Similarly, quercetin supplementation increased adiponectin 
plasma levels and adiponectin mRNA levels in adipose tissue from high fat- or high fructose-
fed rats [187, 188]. Like resveratrol, quercetin increased levels of secreted adiponectin from 
TNFα treated of 3T3/L1 adipocytes [185]. Moreover, in primary human adipocytes treated 
with TNFα, quercetin has been shown to prevent insulin resistance and to reduce 
inflammation by attenuating the expression of adipo(cyto)kines such as IL-6 and IL-8, even 
more effectively than resveratrol [182].  
Taken together, studies indicate that the release of adipo(cyto)kines, implicated in increasing 
the risk of cardiovascular diseases, can be successfully inhibited, at least in vitro, by 
resveratrol or quercetin. This is accomplished through the reduction of mature adipocyte 
mass, with concomitant reductions observed in the secretion/expression of inflammatory 
adipo(cyto)kines. 
I.4.2 Resveratrol and quercetin as therapeutic agents  
The huge amount of in vitro and animal (preclinical) studies within the field of polyphenols 
revealed a plethora of beneficial effects of polyphenols administration in different disease 
states. These preclinical studies suggests that polyphenols can be useful or show their value 
in the treatment and/or alleviation of the consequences of several diseases such as 
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cardiovascular disease, diabetes, cancer… [113]. In some studies using diabetic or obese 
animal models as well as in humans positive effects of resveratrol and quercetin on the 
vascular system have been described [102, 111, 150, 189-191]. For instance resveratrol and 
quercetin supplementation were shown to lower systolic blood pressure, flow mediated 
dilatation and/or the production of inflammatory markers, while they increased eNOS and 
adiponectin production [102, 111, 150, 189-191]. However, it should be noted that a lot of 
animal and clinical studies could not confirm these vascular effects [102, 111, 150, 189-191]. 
It is suggested that the problem for this might be related to the low bioavailability of both 
polyphenols. 
Bioavailability 
The bioavailability and pharmacokinetics of resveratrol and quercetin have been studied in 
experimental animals and humans. Oral administration of high doses of resveratrol or 
quercetin appears to be safe in humans. No major adverse effects were seen when healthy 
volunteers were provided with up to 5 g resveratrol [192]. Similarly high doses of quercetin 
up to 5 g/day (for 28 days) seem to be well tolerated without major adverse events in 
hepatitis C patients [193].  
Upon oral administration, the polyphenols are extensively metabolized in the small intestine 
and later in the liver yielding glucuronide- and sulfate-conjugates [93].  
Pignatelli et al. [194] reported that moderate red wine consumption, which was defined as 
intake of 300 mL red wine during 15 days, increased total (free and conjugated ) plasma 
levels of resveratrol to 1.72 µM. Similarly total resveratrol in human plasma peaked in the 
range of 416 – 491 ng/ml (or 2 µM) 30-60 minutes following administration of a single dose 
of 25 mg resveratrol with a plasma half-life of 9.2 h [195, 196]. Administration of doses up to 
5 g increased plasma levels of unchanged resveratrol to about 539 ng/ml (2.4 µM) [192]. 
However only low levels or even trace amounts (<5 ng/ml) of unchanged resveratrol could 
be found in the plasma following a single or multiple 25 mg oral dose [195-197]. Likewise, in 
rodents, oral intake of milligrams yields only low nanomolar plasma levels of unmetabolized 
resveratrol [198, 199]. An overview of these bioavailability studies is represented in Table 
I.2. 
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Dose Species 
Peak plasma concentration of total and/or 
unmetabolized resveratrol 
Reference 
300 mL red wine during 
15 days 
Human Total: 385 ng/mL (∼1.72 µM) [194] 
25 mg (oral) Human 
Total: 416 - 471 ng/mL (∼1.86 – 2 µM) 
Unmetabolized: 7.1 – 8.5 ng/mL (∼0.03 - 0.04 µM) 
[195] 
25 mg (oral) Human 
Total: 491 ng/mL (∼2 µM) 
Unmetabolized: <5 ng/mL (∼0.02 µM) 
[196] 
Single dose of  25 mg 
(oral) 
13 doses of 25 mg 
(oral) 
Human 
Unmetabolized: 
1 ng/mL – 4 ng/mL  (∼0.004 – 0.018 µM) 
[197] 
5 g (oral) Human Unmetabolized: 539 ng/mL (∼2.4 µM) [192] 
50 µmol/kg  
(11.4 mg/kg) (oral) 
Rat Unmetabolized: 157 ng/mL (∼0.7 µM) [199] 
5 mg/kg (oral) Rat 
Total: 342 ng/mL (∼1.5 µM) 
Unmetabolized: 18.24 ng/mL (∼0.08 µM) 
[198] 
Table I.2. Overview of several studies on bioavailability of resveratrol in human and rodents. 
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Thus both in humans and animals oral administration of resveratrol yields plasma levels of 
the parent molecule that are either not detectable or some orders of magnitude below the 
micromolar concentrations that are used in in vitro experiments i.e. 5 - 100 µM [200]. The 
enterohepatic cycle, in combination with the rapid metabolism in the liver explains this low 
concentration of native compounds in the blood stream. Nonetheless, some of the biological 
effects of resveratrol have been observed at very low concentrations [201, 202]. Some 
mechanisms may contribute to this phenomenon i.e. that low resveratrol concentrations are 
effective, despite the rapid metabolisation into conjugates.  
First, due to the lipophilic character of resveratrol, resveratrol and its metabolites can 
accumulate in tissues and thus tissue levels might be higher than those found in plasma 
[203]. Accumulation of resveratrol has been found in several tissues including the heart, 
liver, kidney and skeletal muscle from rats [204-209]. Therefore, plasma levels might be 
useful in evaluating endothelial exposure, however it might not be an accurate indicator of 
resveratrol potential bioactivity on tissue level [203]. Second, some metabolites themselves 
exert biologically beneficial effects. Resveratrol metabolites were shown to reduce fat 
accumulation in adipocytes, influence adipo(cyto)kine expression and secretion [210, 211] 
and exhibit anti-inflammatory potential [212, 213]. However no effect of resveratrol-sulfates 
and –glucuronides was found on eNOS activity, NO release or ROS levels [214]. Third, some 
metabolites can be converted back to resveratrol in target cells via glucuronidases and 
sulfatases [215]. Hence, resveratrol metabolites can also indirectly contribute to the 
beneficial effects associated with resveratrol administration. 
Total quercetin (= free and metabolized) derived from the diet is normally present in plasma 
in the nanomolar range (<100 nM), however this can be increased to low µM range by 
quercetin supplementation [216, 217]. For example, in healthy volunteers plasma levels of 
quercetin increased to 1.5 µM after 28 days supplementation with a high dose (>1 g/d) of 
quercetin [216]. Interestingly, elimination of quercetin and its metabolites is quite slow, as 
reported plasma half-lives ranges between 11 – 28 h. This suggests that maintenance of high 
plasma concentrations of quercetin could be achieved upon repeated intake [93, 111, 150]. 
Similar to resveratrol, quercetin is extensively metabolized into its sulfate and glucuronide-
conjugates. As a result, quercetin in human plasma is mainly found as glucuronide and 
sulfate conjugates, with very little (<1 µM) unconjugated quercetin present [217, 218]. In 
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humans, 30 minutes following consumption of 10 mg/70 kg body weight quercetin 
(dissolved in 100 mL white wine), plasma of total quercetin (free and conjugated) reaches a 
maximum of 126.8 ng/mL (0.4 µM) of which around 20 % was unmetabolized quercetin 
[195]. However, quercetin metabolites can be biologically active as for instance 
glucuronidated quercetin metabolites were shown to have antioxidant effect in vitro and in 
vivo [219, 220]. Yet, glucuronidated and sulfated metabolites lack a direct acute vasodilator 
effect in isolated arteries and they have only a partial effect in preventing acute endothelial 
dysfunction [221]. Interestingly, like resveratrol a deconjugation process for quercetin 
metabolites has been described [222, 223]. It has been shown that glucurono-quercetin 
conjugates can be deconjugated in the vascular wall of mesenteric arteries, yielding the 
parent quercetin molecule which accumulates in the tissue [222]. Studies in rats and pigs 
have shown that quercetin is distributed to several tissues, especially to lung, kidney, colon 
and liver [224]. 
Enhancing bioavailability 
Given the low bioavailability and extensive metabolism of orally administrated resveratrol 
and quercetin, efforts have been made to identify novel strategies to ameliorate the 
bioavailability of both polyphenols in order to achieve plasma concentrations that have been 
shown to have biological activity.  
The composition of the food matrix can impact the bioavailability of resveratrol and 
quercetin. Trans-resveratrol is better absorbed when ingested through wine or grape juice 
than from tablets [225]. Similarly quercetin bioavailability is greater when quercetin is 
consumed as an integral food component compared to quercetin-filled capsules [226]. 
Several studies suggest that the dietary fat content also influences polyphenolic 
bioavailability. When resveratrol is added to diets with fat contents equal to or greater than 
40 %, significant improvement in energy metabolism and aerobic exercise endurance is seen 
in mice. This was not the case when resveratrol was added to a standard composition diet 
[227, 228]. Likewise, resveratrol increases brain antioxidant enzyme activities by 
approximately 2-fold when given in a high-fat diet, while the same dose in a standard mouse 
diet did not have a significant effect [229]. Dietary fat-dependent improvements in 
polyphenolic bioavailability has also been found for quercetin. In pigs, co-ingesting quercetin 
with a meal containing 32 % fat enhanced quercetin bioavailability with 50 % compared to 
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its ingestion with a 3 % fat meal [230]. Moreover, in rats resveratrol bioavailability is 
enhanced by combining it with piperine, a natural product from black pepper [231]. Thus, 
the in vivo bioavailability could be increased by the food matrix because of the presence of 
other natural compounds, such as other polyphenols that might play a synergic role [232]. 
In search of how metabolic breakdown of resveratrol and quercetin could be bypassed or 
how the absorption of polyphenols could be improved, new delivery strategies are under 
development. Encapsulation into lipid nanoparticles or liposomes are investigated as 
potential carriers of resveratrol and quercetin to delay their metabolism and maintain free 
polyphenol levels in blood and other tissues for a longer period [233-236]. For instance, 
several formulations have been used to generate quercetin-containing lipid nanoparticles 
such as self-nano-emulsifying drug delivery systems (SNEDDS). The bioavailability and 
absorption of quercetin, delivered as quercetin-SNEDDS, was improved in rats after oral 
administration of these quercetin-SNEDSS [237].  
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Chapter II Aims and main research questions 
II.1 General aims 
Part I of this thesis will focus on the perivascular adipose tissue (PVAT), which is now 
considered as an important paracrine modulator of vascular tone through the release of 
various adipo(cyto)kines. These vasoactive substances, which will be discussed in a review in 
chapter III, elicit a net beneficial anticontractile effect on vascular function. Normal 
functioning of PVAT is thus essential for normal vascular function. Hence interfering with 
PVAT (dys)function might alleviate or aggravate vascular complications seen in several 
pathophysiologic conditions. Therefore chapter IV will explore whether the normal 
functioning of PVAT i.e. its relaxing influence, can be affected under several circumstances 
such as resveratrol addition and/or testosterone depletion.  
Part II of this thesis will focus on one of the vascular complications, which is frequently 
associated with pathophysiologic conditions, such as obesity, diabetes and hypertension: 
erectile dysfunction (ED). Like vascular function, normal erectile function and thus penile 
erection relies on a tightly regulated balance between contraction and relaxation. The 
pivotal role of the NO/cGMP pathway in the regulation of normal penile erection is 
nowadays well established [1]. Disturbance or impairment will therefore inevitably result in 
erectile dysfunction [1]. Due to its central role for normal penile erection, current available 
therapies for ED often aim at increasing cGMP concentrations. Indeed, nowadays the golden 
standard for treating ED is the use of phosphodiesterase-5 (PDE5) inhibitors. However, since 
30-35 % of the patients fail to respond to current PDE-5 inhibitors [2] and due to the adverse 
effects of current therapies to treat ED, the search for alternative and better strategies is a 
necessity. Potential alternative options for the treatment of (diabetic) ED will be explored in 
chapters V, VI and VII.  
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II.2 Main research questions 
II.2.1 Chapter IV - Can the relaxing influence of PVAT be positively or negatively modulated 
by resveratrol treatment and/or testosterone depletion? 
In pathophysiologic conditions, such as obesity, diabetes and hypertension the relaxing 
effect of PVAT is lost due to dysfunctional adipose tissue which is characterized by an 
unbalanced secretion of relaxing adipo(cyto)kines [3-5]. Since adipogenesis, body fat 
distribution and/or adip(cyto)kine secretion can be modulated by (i) resveratrol [6-8] or (ii) 
(low levels of) testosterone [9-11], chapter IV will investigate whether resveratrol and 
testosterone depletion (orchidectomy) also affect the vasorelaxing influence of PVAT using 
in vitro tension measurements. 
II.2.2 Chapter V & VI - Do resveratrol and/or quercetin exert positive effects on corpora 
cavernosa? How do they work? Do they work under in vitro-diabetic conditions? 
Since numerous cardiovascular positive effects such as a direct relaxant and antioxidant 
capacity, have been ascribed to red wine polyphenols, resveratrol and quercetin, they might 
be useful for improving erectile function. Chapter V will investigate the ability of resveratrol 
and quercetin to relax mouse corpora cavernosa as well as the underlying mechanism using 
in vitro tension measurements. In addition obesity and type 2 diabetes are characterized by 
elevated levels of free fatty acids, including palmitic acid [12]. Therefore the ability of 
resveratrol and quercetin to improve palmitic acid-induced impairments of corporal 
responses will be studied.  
For our next study, we wondered whether the positive effects of resveratrol and quercetin 
on erectile tissue would still account in pathophysiologic conditions. As in the previous 
study, palmitic acid was found to impair the corporal relaxant responses only to a limited 
extent, other more potent compounds were sought to create an in vitro model for oxidative 
stress. Therefore our next study, described in chapter VI, will evaluate the effect of in vitro 
diabetic mimicking conditions using high concentrations of glucose in combination with 
methylglyoxal, a glucose metabolite which is found in high concentrations in diabetes, on 
vascular and corporal responses. In addition it will be explored whether resveratrol and 
quercetin could be useful in the prevention of in vitro induced diabetic deficits to the 
relaxant responses of mouse arteries and corpora cavernosa.  
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II.2.3 Chapter VII - Does inhibition of cGMP export elicit positive relaxant responses in mouse 
corpora cavernosa? 
In addition to metabolic degradation of cGMP by PDE5, it has recently been suggested that 
cGMP can also be actively transported across the plasma membrane by members of the 
multidrug resistance protein (MRP) 4 and 5 [13-17], both being expressed in smooth muscle 
cells of the corpora cavernosa [18, 19]. Prevention of cGMP-transport out of the cavernosal 
smooth muscle cells might thus represent a new and alternative approach to elevate 
intracellular cGMP levels and thus to treat ED. In the last study, described in chapter VII, the 
functional effect of MRP 4 inhibition as well as the role of MRP 4-mediated cGMP export in 
mouse corpora cavernosa will be investigated in vitro and in vivo.  
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Chapter III Adipose tissue as regulator of vascular tone 
 
III.1 Abstract 
Adipokines secreted by visceral, subcutaneous and perivascular adipocytes are involved in 
the regulation of vascular tone by acting as circulatory hormones (leptin, adiponectin, 
omentin, visfatin, angiotensin II, resistin, tumor necrosis factor alpha, interleukin-6, apelin) 
and/or as local paracrine factors (perivascular adipocyte-derived relaxing and contractile 
factors). Vascular tone regulation by adipokines is compromised in obesitas and obesity-
related disorders. Hypoxia created in growing adipose tissue dysregulates synthesis of 
vasoactive adipokines in favor of harmful proinflammatory adipokines, while the levels of 
the cardioprotective adipokines adiponectin and omentin decrease. Considering the role of 
adipokines in obesity-related vascular diseases potential, strategies to counter these 
diseases by targeting the adipokines are discussed.  
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III.2 Introduction 
The tone of vascular smooth muscle cells importantly determines blood pressure and 
regional blood flow. This vascular tone is regulated by myogenic mechanisms and by 
vasoactive mediators released either by nerves, or endocrine and paracrine tissues. In last 
decennia the cardinal influence of endothelial cells on vascular smooth muscle tone has 
become evident. More recently evidence emerged that also adipocytes are involved [1, 2]. 
Adipokines secreted by adipocytes include circulating hormones, inflammatory cytokines 
and local acting paracrine factors and are involved in various physiological processes [3].The 
role of the vasoactive adipokines in vascular physiology will be highlighted in view of the 
worldwide pandemic character of obesity with its associated cardiovascular diseases [4]. 
III.3 Sources of vasoactive adipokines  
Fat depots are interspersed in many different body locations and includes visceral, 
subcutaneous and perivascular adipose tissues. These depots constitute a variety of mini-
organs with unique proteomics fingerprint. The total number of secreted components of 
adipocytes approaches 100 distinct proteins, a number that is likely to increase [5]. Several 
adipokines possess vasoactive properties and some of them are well characterized as 
circulating hormones (eg adiponectin, leptin …). More recently it has become clear from in 
vitro studies on isolated blood vessels that vascular tone is also importantly influenced by 
paracrine mediators from perivascular adipose tissue. 
III.4 Adipocytes in obesity  
Obesity is associated with a state of chronic low-grade inflammation involving the 
production of pro- and anti-inflammatory cytokines by adipocytes, including those 
surrounding the vasculature [6]. It has been proposed that local hypoxia may be the 
fundamental determinant in the development of this inflammatory response. Hypoxia occurs 
in areas of the fat depots when the vascular oxygen supply is compromised due to tissue 
mass expansion [7]. Direct evidence that growing adipose tissue becomes hypoxic has been 
obtained in mice [8]. Furthermore, cell-culture studies using murine and human adipocytes 
strongly support the modulatory role of hypoxia in the production of several pro-
inflammatory adipokines [9]. A recent study demonstrates that even modest changes in O2-
level already induce specific changes in gene expression and metabolism of human 
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adipocytes [10] indicating that adipocytes are highly sensitive to the prevailing level of O2. 
This is an important observation considering that most studies in vitro are performed using 
cells oxygenated with a gas containing 21 % O2, which is actually well above the O2-tension 
prevailing in tissues were oxygen levels are much lower than in arterial blood. 
It can be noted that hypoxia also promotes angiogenesis [11]. Hypoxia upregulates inducible 
transcription factors, which trigger the expression of angiogenic adipokines such as vascular 
endothelial growth factor (VEGF), hepatocyte growth factor (HGF) and plasminogen activator 
inhibitor-1 (PAI-1). Novel vascularisation can be considered as an automatic fail-safe in order 
to counter hypoxia and to ensure sufficient nutrient and oxygen supply to the different 
tissues. Despite the great angiogenic potential, rapidly expanding fat tissue still experiences 
hypoxia. Also aging is associated with hypoxia and oxidative stress in adipose tissue, similar 
to what is seen in obesity. Aging is associated with altered function, size and number of 
adipose cells and altered distribution of adipose tissues in the body [12]. 
III.5 Vasoactive adipokines (Fig.III.1) 
 
Figure III.1 Adipose tissue releases several vasoactive adipokines. Some of them have vasorelaxing or anti-
inflammatory properties, some have vasocontractile or pro-inflammatory properties and others share both. 
PVADRF: perivascular adipocyte derived relaxing factor, TNFα: tumor necrosis factor alpha, ROS: reactive 
oxygen species. 
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III.5.1 Leptin 
Leptin is best known as the adipokine regulating feeding behavior. However, leptin also has 
vasorelaxing and vasocontractile effects and in that way contributes to a balanced blood 
pressure homeostasis. While the contractile effect of leptin is attributed to activation of the 
sympathetic nervous system, various mechanisms seem to be responsible for the leptin-
induced vasorelaxation including endothelium-dependent release of nitric oxide (NO). Leptin 
levels are markedly increased during obesity [13] and this hyperleptinemia is believed to 
dysregulate blood pressure, resulting in hypertension. Sustained hyperleptinemia leads to 
endothelial dysfunction affecting endothelium-dependent vasorelaxation [14]. This might be 
the result of several leptin-induced effects: increase of vasoconstrictor endothelin-1 [15], a 
leptin-induced expression of endothelin type A receptors in vascular smooth muscle cells 
[16], a leptin-induced depletion of NO and increase of cytotoxic reactive oxygen species 
(ROS) [17]. Leptin also promotes smooth muscle cell proliferation contributing to the 
increased peripheral vascular resistance [18]. Furthermore, it stimulates the release of pro-
inflammatory cytokines from macrophages which may further elevate blood pressure and 
exacerbate the inflammatory process [19]. Significant associations have been found between 
plasma leptin levels and hypertension in both males and females, which makes leptin a 
potential predictor of hypertension [20, 21].  
III.5.2 Adiponectin 
Adiponectin is one of the most abundant adipokines secreted in the circulation [22]. While 
many adipokines are pro-inflammatory and contribute to vascular dysfunction, adiponectin 
has favorable cardiovascular effects and possess potential as a therapeutic target for 
combating obesity-associated vascular disease. 
Both in vivo and in vitro animal studies as well as clinical data consistently support the role 
of adiponectin as vasodilator that induces endothelial NO-synthase (eNOS) activation and 
consequently endothelial NO production. In addition adiponectin protects the endothelium 
from oxidative stress by decreasing ROS production, prevents endothelial cell activation (a 
key pathological event in vascular inflammation and atherosclerosis) and monocyte 
adhesion. Adiponectin also improves endothelial progenitor cell function, leading to 
improved repair after vascular injury. It also inhibits macrophage activation and foam cell 
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formation and it reduces proliferation and migration of vascular smooth muscle cells. 
Adiponectin thus inhibits almost every pathological event involved in vascular disease, 
ranging from endothelial injury and dysfunction to atherosclerotic lesion formation. These 
favorable effects are mediated through its pleiotropic actions on several types of cells in the 
vasculature, including mature endothelial cells, endothelial progenitor cells, monocytes and 
vascular smooth muscle cells [23, 24]. 
Epidemiological studies on different ethnic groups often have identified low level of 
circulating adiponectin as an independent risk factor for type-2 diabetes, hypertension, 
atherosclerosis and myocardial infarction. Hypoadiponectinemia causes endothelial 
dysfunction by increasing superoxide anion production [25, 26], by promoting the 
production of adhesion molecules in endothelial cells and the proliferation of vascular 
smooth muscle cells. Decreased plasma adiponectin concentrations are found in patients 
with essential hypertension [27]. However, it should be noted that after the establishment 
of atherosclerosis, this association may become weaker, especially in the presence of 
conditions inducing a hyper-catabolic state (such as heart or renal failure) which are 
associated with increased plasma adiponectin, accelerated progression of atherosclerosis 
and worse clinical outcome. In fact, several data show that high circulating adiponectin 
levels are associated with increased cardiovascular mortality in patients with coronary artery 
disease [28]. Therefore, hypoadiponectinemia may have a clinical value at the early stages of 
atherogenesis, but at more advanced disease stages its role as a meaningful biomarker is 
questioned. An abundance of epidemiological studies demonstrate that circulating levels of 
adiponectin correlate with increased mortality and severity of cardiac heart failure. It is still 
inconclusive whether the increased adiponectin production plays a detrimental role or a 
protective role in cardiac heart failure as it could be that increased adiponectin production in 
patients with cardiac heart failure serves as a means of compensatory upregulation against 
oxidative stress and inflammation [29]. 
Considering the beneficial effects of adiponectin on vascular system, strategies to increase 
adiponectin levels could be of great therapeutic value. It has already been demonstrated in 
obese adiponectin knockout mice with hypertension that adiponectin replenishment lowers 
the elevated blood pressure [30]. Results from a recent study in mice indicate that 
exogenous adiponectin supplementation might have a prophylactic value against secondary 
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myocardial ischemic injury after a primary non-lethal mechanical trauma [31]. Existing drugs 
like peroxisome proliferator-activated receptor γ (PPARγ) agonists (thiazolidinediones), some 
angiotensin type 1 receptor blockers (telmisartan), angiotensin converting enzyme inhibitors 
and cannabinoid type 1 receptor blockers (rimonabant, taranabant) have been shown to 
increase circulating adiponectin levels [28]. This also occurs with weight loss and physical 
exercise, along with the adaptations of a Mediterranean-type diet [32]. Recent studies 
showed that the antioxidant resveratrol increases the adiponectin expression [33] and that 
the antioxidants NO-acetylcysteine and allopurinol synergistically enhance cardiac 
adiponectin content and reduce myocardial reperfusion injury in diabetic rats [34]. 
Whatsoever, future strategies may focus on up-regulation of adiponectin’s expression 
(and/or its receptors) or on targeting adiponectin’s receptors through the development of 
specific agonists. As yet direct evidence that adiponectin as such protects against vascular 
disease in humans is still lacking. Adiponectin-based therapeutics are not available partly 
due to difficulties in converting the full size adiponectin protein into a viable drug. A recent 
study reports on the design and initial preclinical development of the first adiponectin 
receptor agonist which may be promising to substitute for the low adiponectin levels in 
obesitas-related diseases [35]. 
III.5.3 Omentin 
Omentin is a recently identified adipose tissue-derived cytokine expressed in visceral rather 
than in subcutaneous adipose tissue and exists in 2 isoforms of which omentin-1 is the major 
circulating isoform in human plasma. In isolated arteries, omentin induces relaxations [36]. 
As yet only in vitro studies on isolated blood vessels have been performed. In vivo studies 
are required to explore the influence of omentin on blood pressure and its chronic influence 
on vascular reactivity. 
Omentin plasma levels and the adipose tissue gene expression are decreased in obesity [36] 
and even more when overweight is combined with type-2 diabetes [37]. Furthermore, 
decreased omentin-1 levels are associated with low plasma adiponectin and high-density 
lipoprotein (HDL) levels. In addition, omentin-1 levels are negatively correlated with leptin 
levels, waist circumference, body mass index and insulin resistance [38]. Like adiponectin, 
circulating omentin-1 concentrations increase after weight loss-induced improvement of 
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insulin sensitivity [39]. Although further research is necessary, elevating the omentin levels 
might be an interesting therapeutic strategy in obesity and obesity-related disorders.  
III.5.4 Visfatin 
Visfatin is another novel identified cytokine with multiple functions in the vasculature. 
Visfatin relaxes isolated arteries, stimulates growth of vascular smooth muscle cells [40 and 
endothelial angiogenesis [41]. Most studies, but not all, showed an increase in visfatin levels 
in obesity [42]. It has been reported that the expression of visfatin is high at plaque rupture 
sites in patients with coronary artery disease [43]. Visfatin accelerates monocyte adhesion to 
endothelial cells by up-regulating intercellular (ICAM-1) and vascular (VCAM-1) cell adhesion 
molecule-1 due to ROS overproduction, suggesting a possible role for visfatin in the 
development of atherosclerosis [44]. Further studies are necessary to clarify the atherogenic 
and vasoactive effects of visfatin and its potential clinical relevance. 
III.5.5 Angiotensinogen/Angiotensin II 
Adipocytes are rich sources of angiotensinogen, the precursor protein of a major 
vasocontractile peptide called angiotensin II [45]. They possess all the enzymes necessary to 
produce angiotensin II [46], suggesting the existence of a local renin-angiotensin system in 
adipose tissue. An important effect of angiotensin II is that this peptide enhances the 
metabolism of NO into ROS, which damage the vascular tissue [47]. An imbalance between 
angiotensin II and NO leads to endothelial dysfunction resulting in a loss of vasodilator 
capacity. This results in an increased expression of adhesion molecules and pro-
inflammatory cytokines in endothelial cells promoting monocyte and leukocyte adhesion 
plus migration to the vessel wall [48]. Furthermore angiotensin II exerts detrimental effects 
on progression and destabilization of atherosclerotic plaque due to an increased release of 
plasminogen activator inhibitor (PAI-1) causing thrombosis and an increased expression of 
growth factors leading to smooth muscle cell proliferation and migration [48]. 
Most data support an elevation of angiotensinogen mRNA expression in adipose tissue 
during obesity [49]. Several studies highlight a contribution of adipose tissue-derived 
angiotensinogen and/or angiotensin peptides to obesity-related hypertension [49]. High 
angiotensin II levels may deteriorate obesity-related hypertension due to an increased 
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secretion of pro-inflammatory cytokines [50], decreased adiponectin secretion [51] or 
increased leptin production in adipocytes [52]. 
III.5.6 Resistin 
Resistin is secreted into the medium by cultured adipocytes and circulates in plasma. 
However, especially circulating monocytes and macrophages seem to be responsible for 
resistin production in humans [41]. Although resistin does not directly affect the contractility 
of isolated blood vessels [41, 53], coronary blood flow, mean arterial pressure or heart rate 
[54], it has been associated with endothelial dysfunction and coronary heart disease [55]. It 
has also been shown that high plasma resistin levels independently associate with an 
increased risk for hypertension among non-diabetic women [56]. 
III.5.7 Tumor necrosis factor alpha (TNFα)  
The cytokine TNFα is an adipokine showing both vasoconstrictor and vasodilator activity. 
TNFα-mediated vasoregulation can occur through both endothelium-dependent [57] and 
endothelium-independent mechanisms [58]. An increased adipose tissue expression of TNFα 
mRNA has been reported in different rodent models of obesity as well as in clinical studies 
involving obese patients [13]. TNFα is considered to be a molecule that links inflammation to 
obesity [13]. Moreover, the infiltration of macrophages in adipose tissue during obesity 
contributes to increased TNFα production [59]. Increased TNFα expression induces the 
production of ROS, resulting in endothelial dysfunction in obesity and obesity-related 
disorders like hypertension, atherosclerosis and type-2 diabetes [60].  
III.5.8 Interleukin-6 (IL-6) 
Acute exposure to IL-6 in vitro relaxes aortas [61]. However, a sustained increase of IL-6 
plasma levels is associated with high blood pressure [62, 63]. In obesity an increase in 
cytokine IL-6 has been observed at mRNA and protein level in white adipose tissue [64]. IL-6 
has been shown to be a predictor of future myocardial infarction [63] and is highly 
associated with cardiovascular mortality [65]. Some studies have suggested that IL-6 is 
rather an indirect marker of vascular dysfunction, while others have suggested a more active 
role for IL-6 in vascular dysfunction. Long term elevation of IL-6 in mice has shown to impair 
endothelial function by increasing angiotensin II-stimulated production of ROS and by 
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reducing eNOS mRNA expression [66]. In addition, IL-6 enhances vascular smooth muscle cell 
proliferation [67], a key event in the genesis of atherosclerotic lesions. Genetic deletion of IL-
6 attenuates angiotensin II-induced hypertension in mice [62], suggesting that elevated IL-6 
in obesity might contribute to hypertension via angiotensin II. In addition, IL-6 inhibits 
adiponectin gene expression in cultured adipocytes [64] which may exacerbate obesity-
related hypertension.  
III.5.9 Apelin 
Apelin causes NO-dependent vasorelaxation of human arteries both in vitro and in vivo [68, 
69]. Exogenous apelin administration causes a rapid NO-dependent fall in blood pressure in a 
rodent model, confirming its powerful vasorelaxing effect [70]. However, some reports 
associate apelin with an increase in arterial pressure [71]. In contrast to acute exposure, long 
term exposure to apelin does not affect blood pressure [72]. 
Apelin production in adipose tissue is strongly up-regulated by insulin and plasma 
concentrations are increased in obese and hyperinsulinemic mice and humans [73]. In 
atherosclerosis, apelin might have beneficial effects as apelin stimulates endothelial NO-
production and antagonizes the angiotensin II-induced formation of atherosclerotic lesions 
and aortic aneurysm in mice [74].  
III.5.10 Perivascular adipocyte-derived relaxing and contractile factors (PVADRF and PVADCF) 
Virtually all blood vessels are surrounded by adventitial adipose tissue. Adipocytes in 
perivascular adipose tissue (PVAT) are very inhomogeneous and differ from subcutaneous 
and visceral adipocytes. Because PVAT encroaches into the adventitia without a fascial layer 
as barrier, humoral factors secreted by PVAT have easy access to the blood vessel wall, 
indicating that PVAT can function as a paracrine organ transducing metabolic signals directly 
to the vascular cells. 
Several in vitro studies have shown that the presence of adhering PVAT reduces contractility 
of isolated blood vessels. Verlohren et al. even showed a positive correlation between the 
vasorelaxing influence and the amount of perivascular adipose tissue [75]. Whether NO 
formation and endothelium are involved in the vasorelaxation effect by PVADRF is still a 
matter of debate [75, 76]. The vasorelaxing effect of PVADRF is likely mediated by the 
Chapter III 
Adipo(cyto)kines and vascular tone 
66 
 
opening of different K+ channels in vascular smooth muscle cells, depending on the tissue 
and species studied [75-80]. These divergent observations suggest a different distribution of 
K+ channels in different vessels and/or species or the existence of different PVADRFs. This 
relaxing effect is mediated by (a) factor(s) which are as yet not fully established although 
several candidates have already been proposed.  
Reactive oxygen species (ROS) are a class of oxygen-derived molecules including superoxide 
anion and hydrogen peroxide, both modulators of vascular tone and released from PVAT. 
Hydrogen peroxide is a more likely paracrine ROS as it is not a free radical and therefore 
more stable and less reactive with other tissue radicals [81]. Hydrogen peroxide is known to 
induce both vasorelaxation and –constriction depending on species, type of vascular bed, 
concentration, membrane potential and degree of obesity [81, 82]. In general, superoxide 
and hydrogen peroxide production in adipose tissue is increased in obese mice, which 
promotes endothelial dysfunction. Hydrogen peroxide produced from the NAD(P)H oxidase 
has been described to be involved in the endothelium-independent pathway of the PVADRF 
[76]. Superoxide anions impair endothelium-dependent vasorelaxation by decreasing NO 
bioavailability via formation of another ROS peroxynitrite [27, 83]. Furthermore, ROS 
contributes to endothelial dysfunction by up-regulating the expression of adhesion and 
chemotactic molecules in endothelial cells, which promote monocyte adhesion and 
migration to the vessel wall [84]. The adhesion of these circulating blood cells to vascular 
endothelium is a key element in the development of inflammation and thrombosis within 
the vasculature in vascular diseases associated with oxidative stress like atherosclerosis [84]. 
Ketonen et al. [82] showed that endothelium-dependent vasodilation is impaired in aorta of 
mice fed a high fat diet. The impaired endothelium-dependent vasodilation was restored by 
removal of PVAT or by quenching ROS indicating that PVAT-derived oxidative stress impairs 
endothelial function [82]. 
Another PVADRF candidate is the peptide angiotensin (1-7) which is a vasodilator released 
by adipose tissue surrounding rat aorta [85]. Blocking this particular peptide inhibits the 
vasorelaxing effect of PVAT and induces endothelium-dependent relaxation via NO-release 
[85]. In a recent study Lu et al. reported that besides arteries also veins are surrounded by 
PVAT and that it attenuates venous contractile tone by releasing Ang-(1-7). PVAT thus may 
also modulate venous function [86] 
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Also hydrogen sulfide has been proposed as a PVADRF or at least as a mediator in the ADRF 
effect [80, 87]. Hydrogen sulfide is generated by cystathionine gamma-lyase (CSE) in PVAT 
tissue [88, 89]. Blocking CSE inhibits the vasorelaxing effect of PVAT in rat aorta and mice 
mesenteric arteries [80, 87]. Moreover, hydrogen sulfide-induced vasorelaxation of rat aorta 
was inhibited by a blocker of a particular ADRF-related K+-channel (KCNQ) blocker [80].  
A recent study suggested that one of the PVADRFs could be identified as methylpalmitate 
[90], an enigmatic factor which according to the same authors is also released from superior 
cervical ganglia and retina. It should however be noted that the relaxing capacities of 
methylpalmitate could not be confirmed by Takir et al.[91].  
Adipokines from PVAT also seem to be involved in the vasorelaxing effects of insulin. Insulin 
dilates vasculature in muscle tissue with high glucose uptake. This insulin-mediated diversion 
of blood flow to active tissues is disturbed in obesity. Adipokines might be involved, as TNFα 
and IL-6 impair insulin-induced vasodilation while adiponectin increases sensitivity to insulin 
and increases glucose uptake [92, 93]. 
Factors from PVAT can also stimulate vasoconstriction. Perivascular nerve activation by 
electric stimulation in rat aorta induces vasoconstriction dependent on the presence of 
PVAT. In dogs PVAT releases a vasocontractile factor that impairs coronary endothelial NO 
production. Lu et al. recently showed that adipocyte-derived angiotensin II is critically 
involved in PVAT-mediated potentiation of perivascular neuronal stimulation-evoked 
contraction in rat mesenteric arteries [94]. 
Lu et al. recently showed that PVAT-associated inhibition of a contractile response to agonist 
was impaired in SHR and that this impairment is not due to reduced PVAT mass in SHR [95]. 
Using a bio-assay cascade technique Lee et al. also found a decreased release of PVADRF 
from PVAT of hypertensive SHR rats. This supports the hypothesis that continuously released 
PVADRF from PVAT protects against the development of hypertension [90]. 
Obesity is characterized by a decrease in vasorelaxing effect of PVAT [82, 96, 97]. In a study 
in which rats were fed a fructose-rich diet, inducing metabolic alterations resembling the 
profile of the human metabolic syndrome, it was found that vascular smooth muscle 
response was unaffected but that the PVAT-dependent vascular relaxant influence was 
diminished, illustrating the strong association between adipose tissue and vascular 
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dysfunction [98]. This might imply a decrease in ADRF release or an imbalance in adipose 
tissue-derived relaxing and vasocontractile factors during obesity leading to hypertension. In 
obese patients there is an increased production of TNFα in PVAT and TNFα inhibits the 
relaxing influence of PVAT. However, incubation of PVAT from obese patients with an anti-
TNFα antibody did not restore the anti-contractile response, suggesting that TNFα is just one 
of many perivascular adipokines with complex effects on vascular function. On the other 
hand, hypoxia, which develops within adipose tissue during obesity, has recently been 
shown to enhance (acute hypoxia) [78] or to inhibit (chronic hypoxia) the anti-contractile 
properties of PVAT [97]. Interesting is the finding that macrophage activation might be 
responsible for loss of anti-contractile function in inflamed PVAT [99]. 
Also the heart is surrounded by fat depots. Risk factors for cardiovascular disease associate 
with the expansion of the fat depot surrounding the heart and coronary vessels. Epicardial 
adipose tissue (EAT) is located between the myocardium and the visceral pericardium and 
secretes adipokines like adiponectin, adrenomedullin and omentin that may have protective 
effects on the myocardium and vasculature. Experimental evidence for this is limited since 
very small amount of EAT is present in laboratory rodents compared to larger mammals and 
human beings. Several studies reported alterations in adipokine expression in EAT during 
pathological states like coronary artery disease, metabolic syndrome or following cardiac 
surgery. Resistin secretion is enhanced from EAT in patients with coronary artery disease. 
Resistin may directly interfere with cardiac function as overexpression of resistin was found 
to impair contractile function in rat cardiomyocytes [100].  
III.6 Conclusions 
Under normal circumstances, vascular tone is influenced by adipokines. Arterial tone can be 
controlled through the release of ROS, leptin, adiponectin, TNFα, IL-6, Ang II, omentin, 
resistin, visfatin, apelin, PVADRF and PVADCF from adipose tissues. Maintenance of a normal 
amount of adipose tissue is essential. It is thought that vascular tone regulation is 
compromised in obesity and obesity-related disorders, in which the amount of adipose 
tissue has grown out of proportion and hypoxic conditions are created. This eventually leads 
to a dysregulated synthesis of vasoactive adipokines by dysfunctional adipose tissue in 
favour of harmful pro-inflammatory adipokines. Circulating levels of adiponectin and 
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omentin are decreased while levels of leptin, resistin, apelin and pro-inflammatory cytokines 
are increased. The dysregulated synthesis/secretion of adipokines and the infiltration of 
macrophages into adipose tissue lead to a state of inflammation. A pro-inflammatory state 
in adipose tissue can not only induce a dysregulation of vascular tone but also local insulin 
resistance, adhesion of monocytes, vascular remodelling, foam cell formation in the arterial 
wall and endothelial dysfunction. Endothelial dysfunction is reflected as a decrease in NO 
bioavailability and endothelium-dependent relaxation and as impaired ability of the 
endothelium to respond to circulating hormones. All these changes clearly promote the 
development of cardiovascular diseases and type-2 diabetes. 
Whatsoever, increasing adiposity is associated with adipose tissue inflammation and 
dysregulation of adipokines. The anatomic proximity of PVAT to the vasculature suggests 
that this dysregulation of adipokines in obesity and other disease states may have local 
pathogenic effects on blood vessels. Because PVAT likely contributes to vascular diseases it is 
suggested that PVAT may be a novel target for the treatment of atherosclerosis and 
restenosis after coronary intervention. The emerging knowledge of the regulatory influence 
of the PVAT and its contribution to diseases associated with metabolic syndrome brings 
hope that better medications become available to control the complications associated with 
obesity, as adjuncts to what remains the mainstay of management of this condition namely 
exercise and a low fat intake. 
One therapeutic strategy to counter the progression of obesity-related vascular diseases is 
elevating adiponectin and omentin levels. Adiponectin levels are already elevated when 
using thiazolidinediones, telmisartan, angiotensin-converting enzyme inhibitors, rimonabant 
and taranaban. On the other hand, development of specific agonists to target adiponectin 
and omentin receptors or inhibition of detrimental adipokines signaling pathways may be 
new and promising to attenuate the pro-inflammatory effects and ultimately to reduce the 
progression of obesity-related vascular diseases.  
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Chapter IV Effect of resveratrol and orchidectomy on the vasorelaxing 
influence of perivascular adipose tissue 
IV.1 Abstract 
INTRODUCTION. Perivascular adipose tissue (PVAT) releases several adipo(cyto)kines. Some 
are vasoactive substances that elicit a net beneficial anticontractile effect. Resveratrol and 
testosterone are known to modulate adipo(cyto)kine release from adipose tissue and could 
therefore influence the anticontractile effect of PVAT. 
MATERIALS AND METHODS. In vitro tension measurements were performed using thoracic 
aorta segments with and without adipose tissue from sham-operated or orchidectomized 
male Swiss mice. Concentration-response curves to norepinephrine (NOR) were constructed 
in the presence and absence of resveratrol (10 µM, 15 min) or the relaxant effect of 
resveratrol (10-100 µM) was investigated after inducing tone with NOR (5 µM). 
RESULTS. Aortas with PVAT displayed significantly attenuated contractions to NOR compared 
to aortas without PVAT. In aortas without PVAT, resveratrol (10 µM) significantly decreased 
NOR responses and elicited concentration-dependent (10-100 µM) relaxations. However in 
aortas with adherent PVAT, resveratrol (10 µM) neither decreased NOR responses, nor did 
resveratrol (10-100 µM) induce arterial relaxations. The anticontractile effect of PVAT was 
less pronounced in presence of resveratrol and unaltered by orchidectomy. Orchidectomy 
did not influence contractions induced by NOR.  
CONCLUSION. Orchidectomy does not modulate the anticontractile capacity of PVAT, while 
resveratrol decreases the vasorelaxing influence of PVAT. The positive effects associated 
with resveratrol addition are neutralized by the presence of PVAT. This is thought to result 
from a dual effect of resveratrol: (i) inhibition of the influence of vasodilatory 
adipo(cyto)kines and (ii) a direct relaxant effect on the vascular smooth muscle. Overall the 
beneficial relaxing effect of resveratrol is lost in mice thoracic aorta surrounded by PVAT. 
Keywords perivascular adipose tissue, resveratrol, orchidectomy, vascular 
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IV.2 Introduction 
Until recently adipose tissue was considered as only being involved in total body lipid and 
energy homeostasis. However nowadays it is well accepted that adipose tissue also acts as a 
major endocrine and paracrine organ through the release of a variety of inflammatory 
adipo(cyto)kines and other factors which also influence vascular tone [1]. Several studies 
revealed that also perivascular adipose tissue (PVAT) is not just structural support for blood 
vessels, but plays an important role in the regulation of vascular function. Under normal 
physiological circumstances PVAT releases several vasoactive substances that elicit a net 
beneficial and protective anticontractile effect on vascular tone [1-6], which directly 
depends on the amount of PVAT [2]. Surprisingly in case of increased amounts of PVAT the 
anticontractile effect of PVAT is not enhanced. In contrast, it has been reported that 
excessive amounts of PVAT are deleterious as in obesity the protective anticontractile 
capacity of PVAT is lost [7]. Although the exact underlying mechanism remains unclear, 
imbalanced release of adipo(cyto)kines in favour of pro-inflammatory ones due to hypoxia-
induced dysfunctional adipose tissue has been proposed [8, 9]. It thus seems that the release 
of adipo(cyto)kines can be influenced under certain circumstances. In this perspective it has 
been shown that also resveratrol, a naturally occurring polyphenol found in the skin of 
grapes and thus abundant in red wine, reverses the adipocyte secretion profile towards a 
less inflammatory phenotype by for instance decreasing the expression of detrimental 
adipo(cyto)kines and increasing the production of anti-inflammatory ones [10-16]. Together 
with other beneficial properties associated with resveratrol administration, such as its 
relaxant and antioxidant [17] and anti-atherogenic capacity [18], resveratrol could be a 
promising therapeutic target to alleviate obesity-induced metabolic complications. Besides 
resveratrol treatment also sex hormones can influence adipo(cyto)kine secretion from 
adipose tissue. In female mice, estrogen depletion by ovariectomy increases adiponectin 
levels [19] and the production of IL-6 and TNFα, two pro-inflammatory adipo(cyto)kines [20]. 
This enhanced adipo(cyto)kine secretion can be reversed by estradiol replacement or by 
administration of estrogens [19, 20]. Moreover, it has been reported that in ovariectomized 
rats the relaxing effect of PVAT is attenuated [21]. The effect of orchidectomy (testosterone 
depletion) on the anticontractile effect of PVAT is unknown. This could be of interest as also 
an interrelationship between testosterone and adipo(cyto)kine levels has been reported in 
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different studies. In rodents testosterone injection decreases adiponectin levels [22], 
hypogonadal men have increased adiponectin levels compared to eugonadal subjects, which 
can be reduced by testosterone replacement therapy [23]. Moreover, testosterone therapy 
reduces serum leptin concentration in subjects with low testosterone levels [24]. Therefore, 
as adipo(cyto)kine secretion can be influenced by resveratrol and testosterone, the aim of 
the present study was to find out whether (i) resveratrol or (ii) orchidectomy can modulate 
the anticontractile effect of PVAT in mice aorta. 
IV.3 Materials and methods 
IV.3.1 Animals and orchidectomy  
Adult (8-12 weeks) male Swiss mice were obtained from Janvier (Saint-Berthevin, France). 
Food and water was provided ad libitum and all animals were treated in accordance with the 
Guide for the Care and Use of Laboratory Animals published by the US National Institutes of 
Health. This study was also approved by the local Ethical Committee for Animal Experiments, 
Faculty of Medicine and Health Sciences, Ghent University, Belgium. Under 2-4 % isoflurane 
inhalation, mice were sham-operated (Sham, n=10) or orchidectomized (Orx, n=10). Four 
weeks post orchidectomy the effectiveness of the orchidectomy was confirmed by atrophy 
of the testosterone-dependent seminal vesicles.  
IV.3.2 Tissue preparation 
After cervical dislocation, thoracic aortas surrounded by adipose tissue were isolated and 
kept in cooled and oxygenated (5 % CO2, 95 % O2) Krebs-Ringer bicarbonate (KRB) solution. 
The aortas were mounted into a wire myograph for isometric tension recording. Two 
stainless steel wires (40 µM diameter) were guided through the lumen of the segments. In 
order to measure changes in isometric tension, one wire was fixed to a force-displacement 
transducer and the other was connected to a micrometer. Two different types of aortic 
segments were prepared: segments cleaned of adipose tissue ((-)PVAT) and segments with 
adherent adipose tissue ((+)PVAT). In some experiments the removed adherent adipose 
tissue was kept in cooled and oxygenated (5 % CO2, 95 % O2) KRB solution. Just before 
starting the experimental protocol it was placed in the organ bath but not in close proximity 
of cleaned aortic segments. In addition some aortic segments were used from which 50 % of 
the adherent adipose tissue was removed ((+)½ PVAT). All preparations were equilibrated 
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for approximately 30 min in oxygenated KRB solution at 37°C (pH 7.4) and gradually 
stretched until a stable preload of 0.5 g was obtained. At the start of each experiment, aorta 
segments were activated with 120 mM K+ and 5 µM norepinephrine (NOR). Thereafter the 
tissues were rinsed until their basal tension was reached again. Subsequently segments were 
precontracted with 5 µM NOR and after obtaining a stable contraction, 10 µM acetylcholine 
(Ach) was added to evaluate the functionality of the endothelium. Only tissues that relaxed 
more than 50 % to Ach, were included in this study. Then preparations were washed and 
allowed to relax again to their basal tension before starting the experimental protocol.  
 
Figure IV.1 A photograph of the organ bath for the wire myograph, a schematic detail of a pair of holders and 
vessel segments with and without adherent adipose tissue. Vessel segments are mounted on two stainless 
steel wires (40 µm), fixed on the two holders in the organ bath. One holder is connected to a micrometer 
which is used to change the distance between the wires. The other holder is connected to a force transducer 
which measures isometric tension changes in the vessel segment.  
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IV.3.3 Experimental protocol 
Cumulative concentration-response curves to NOR were constructed in presence and 
absence of resveratrol (10 µM, 15 min) or in aorta from sham-operated or ochidectomized 
mice. In all experiments the basal influence of cyclooxygenase metabolites and NO was 
excluded by incubating the preparations with the cyclooxygenase (COX) inhibitor 
indomethacin (indo, 10 µM, 20 min) and the NO-synthase inhibitor Nω-nitro-L-arginine 
methyl ester hydrochloride (L-NAME, 0.1 mM, 20 min), except in the first series. In another 
set of experiments concentration-response curves to resveratrol (10-100 µM, 15 min) were 
obtained after precontracting the aortas with NOR 5 µM. 
IV.3.4 Drugs and chemicals 
The experiments were performed in a KRB solution of the following composition (mM): NaCl 
135, KCl 5, NaHCO3 20, glucose 10, CaCl2 2.5, MgSO4 1.3, KH2PO4 1.2 and EDTA 0.026 in H2O. 
KRB solution containing 120 mM K+ was prepared by equimolar replacement of NaCl by KCl. 
Resveratrol, dimethylsulfoxide (DMSO), NOR, Ach, L-NAME and indo were obtained from 
Sigma (St. Louis, MO). Stock solution of 100 mM of resveratrol was made in DMSO, but was 
further diluted in distilled water (10 mM) before adding to the organ baths. Other stock 
solutions were made in water, except for indomethacin (dissolved in ethanol). The final 
concentration of DMSO or ethanol in the organ bath never surpassed 0.1 %. 
IV.3.5 Statistics 
The data were computed as means ± S.E.M. and evaluated statistically using one-way 
ANOVA with Bonferroni post hoc test. Two groups of data were considered significantly 
different when P<0.05. Contractions are expressed as mN contractions, relaxations as % 
decrease in precontractile tone. N is the number of tissues used. 
IV.4 Results 
IV.4.1 Influence of resveratrol on PVAT modulated contractility 
Concentration-response curves to NOR in absence of indo and L-NAME showed cumulative 
contractions in both (-)PVAT and (+)PVAT segments (Fig. IV.2). (+)PVAT preparations 
displayed attenuated overall and maximal contractile responses to NOR which significantly 
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differed from (-)PVAT controls. (Emax: 9.18 ± 0.67 mN for (-)PVAT vs. 5.33 ± 1.04 mN for 
(+)PVAT, p<0.05) (Fig. IV.2a). In presence of resveratrol (10 µM, 15 min) the anticontractile 
effect of PVAT was only moderately observed (Fig. IV.2b). Pre-incubating the (-)PVAT 
preparations with resveratrol (10 µM, 15 min) significantly decreased maximal NOR 
responses (Emax: 9.18 ± 0.67 mN in absence vs. Emax: 5.76 ± 1.05 mN in presence of 
resveratrol, p<0.05) (Fig. IV.2c). In contrast incubation with resveratrol (10 µM, 15 min) did 
not influence contractility of (+)PVAT segments (Emax: 5.33 ± 1.04 mN; pEC50: 6.75 ± 0.22 in 
absence vs. Emax: 4.59 ± 0.67 mN; pEC50: 6.56 ± 0.08 in presence of resveratrol, p>0.05) (Fig. 
IV.2d). 
 
In presence of indo (10 µM, 20 min) and L-NAME (0.1 mM, 20 min), the contractions induced 
by NOR were more stable compared to the control conditions. In presence of both inhibitors 
(+)PVAT segments displayed significantly lower contraction responses to NOR compared to (-
 
Figure IV.2 shows that norepinephrine (NOR, 1 nM – 10 µM) evoked concentration-dependent contractions in 
aorta without ((-)PVAT) and with ((+)PVAT) adherent adipose tissue. The presence of PVAT (a) significantly 
attenuated contraction responses to NOR in control conditions but not (b) in presence of resveratrol (10 µM, 
15 min). Incubation with resveratrol (10 µM, 15 min) significantly decreased NOR responses in (c) (-)PVAT 
segments, but not in (d) (+)PVAT preparations. Data are expressed as mN contraction; one-way ANOVA with 
Bonferroni post hoc test; #p<0.01, *p<0.05; n=6-8. 
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)PVAT segments (pEC50: 7.87 ± 0.08 for (-)PVAT vs. 6.73 ± 0.13 for (+)PVAT, p<0.01) (Fig. 
IV.3a). The maximal contractile response however was comparable for (-)PVAT (11.40 ± 1.45 
mN) and (+)PVAT (11.21 ± 1.65 mN, p>0.05) vessels. Pre-incubating the (-)PVAT preparations 
with resveratrol (10 µM, 15 min) significantly decreased maximal as well as overall NOR 
responses (Emax: 11.40 ± 1.45 mN; pEC50: 7.87 ± 0.08 in absence vs. Emax: 5.61 ± 1.11 mN; 
pEC50: 7.54 ± 0.11 in presence of resveratrol, p<0.05) (Fig. IV.3b). In presence of indo (10 
µM, 20 min) and L-NAME (0.1 mM, 20 min) incubation with resveratrol (10 µM, 15 min) did 
not modify the contractility of (+)PVAT segments (Emax: 11.21 ± 1.65 mN; pEC50: 6.73 ± 0.13 
in absence vs. Emax: 9.82 ± 0.66 mN; pEC50: 6.60 ± 0.18 in presence of resveratrol, p>0.05) 
(Fig. IV.3c). 
Taken together, the presence of indo and L-NAME yielded similar differences in contractile 
responses to NOR between (-)PVAT and (+)PVAT segments with or without resveratrol as 
observed in absence of indo and L-NAME. 
 
 
Figure IV.3 shows that norepinephrine (NOR, 1 nM – 10 µM) elicited concentration-dependent contractions in 
aorta without ((-)PVAT) and with ((+)PVAT) adherent adipose tissue in presence of indomethacin (indo, 10 µM, 
20 min) and Nω-nitro-L-arginine methyl ester hydrochloride (L-NAME, 0.1 mM, 20 min). (a) The presence of 
PVAT significantly attenuated contraction responses to NOR. Incubation with resveratrol (10 µM, 15 min) 
significantly decreased NOR responses in (b) (-)PVAT segments, but not in (c) (+)PVAT preparations. Data are 
expressed as mN contraction; one-way ANOVA with Bonferroni post hoc test; #p<0.01, *p<0.05; n=6-7. 
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IV.4.2 Concentration-response curves of resveratrol in (-)PVAT and (+)PVAT preparations 
In (-)PVAT segments resveratrol (10-100 µM, 15 min) evoked concentration-dependent 
relaxations, after incubation with indo (10 µM, 20 min) and L-NAME (0.1 mM, 20 min) (Fig. 
IV.4). However, in presence of PVAT resveratrol-induced relaxations were significantly 
reduced. The lowest concentration of resveratrol (10 µM) even induced contractions. In 
aortas with 50 % PVAT, resveratrol was able to evoke concentration-dependent relaxations, 
however these were clearly reduced compared to cleaned aortas. In contrast, when placing 
PVAT in the organ bath, but not in direct contact with the vascular smooth muscle cells 
(VSMCs), full response to resveratrol was seen (Fig. IV.4). 
 
Figure IV.4 shows that after incubation with indomethacin (10 µM, 20 min) Nω-nitro-L-arginine methyl ester 
hydrochloride (0.1 mM, 20 min) resveratrol (10-100 µM, 15 min) evoked concentration-dependent relaxations 
in mice aorta without adipose tissue ((-)PVAT, but not in aorta surrounded by adipose tissue ((+)PVAT). In 
(+)PVAT preparations 10 µM resveratrol caused small contractions. Full response to resveratrol was seen, when 
placing adipose tissue in the organ bath, but not in direct contact with the vascular smooth muscle cells. In 
presence of 50 % adipose tissue ((+)½ PVAT), resveratrol elicited reduced relaxations. Data are expressed as % 
relaxation of NOR-induced tone; one-way ANOVA with Bonferroni post hoc test; #p<0.01, *p<0.05, n=6. 
 
IV.4.3 Influence of orchidectomy on PVAT modulated contractility. 
Atrophy of seminal vesicles (Sham: 337.78 mg ± 21.31 versus Orx: 44.86 mg ± 4.29; p<0.01; 
n=10) indicated that ochidectomy was successfully performed. After pretreatment with indo 
(10 µM, 20 min) and L-NAME (0.1 mM, 20 min) NOR elicited concentration-dependent 
contractions in aortic tissues from all groups (Sham/(-)PVAT, Sham/(+)PVAT, Orx/(-)PVAT and 
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Orx/(+)PVAT) (Fig. IV.5). The presence of PVAT attenuated NOR responses in the sham-group 
(pEC50: 8.17 ± 0.25 in absence vs. 6.24 ± 0.13 in presence of PVAT, p<0.01) (Fig. IV.5a). In the 
Orx-group PVAT clearly shows a trend to decrease contractile responses, however this was 
only found significant at two concentrations (pEC50: 7.94 ± 0.31 vs. 6.85 ± 0.38, p>0.05) (Fig. 
IV.5b). Maximal contractions were not influenced by the presence of PVAT neither in the 
sham-group (12.44 ± 2.13 mN in absence vs. 8.81 ± 1.06 mN in presence of PVAT, p>0.05) 
nor in the Orx-group (12.39 ± 1.66 mN in absence vs. 7.81 ± 1.37 mN in presence of PVAT, 
p>0.05) (Fig. IV.5a and IV.5b). Orchidectomy neither changed the contractility of the aorta 
(Fig. 4c), nor did it influence the anticontractile effect of PVAT (Fig. IV.5d). 
 
Figure IV.5 illustrates the effect of orchidectomy on contractions in response to norepinephrine (NOR 1 nM – 
10 µM) in the presence and absence of adipose tissue, after incubation with indomethacin (10 µM, 20 min) Nω-
nitro-L-arginine methyl ester hydrochloride (0.1 mM, 20 min). NOR elicited concentration-dependent 
contractions in aortic tissue of (a) sham and (b) orchidectomized (Orx) mice with ((+)PVAT) and without ((-
)PVAT) adherent adipose tissue. (a, b) Both in the sham-group and the Orx-group PVAT attenuated responses 
to NOR. However in the Orx-group this was only found significant at two concentrations of NOR. Orchidectomy 
neither changed the contractility of the aorta (c), nor did it influence the anticontractile effect of PVAT (d). Data 
are expressed as mN contraction; one-way ANOVA with Bonferroni post hoc test; #p<0.01, *p<0.05; n=10. 
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IV.5 Discussion 
Since nowadays PVAT is recognized as a highly active endocrine and paracrine organ being 
able to influence vascular tone, it has become clear that functional PVAT is necessary to 
maintain vascular physiology [1]. Under normal physiological circumstances PVAT exerts a 
net beneficial anticontractile effect through the release of adipo(cyto)kines [1-5]. In the 
present study, aortas without PVAT also displayed a stronger contraction in response to NOR 
than aortas with adherent PVAT. These results confirm that PVAT indeed releases relaxation 
factors. As the relaxing effect of PVAT was still observed even in presence of indo and L-
NAME, our results furthermore suggest that this anticontractile effect of PVAT is not 
mediated by COX products or NO, which is in line with others [3, 6]. However it should be 
noted that several studies did report a role for NO or COX products in the relaxing influence 
of adipose tissue [7, 25-27]. 
Resveratrol is a naturally occurring polyphenol, found in the skin of grapes and is thus 
abundant in red wine. Resveratrol is believed to contribute to the cardiovascular benefits 
associated with moderate red wine consumption (the ‘French paradox’) [17]. For example it 
has been reported that resveratrol exerts a direct relaxant effect in several vascular beds 
[28-31]. Indeed, also in our study resveratrol elicits concentration-dependent relaxations in 
mice aorta without PVAT, which are independent of K+ channels (own unpublished 
observations). Furthermore, in aortas without PVAT, incubation with resveratrol clearly 
attenuated NOR responses. This might explain the less pronounced anticontractile effect of 
PVAT after resveratrol treatment. This could be explained by resveratrol’s direct relaxant 
effect on the smooth muscle cells of the arteries. Resveratrol has been reported to target 
NO [28, 30, 31] or COX products to exert its effect [32]. However in our study both can be 
excluded as possible mediators of resveratrol’s relaxant effect, as even in presence of 
indomethacin and L-NAME resveratrol induced relaxations and attenuated NOR responses of 
aortas without PVAT.  
Taken together, both PVAT and resveratrol thus independently elicit a protective effect on 
the vascular tone: PVAT through its anticontractile effect, resveratrol through its direct 
relaxant effect. Therefore it would be conceivable to think that in presence of both PVAT and 
resveratrol, an enhanced protective effect would be observed. Surprisingly, in aortas with 
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adherent PVAT resveratrol neither attenuated NOR responses, nor did it relax the aortas. 
Moreover, in aortas with 50 % PVAT, resveratrol only partly evoked relaxations. It thus 
seems that the presence of PVAT inhibits resveratrol’s protective effect. Different 
hypotheses could explain this observation. First, the presence of adipose tissue surrounding 
the arteries could act as a structural barrier that limits resveratrol to reach the VSMCs. As 
resveratrol is lipophilic it is assumable that resveratrol would accumulate in PVAT and 
therefore be unable to induce relaxation of the VSMCs. However, our results indicate that 
this is not the case as in experiments where PVAT is present in the organ bath, but not in 
close contact with VSMCs, resveratrol relaxed arteries to a similar extent as arteries without 
PVAT. These results suggest that the presence of adipose tissue, does not impede resveratrol 
to reach the VSMCs to evoke relaxations. This is not surprising since the arteries are 
mounted in the organ bath with their lumen stretched. Hence compounds added to the 
organ bath, even in presence of PVAT, can easily reach the VSMCs through the lumen. In 
such way, resveratrol could still directly relax VSMCs, while it does not necessarily has to 
pass through the PVAT to reach the VSMCs. 
Second, PVAT could release factors which inactivate resveratrol. Besides secretion of anti-
inflammatory adipo(cyto)kines PVAT also releases several pro-inflammatory adipo(cyto)kines 
such as TNFα and IL-6 [1, 8]. It is known that TNFα and IL-6 can reduce the vasorelaxing 
influence of PVAT due to increased reactive oxygen species (ROS) production [7]. Moreover 
it has been reported that in adipocytes oxidative stress, as a result from increased ROS 
production, can be reduced or restored by resveratrol [33, 34]. Though, the amount of 
oxidative stress could be too high for resveratrol to cope with, so that resveratrol no longer 
exerts its protective effect. However increased ROS production seems to be unlikely as tissue 
from ‘healthy’ mice was used which in resting conditions is protected against oxidative stress 
by antioxidants.  
Third, perhaps one has to consider the relationship between PVAT and resveratrol’s action in 
an inverse way as assumed above. Indeed the presence of PVAT seems to limit resveratrol’s 
relaxing effect, but maybe one should consider the idea that also resveratrol might limit the 
protective effect of PVAT. In this perspective, it is known that resveratrol can influence the 
secretion of adipo(cyto)kines released from adipose tissue [10-16]. For instance resveratrol 
decreases the production of visfatin and leptin [11, 13] two adipo(cyto)kines able to cause 
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vasorelaxation [1]. So, considering that resveratrol can decrease the secretion of some 
vasodilatory adipo(cyto)kines, this would mean that the relaxing influence of PVAT, caused 
by vasodilatory adipokines, would partly be limited by resveratrol. This in turn would cause 
an increased contractility and would eventually result in an upward shift of the NOR 
response curve in arteries with PVAT. However, since resveratrol also has a direct 
pronounced relaxing effect on arteries, this upward shift of the NOR response curve is 
counteracted by resveratrol’s direct action on the VSMCs. In summary, resveratrol can act on 
two levels (i) decreasing the relaxing influence of PVAT by diminishing the secretion of 
vasodilatory adipo(cyto)kines, and thus causing an upward shift of the NOR response curve 
and (ii) a relaxing effect on the arteries, causing a downward shift of the NOR response 
curve. Taken together, the net effect of resveratrol on the contractility of aortas with 
adherent adipose tissue will be zero. Hence the display of a NOR response curve similar to 
those from aortas with PVAT without resveratrol. This third hypothesis, albeit complicated, 
would explain all of our results, including the small contractions observed with resveratrol 10 
µM in presence of PVAT. In this case the concentration of resveratrol was too low to elicit 
arterial relaxations, but sufficient to inhibit vasodilatory adipo(cyto)kines. This leads to 
imbalanced release of vasodilatory and vasocontractile adipo(cyto)kines, favouring secretion 
of the latter ones, without resveratrol being able to counteract this effect by eliciting direct 
arterial VSMCs relaxation. The net effect in this case is therefore a small contraction. 
Our results suggest that, with respect to adipose tissue functioning, acute resveratrol 
administration decreases the relaxing influence of PVAT. However it has been shown that 
long-term treatment with resveratrol can improve adipose tissue function [13, 35, 36]. It is 
important to mention that in these studies, in contrast to our study, the ability of resveratrol 
to improve adipose tissue function (i) was investigated in obesity-mimicking conditions and 
(ii) did not focus on the function of PVAT. However, it cannot be excluded that the overall 
neutral effect of acute resveratrol administration in presence of PVAT is shifted to a 
protective effect when administered chronically.  
Besides resveratrol also testosterone has been reported to influence the levels of some 
adipo(cyto)kines such as adiponectin and leptin [22-24]. Moreover androgen deprivation 
therapy, as treatment of prostate cancer, is a risk of coronary heart disease, diabetes and 
cardiovascular death [37]. In animal models castration accelerates aortic plaque build-up 
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[38-40] and can increase vasoreactivity [41]. Furthermore low testosterone levels promote 
an increase in fat deposition and adipocyte number [42]. As testosterone depletion plays a 
role in the impairment of vascular function and induces changes in the adipose tissue, it is 
not surprising to assume that orchidectomy could modulate the anticontractile capacity of 
PVAT resulting in a higher contractility of arteries. However, our study suggests that 4 weeks 
of testosterone depletion by orchidectomy, does not affect the protective influence of PVAT. 
It should be noted that, changes in adipose tissue by low testosterone levels are often 
displayed in white or visceral adipose tissue [42-44]. The fact that thoracic aorta is in 
contrast surrounded by brown adipose tissue [45], could explain the inability of 
orchidectomy to influence anticontractile effect of PVAT. 
In conclusion it was shown that orchidectomy does not modulate the vasorelaxing influence 
of PVAT while resveratrol treatment might decrease the anticontractile effect of PVAT. 
Furthermore our results indicate that the positive effects associated with resveratrol 
addition are neutralized by the presence of PVAT. The exact underlying mechanism remains 
unclear but we hypothesize that this might be the result of resveratrol’s dual effect (i) 
inhibition of the release/influence of vasodilatory adipo(cyto)kines and in the meantime (ii) a 
direct relaxant effect on the VSMCs. Overall resveratrol thus causes a net unchanged 
contractility of the mice thoracic aorta surrounded by PVAT. 
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Chapter V Relaxant and antioxidant capacity of the red wine polyphenols, 
resveratrol and quercetin, on isolated mice corpora cavernosa 
V.1 Abstract 
INTRODUCTION. The red wine polyphenols resveratrol and quercetin are known for their 
vasorelaxant and antioxidant capacity which is assumed to rely on the activation of the 
NO/sGC pathway. Vasodilators as well as antioxidants can regulate penile erection and be 
beneficial for the treatment of erectile dysfunction (ED). 
AIMS. The goal of this study was to evaluate the NO/sGC dependency of the relaxant effect 
of resveratrol and quercetin on mice aorta and corpora cavernosa as well as to explore their 
influence on oxidative stress-induced ED. 
METHODS. Isolated mice aorta and corpora cavernosa were mounted for isometric tension 
recordings into organ baths. Cumulative concentration-response curves were constructed 
for resveratrol and quercetin in the absence/presence of inhibitors of the NO/sGC pathway. 
In addition, in corpora cavernosa the effect of resveratrol and quercetin was studied on NO-
mediated relaxations using acetylcholine (Ach), sodium nitroprusside (SNP) and electrical 
field stimulation (EFS). In certain experiments corporal tissues were exposed to oxidative 
stress using palmitic acid (PA, 0.5 mM). 
MAIN OUTCOME MEASURES. Corporal responses to resveratrol and quercetin were 
measured in the presence/absence of inhibitors of different molecular pathways. The effect 
of resveratrol and quercetin incubation on Ach-, SNP- or EFS-mediated responses was 
explored in presence/absence of PA. 
RESULTS. While both polyphenols are potent vasodilators of mice aorta, only resveratrol 
relaxes mice corpora cavernosa. The relaxation response to resveratrol on aorta was 
diminished in sGCα1
-/- mice, but not on corpora cavernosa. The polyphenols did not influence 
Ach-, SNP- or EFS-mediated relaxations as such. Resveratrol, but not quercetin, was able to 
significantly reverse PA-induced decrease of EFS relaxations.  
CONCLUSION. The red wine compound resveratrol, but not quercetin, relaxes isolated mice 
corpora cavernosa concentration-dependently through mechanisms independent of the 
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NO/sGC pathway. Resveratrol is a more potent antioxidant than quercetin being able to 
restore decreased neuronal NO responses in mice corpora cavernosa. 
Keywords. Corpora cavernosa; resveratrol; quercetin; antioxidant; erectile function  
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V.2 Introduction 
Resveratrol and quercetin are naturally occurring polyphenols present in the skin of grapes 
and are thus abundant in red wine. These compounds are thought to contribute to the 
cardiovascular benefits associated with moderate red wine consumption (often referred to 
as ‘the French paradox’) [1, 2]. Both resveratrol and quercetin are known to relax arteries in 
different vascular beds, mainly by activation of the NO/sGC pathway [3-7]. However some 
part of the relaxation induced by these polyphenols occurs NO/sGC-independent, through 
activation of different types of K+ channels [7-10]. Several studies showed that, besides their 
vasorelaxant effect, resveratrol and quercetin can reduce oxidative stress [11-17]. This could 
be of interest in the field of ED as several pathophysiological conditions (diabetes, 
hypercholesterolemia and atherosclerosis), which are linked to enhanced oxidative stress 
due to elevated ROS levels [18], show a higher prevalence of ED [18, 19]. Nowadays there is 
growing evidence for the role of ROS in the aetiology of ED as the interaction of superoxide 
anion with NO impairs cavernosal smooth muscle cell relaxation [18, 20]. Thus elimination of 
ROS using antioxidants may have a beneficial therapeutic effect on ED [18, 19]. Considering 
that vasodilators and antioxidants possess pro-erectile effects, resveratrol and quercetin 
may be useful for the treatment of ED. 
V.3 Aim 
The aim of this study was to evaluate the extent of NO/sGC dependency in the relaxant 
capacity of resveratrol and quercetin on isolated mice corpora cavernosa. In addition the 
antioxidant capacity of both polyphenols was explored in presence and absence of palmitic 
acid (PA). 
V.4 Materials and methods 
V.4.1 Animals 
All experiments were performed on adult (8-12 weeks) male Swiss mice (n=143), obtained 
from Janvier (Saint-Berthevin, France) or on 129SvEvS7 sGC wild type (n=15, sGCα1
+/+) or sGC 
alpha1 knock-out (n=15, sGCα1
-/-) mice. These 129SvEvS7 mice were bred in the SPF facility 
of the Inflammation Research Center, VIB, Ghent, Belgium [21]. Food and water was 
provided ad libitum and all animals were treated in accordance with the Guide for the Care 
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and Use of Laboratory Animals published by the US National Institutes of Health. This study 
was approved by the local Ethical Committee for Animal Experiments, Faculty of Medicine 
and Health Sciences, Ghent University, Belgium. 
V.4.2 Tissue preparation 
After cervical dislocation, thoracic aorta was carefully dissected and corpora cavernosa were 
separated from each other and excised at the base. Tissues were kept in cooled Krebs Ringer 
bicarbonate solution (KRB). Ring segments of the aorta were mounted in a wire myograph 
organ bath filled with 10 mL KRB solution. Two stainless steel wires (40 µM diameter) were 
guided through the lumen of the segments. In order to measure changes in isometric 
tension, one wire was fixed to a force-displacement transducer and the other was connected 
to a micrometer. The corpora cavernosa were mounted horizontally for isometric tension 
measurements in 10 mL myograph chambers, containing KRB solution. Changes in isometric 
force of the corpora cavernosa were recorded as one end was fixed to a force displacement 
transducer and the other to a micrometer. After mounting, the tissues were allowed to 
equilibrate for 30 minutes in KRB solution that was frequently replaced (37°C, pH 7.4; 
bubbled with 95 % O2–5 % CO2). Next, the aorta and the corpora cavernosa were gradually 
stretched until a stable preload of 0.5 g (aorta) and 0.45 g (corpora cavernosa) was obtained 
and allowed to equilibrate during 30 or 60 minutes. At the end of the equilibration period 
aortic rings and corpora cavernosa were repeatedly activated in order to obtain maximal and 
stable contractions and relaxations. Aortic rings were activated using 120 mM K+ and 5 µM 
norepinephrine (NOR), corpora cavernosa were repeatedly activated using two times 5 µM 
NOR. Thereafter the tissues were washed and allowed to relax to the basal tension before 
starting the actual protocol. The tissues were precontracted with 5 µM NOR and after 
obtaining a stable contraction, 1 µM (corpora cavernosa) or 10 µM (aorta) acetylcholine 
(Ach) was added to evaluate the functionality of the endothelium. Only tissues that relaxed 
more than 50 % to Ach, were included in this study. 
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V.4.3 Experimental protocol 
Direct relaxant effect of resveratrol and quercetin 
Cumulative concentration-response curves to resveratrol or quercetin (10-100 µM, 15 min) 
were obtained in corpora cavernosa or aorta precontracted with 5 µM NOR. In parallel, 
responses to resveratrol were examined in the presence/absence of inhibitors of different 
molecular pathways. 
Antioxidant capacity 
In another set of experiments the effect of resveratrol or quercetin was studied on NO- 
mediated relaxations in corpora cavernosa. In the absence and presence of resveratrol, 
quercetin (100 µM, 15 min) or tempol (100 µM, 20 min) concentration-response curves to 
Ach or sodium nitroprusside (SNP) were constructed or electrical field stimulation (EFS; 
parameters: train duration 40 s; 1, 2, 4 and 8 Hz; pulse duration 5 ms and 80 V) was applied 
to the corpora cavernosa. In order to obtain comparable precontraction levels between 
control conditions and resveratrol conditions, the precontractile tone of the resveratrol-
treated tissues was adjusted by adding 10 µM NOR instead of 5 µM NOR. In some 
experiments acute oxidative stress was induced by pretreating the corpora cavernosa with 
palmitic acid (PA, 0.5 mM, 30 min) or its solvent ethanol before constructing Ach-, SNP-, or 
EFS curves. Between the response-curves, the corpora cavernosa were washed and allowed 
to recover for 20-30 min.  
V.4.4 Drugs and chemicals 
The experiments were performed in a KRB solution of the following composition (mM): NaCl 
135, KCl 5, NaHCO3 20, glucose 10, CaCl2 2.5, MgSO4 1.3, KH2PO4 1.2 and EDTA 0.026 in H2O. 
KRB solutions containing 30 mM (K30) and 120 mM K
+ (K120) were prepared by equimolar 
replacement of NaCl by KCl. Resveratrol, quercetin, dimethylsulfoxide (DMSO), 
norepinephrine (NOR), acetylcholine (Ach), sodium nitroprusside (SNP), 1 H-[1, 2, 
4]oxadiazolo[4,3-A]quinoxalin-1-one (ODQ), Nω-Nitro-L-arginine methyl ester hydrochloride 
(L-NAME), tetraethylammoniumchloride (TEA), glibenclamide (Glib), 4-aminopyridine (4-AP), 
palmitic acid (PA), tempol, indomethacin (indo), dihydrochloride hydrate (H-89), 8-(p-
sulfophenyl)-theophylline (8-SPT) and zinc protoporphyrin IX (ZnPPIX) were obtained from 
Sigma (St. Louis, MO). Stock solutions of 100 mM of resveratrol and quercetin were made in 
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DMSO, but were further diluted in distilled water (10 mM) before adding to the organ baths. 
Other stock solutions were made in water, except for ODQ and PA (dissolved in ethanol), 
Glib (dissolved in DMSO). The final concentration of DMSO in the organ bath never 
surpassed 0.1 %. 
V.4.5 Statistics 
The data were computed as means ± S.E.M. and evaluated statistically using the Mann-
Whitney U test, Wilcoxon test or repeated measures ANOVA with Bonferroni post hoc test, 
when appropriate. Two groups of data were considered significantly different when P<0.05. 
Relaxations are expressed as % decrease in precontractile tone. N is the number of tissues 
used. 
V.5 Main outcome measures 
Organ bath experiments demonstrate that resveratrol but not quercetin relaxes isolated 
corpora cavernosa in a concentration-dependent manner through mechanisms independent 
of NO/sGC. Resveratrol is more potent than quercetin to reverse the PA-induced impairment 
of neuronal NO-mediated responses. 
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V.6 Results 
V.6.1 Effect of resveratrol and quercetin on precontracted mice aorta and corpora cavernosa  
Resveratrol as well as quercetin (10 nM - 100 µM, 15 min) relaxed Swiss mice aorta (Fig. V.1A 
and V.1B). Time and vehicle control aortic segments showed a spontaneous, nonvehicle 
related steady further increase in tone (Fig. V.1A and V.1B). Contrary in corpora cavernosa, 
only resveratrol was able evoke concentration-dependent relaxations. Although time and 
vehicle controls demonstrate the presence of a spontaneous loss of tone, resveratrol (10 µM 
and 100 µM) still induced significantly greater corporal relaxations compared to vehicle and 
time controls (Fig. V.1C). To elucidate the mechanisms involved in resveratrol-induced 
corporal relaxations, responses to resveratrol (10 - 100 µM) were further studied in the 
presence of inhibitors of specific molecular pathways. As quercetin did not evoke significant 
corporal relaxations (Fig.V.1D), no further efforts were made examining the effects of 
inhibitors. 
 
 
 
Chapter V 
Relaxant and antioxidant capacity of RWPs on mice corpus cavernosum 
102 
 
 
Figure V.1 shows the effect of resveratrol (10 nM-100 µM, 15 min) and quercetin (10 nM-100 µM, 15 min) on 
mice corpora cavernosa (CC) and aorta versus time and vehicle controls. (A, B) indicate that (A) resveratrol as 
well as (B) quercetin evoke concentration-dependent relaxations in aorta after precontraction with 
norepinephrine (NOR) 5 µM. (C) shows that resveratrol elicits concentration-dependent relaxations of mice 
corpora cavernosa after precontraction with NOR 5 µM, whilst (D) quercetin does not cause significant 
relaxations. Data are expressed as % relaxation of the NOR-induced tone; Mann-Whitney U test; #p<0.01 
*p<0.05; n=7-8.  
 
V.6.2 Involvement of NO/sGC pathway 
The involvement of the NO/sGC pathway in the vasodilatory effect of quercetin and 
resveratrol on aorta and in the relaxant effect of resveratrol on corpora cavernosa, was 
evaluated using aorta and corpora cavernosa from sGCα1
-/- mice. Quercetin- and resveratrol-
induced relaxations in aorta from sGCα1
-/- mice were both significantly diminished compared 
to sGCα1
+/+ controls (Fig. V.2A and V.2B), indicating the NO/sGC dependency of the 
polyphenols relaxant effect in aorta. In contrast, resveratrol-induced relaxations of corpora 
cavernosa from sGCα1
-/- mice were not decreased compared to sGCα1
+/+ controls (Fig. V.2C). 
In Swiss mice, the presence of the sGC inhibitor ODQ (10 µM, 10 min), or the NOS-inhibitor 
L-NAME (100 µM, 20 min) did not significantly influence resveratrol-induced corporal 
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relaxations. L-NAME only significantly reduced resveratrol relaxation induced at a 
concentration of 10 µM (Fig. V.3A and V.3B). 
 
Figure V.2. indicates the effect of resveratrol (10-100 µM, 15 min) and quercetin (10-100 µM, 15 min) on aorta 
and corpora cavernosa (CC) from sGCα1
-/- 
mice after precontraction with norepinephrine 5 µM. (A, B) show that 
(A) resveratrol- as well as (B) quercetin-induced relaxations in aorta are significantly decreased in aorta from 
sGCα1
-/- 
mice. In contrast resveratrol-induced corporal relaxations in corpora cavernosa from sGCα1
-/- 
mice did 
not differ from control segments (C). Data are expressed as % relaxation of the NOR-induced tone; Mann-
Whitney U test; #p<0.01 *p<0.05; n=6-15.  
 
 
Figure 3. illustrates that resveratrol (10–100 µM, 15 min) causes concentration-dependent relaxations in 
precontracted (NOR 5 µM) mice corpora cavernosa that is similar in presence and absence of (A) ODQ (10 µM, 
10 min) or (B) L-NAME (100 µM, 20 min). Incubation with L-NAME (100 µM, 20 min) slightly inhibited corporal 
relaxations induced by resveratrol 10 µM but not by resveratrol 30 µM or 100 µM (B). Data are expressed as % 
relaxation of the NOR-induced tone; Mann-Whitney U test; *p<0.05; n=8-10. 
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V.6.3 Involvement of other possible mediators 
To study the involvement of potassium channels, the relaxation effect of resveratrol was 
examined in corporal tissues precontracted using 5 µM NOR in combination with a high K+ 
(30 or 120 mM) solution. However the presence of these higher K+ concentrations did not 
alter the corporal responses to resveratrol (Table V.1). In addition, the resveratrol-induced 
corporal relaxations remained similar in the presence and absence of the non-selective K+ 
channel blocker TEA (3 mM, 15 min) as well as the selective K+ channel blockers such as the 
ATP-sensitive K+ channel blocker (KATP) Glib (3 µM, 10 min) or the voltage-dependent K
+ 
channel blocker (Kv) 4-AP (3 mM, 20 min) (Table V.1). The involvement of other mediators 
was explored by pretreating the corpora cavernosa with the COX inhibitor, indomethacin (10 
µM, 20 min), heme oxygenase inhibitor, ZnPPIX (10 µM, 60 min), the adenosine receptor 
antagonist, 8-SPT (100 µM, 10 min) or the cAMP-dependent protein kinase inhibitor, H-89 
(10 µM, 20 min). None of these inhibitors altered the relaxant effect of resveratrol on mice 
corpora cavernosa.  
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Table V.1. % Relaxation (± SEM) induced by 10, 30 and 100 µM resveratrol in mice corpora cavernosa in 
absence and presence of several inhibitors of molecular pathways. 
 Resveratrol 
10 µM  
Resveratrol 
30 µM 
Resveratrol 
100 µM 
Control 
+ K120 
13.7 ± 3.7 
13.3 ± 3.1 
27.0 ± 6.9 
23.6 ± 10.4 
41.4 ± 7.8 
38.1 ± 11.4 
Control 
+ K30 
12.2 ± 5.6 
8.6 ± 2.3 
27.0 ± 10.3 
17.4 ± 6.6 
45.0 ± 10.0 
42.3 ± 7.9 
Control 
+ TEA (3 mM) 
11.4 ± 2.1 
10.7 ± 3.3 
28.3 ± 4.1 
26.6 ± 7.3 
36.8 ± 6.7 
40.3 ± 9.9 
Control 
+ Glib (3 µM) 
9.5 ± 3.0 
15.2 ± 4.2 
18.1 ± 3.8 
23.3 ± 5.2 
37.7 ± 7.1 
41.9 ± 6.7 
Control 
+ 4-AP (3 mM) 
13.9 ± 3.1 
14.9 ± 7.7 
28.6 ± 5.1 
31.8 ± 4.3 
52.0 ± 5.0 
61.8 ± 4.1 
Control 
+ Indo (10 µM) 
4.8 ± 4.9 
12.1 ± 4.5 
22.2 ± 5.6 
27.8 ± 7.6 
53.3 ± 6.2 
44.2 ± 10.8 
Control 
+ ZnPPIX (10 µM) 
18.3 ± 5.9 
11.4 ± 5.6 
39.7 ± 7.4 
33.8 ± 11.1 
67.4 ± 11.9 
57.6 ± 7.3 
Control 
+ 8-SPT (100 µM) 
18.7 ± 4.2 
12.4 ± 2.2 
28.6 ± 5.9 
20.4 ± 4.1 
38.4 ± 4.5 
37.9 ± 5.1 
Control 
+ H-89 (10 µM) 
10.5 ± 2.4 
15.6 ± 2.1 
19.0 ± 3.6 
24.9 ± 3.0 
39.1 ± 4.0 
38.6 ± 3.3 
K120, Krebs-Ringer bicarbonate solution with 120 mM K
+
; K30, Krebs-Ringer bicarbonate solution with 30 mM K
+
, 
TEA, tetraethylammoniumchloride; Glib, glibenclamide; 4-AP, 4-aminopyridine; Indo, indomethacin; ZnPPIX, 
zinc protoporphyrin IX; 8-SPT, 8-(p-sulfophenyl)-theophylline; H-89, dihydrochloride hydrate 
 
V.6.4 Effect of resveratrol and quercetin on NO-mediated relaxation of corpora cavernosa 
Ach and SNP induced concentration-dependent relaxations of Swiss corpora cavernosa 
preparations (Fig. V.4A-V.4F). These relaxations were not or only to a low extent influenced 
by preincubation with resveratrol (Fig. V.4A and V.4B), quercetin (100 µM, 15 min) (Fig. V.4C 
and 4D) or PA (0.5 mM, 30 min) (Fig. V.4E and V.4F). 
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The effect of neuronal NO was examined by stimulating the nerves with EFS. EFS relaxed 
corpora cavernosa in a frequency-dependent manner (Fig. V.5A-V.5E). These relaxations 
were not influenced by the presence of resveratrol or quercetin (100 µM, 15 min) (Fig. V.5A 
and V.5C). Pretreatment with PA (0.5 mM, 30 min) significantly reduced EFS evoked 
relaxations (Fig. V.5E). Co-administration of quercetin showed a clear trend in reversing PA-
decreased EFS relaxations (Fig. V.5D). Co-administration of resveratrol however completely 
restored PA-induced impaired EFS responses to the level of controls (Fig. V.5B). In 
comparison, pretreatment with a known antioxidant, tempol, only partly reversed PA-
impaired EFS relaxations (Fig. V.5F). 
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Figure V.4 demonstrates that Ach and SNP (1 nM-10 µM) evoke concentration-dependent relaxations of 
precontracted (NOR 5 µM or 10 µM (resveratrol)) mice corpora cavernosa. Incubation with (A, B) resveratrol 
(100 µM, 15 min), (C, D) quercetin (100 µM, 15 min) or (E,F) PA (0.5 mM, 30 min) did not or hardly influence 
Ach-or SNP-induced corporal relaxations. Data are expressed as % relaxation of the NOR-induced tone; 
Wilcoxon test; *p<0.05; n=6-9. 
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Figure V.5. shows the effect of electrical field stimulation (EFS; parameters: train duration 40s; 1, 2, 4 and 8 
Hz; pulse duration 5 ms and 80V) on precontracted (NOR, 5 µM or 10 µM (resveratrol)) mice corpora 
cavernosa. EFS induced frequency-dependent corporal relaxations, which were not influenced by the 
presence of (A) resveratrol or (C) quercetin (100 µM, 15 min). Incubation with PA (0.5 mM, 30 min) 
significantly reduced EFS evoked relaxations. Co-administration of PA (0.5 mM, 30 min) with (B) resveratrol 
(100 µM, 15 min) but not (D) quercetin (100 µM, 15 min) significantly reversed PA diminished EFS responses, 
whereas co-administration of PA with (F) tempol (100 µM, 20 min) only partly restored PA-impaired EFS 
relaxations. Data are expressed as % relaxation of the NOR-induced tone; (A,C,E) Wilcoxon test; *p<0.05; 
n=7-8; (B,D,F) repeated measures ANOVA with Bonferroni post hoc test; #p<0.01 *p<0.05 (as compared to 
controls); ##p<0.01 **p<0.05 (as compared to PA treatment); n=8-9. 
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V.7 Discussion 
The main finding of this study is twofold: (i) Resveratrol but not quercetin relaxes isolated 
mice corpora cavernosa in a concentration-dependent manner through mechanisms 
independent of NO/sGC. (ii) Resveratrol is more potent than quercetin in reversing PA-
induced decrease in nNOS responses. 
As resveratrol and quercetin are believed to contribute to the cardiovascular benefits of 
moderate red wine consumption, numerous studies have shown that both polyphenols can 
induce vasorelaxation [3-10]. Even in corporal tissues positive effects to resveratrol and 
quercetin administration have been reported [22-27]. However, this study is the first to 
report a relaxant capacity of resveratrol on isolated mice corpora cavernosa. Surprisingly, 
our results demonstrate that both polyphenols are potent vasodilators of mice aorta, but 
only resveratrol is able to induce corporal relaxation. The failure of quercetin to relax mice 
corpora cavernosa in contrast to human corpora cavernosa [25] could be due to species 
differences. In addition in mice aorta, in contrast to corpora cavernosa, a specific molecular 
target for quercetin could exist or this target could have a higher activity/sensitivity in mice 
aorta. Moreover, as resveratrol and quercetin belong to a different subclass of the 
polyphenol family (resveratrol being a stilbene, quercetin being a flavonoid), also structural 
features could take account for the inability of quercetin to relax mice corpora cavernosa. 
The idea that the vasorelaxant capacity of polyphenols could be related to structural 
features has already been proposed [28]. Therefore it is rational to assume that for instance 
the presence of the flavan moiety may limit the relaxant capacity of quercetin in corporal 
tissue. 
It is well established that resveratrol and quercetin can relax different types of arteries 
through activation of the NO/sGC-dependent pathway [3-7]. In contrast, the contribution of 
the NO/sGC-pathway in the relaxant effect of resveratrol on mice corpora cavernosa is 
unknown. Therefore this was evaluated using sGCα1
-/- mice. sGC exists as an αβ heterodimer 
of which two isoforms for each subunit have been characterized (α1/α2 and β1/β2). However, 
only the α1β1 and α2β1 heterodimers are catalytically active [29]. Studies suggested that 
sGCα1β1 is predominantly expressed in corpora cavernosa and is the most important sGC 
heterodimer responsible for corporal smooth muscle relaxation [30-32]. In aorta from 
Chapter V 
Relaxant and antioxidant capacity of RWPs on mice corpus cavernosum 
110 
 
sGCα1
-/- mice the resveratrol- and quercetin-induced relaxations were significantly inhibited, 
confirming the NO/sGC dependency by which polyphenols relax arteries. On the other hand, 
in corpora cavernosa the resveratrol-induced relaxations were comparable in sGCα1
-/- and 
sGCα1
+/+ mice. Moreover, pretreatment with the NOS inhibitor L-NAME or the sGC inhibitor 
ODQ did not influence the resveratrol-induced corporal relaxations. In contrast to mice 
aorta, these results suggest a NO/sGC-independent mechanism of resveratrol to relax mice 
corpora cavernosa. Surprisingly Fukuhara et al. [24] reported that resveratrol acts NO-
dependently to elevate cGMP levels in corpora cavernosa smooth muscle cells. Species 
differences and different experimental set–ups may explain this discrepancy as in the study 
of Fukuhara et al. [24] no functional experiments were performed. Moreover, it is well 
known that the resveratrol-induced relaxations do not solely depend on the activation of the 
NO/sGC pathway. Other mechanisms have been suggested as well, including activation of K+ 
channels [7, 8, 10]. Within this respect, Dalaklioglu et al. [22] reported that resveratrol could 
relax rat corpora cavernosa independent of the NO/sGC pathway by activation of different 
types of K+ channels. In our study, neither the presence of high K+ concentrations nor 
pretreatment of the corpora cavernosa with the non-selective (TEA) as well as the selective 
KATP
 (Glib) or Kv (4-AP) channel blockers modified resveratrol-induced corporal relaxations. 
Therefore, it is unlikely that opening of K+ channels is involved in the mice corporal relaxant 
effect of resveratrol. Other mediators such as prostaglandins, heme oxygenase, adenosine 
receptors or cAMP pathway, which have been reported to be involved in the resveratrol’s 
mechanism of action [33-36], can also be excluded since pretreatment of de corpora 
cavernosa with indomethacin, ZnPPIX, 8-SPT or H-89 respectively did not alter corporal 
relaxations induced by resveratrol. The exact mechanism by which resveratrol relaxes mice 
corpora cavernosa remains elusive. 
It has been shown that resveratrol and quercetin increase endothelium-dependent 
relaxations to Ach in different rat models with endothelial dysfunction [14, 27, 37]. 
Interestingly, resveratrol can improve Ach-induced relaxations even in aortic strips from 
normal mice [39]. In our study neither resveratrol nor quercetin enhanced endogenously 
(Ach), exogenously (SNP) or neuronal (EFS) NO-mediated relaxation responses of corpora 
cavernosa. However when oxidative stress was enhanced using PA, resveratrol was able to 
reverse the decreased EFS-induced relaxations. This finding is in line with what was observed 
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by Ertug et al. [23] who found that quercetin restored exogenous NO responses when mice 
corpora cavernosa were exposed to free radicals. This could imply that a certain amount of 
oxidative stress is required in order for quercetin or resveratrol to exert their beneficial 
effect. As in resting conditions corpora cavernosa are exposed to a limited amount of 
oxidative stress, resveratrol and quercetin failed to improve NO-mediated corporal 
relaxations. Quercetin treatment clearly shows a trend to reverse PA-related decreases in 
corporal EFS responses. However, resveratrol completely reversed PA-induced impairment 
of EFS responses. In addition, as incubation of the corpora cavernosa with a known 
antioxidant, tempol, only partly restored PA-induced impaired EFS relaxations, it seems that 
on corpora cavernosa resveratrol exerts a greater beneficial effect than tempol. 
PA is one of the most abundant free fatty acids (FFA) found in plasma. In addition elevated 
FFA are a common feature in obesity and diabetes [38], two conditions which are frequently 
associated with ED [18]. Furthermore, PA incubation can stimulate ROS generation in vitro 
and impair endothelium-dependent relaxation responses [39-41]. As increased ROS could 
result in ED, elevated PA levels could be a cause of ROS-related ED. In our study however PA 
incubation did not cause endothelial or vascular damage since Ach and SNP responses of the 
corpora cavernosa were not influenced by PA incubation. Therefore it seems that PA causes 
only a low degree of oxidative stress, which was too low to impair Ach or SNP responses. 
Despite the mild oxidative stress, EFS-evoked relaxations were significantly decreased by PA, 
indicating that even mild oxidative stress is sufficient to cause lower neuronal NO 
bioavailability. In corpora cavernosa this could be physiological relevant as neuronal NO is 
the primary trigger for erection. If the primary trigger to induce erection is decreased, this 
might lead to ED since NO derived from other sources cannot completely serve as back-up 
for the decrease in primary NO source [18, 42]. Regardless of the severity of oxidative stress 
induced by PA, our results suggest that in mice corpora cavernosa resveratrol is more potent 
than quercetin to reverse PA-related decreases in neuronal NO-mediated responses.  
It should be noted that our study has limitations hampering to draw firm conclusions. First, 
our study represents a strictly in vitro approach. Therefore our results cannot be 
extrapolated as such to the in vivo situation or be compared to the effect of orally ingested 
polyphenols. This latter should be taken into account since polyphenols are rapidly 
metabolized and thus have a poor oral bioavailability [43]. This raises the question whether 
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the beneficial effects observed in vitro can be reproduced in vivo. However considering the 
recent study by Yu et al. [44] it seems that resveratrol even in vivo has positive effect on 
corporal tissues as resveratrol improved erectile function in streptozocin-induced diabetic 
rats by preventing oxidative stress. In addition as low testosterone levels are more often 
associated with ED [45] also hormonal status can influence the responsiveness of corporal 
tissues and thus the responsiveness to resveratrol. A second limitation is the lack of direct 
measurements of the effect of resveratrol and quercetin on oxidative stress. However 
substantial data is available indicating that resveratrol is able to reduce ROS production in 
vitro [12, 15-17] as well as in vivo [11, 44] even in corporal tissue. 
V.8 Conclusions 
In conclusion, our study shows that the wine compounds resveratrol and quercetin are both 
potent vasodilators of mice aorta, however only resveratrol exerts a relaxant effect in mice 
corpora cavernosa which is independent of the NO/sGC pathway. The exact mechanism 
underlying resveratrol’s relaxant effect on mice corpora cavernosa remains elusive. 
Furthermore, our study indicates that resveratrol is a more potent antioxidant than 
quercetin being able to restore decreased neuronal NO responses in mice corpora 
cavernosa. 
It is necessary to consider back-up therapeutic approaches in the treatment of ED as specific 
patient populations are refractory to first-line therapy with PDE5 inhibitors [19]. In this 
perspective, our results demonstrate that resveratrol, a naturally occurring polyphenol with 
direct relaxant and antioxidant effects on mice corpora cavernosa, is potentially beneficial 
for patients suffering from ED. Still, additional pharmacological and toxicological research is 
needed to elucidate whether resveratrol also exerts these relaxant and antioxidant 
properties in vivo and thus possesses strong therapeutic value for patients suffering from 
ED. 
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Chapter VI Protective effect of resveratrol and quercetin on in vitro-induced 
diabetic mouse corpus cavernosum 
VI.1 Abstract 
BACKGROUND. Hyperglycemia and increased levels of methylglyoxal (MGO) can trigger the 
development of vascular complications in diabetes. Resveratrol and quercetin are red wine 
polyphenols with known beneficial cardiovascular properties, including an antioxidant 
capacity. This study evaluated whether resveratrol and/or quercetin could prevent in vitro-
induced diabetic changes in neurogenic and vascular relaxant responses of mouse arteries 
and corpora cavernosa. 
METHODS Isometric tension of isolated aorta, mesenteric arteries and corpora cavernosa 
was measured using organ bath systems. Diabetic conditions were mimicked in vitro by co-
incubating the tissues for 2 h with high glucose (HG, 30 mM) and MGO (120 µM). 
RESULTS. The presence of HG and MGO significantly blunted acetylcholine (Ach)-induced 
relaxations in corpora cavernosa and mesenteric arteries but not in aorta. Electrical field 
stimulated (EFS) responses of corpora cavernosa were also significantly inhibited by these 
diabetic conditions. In corpora cavernosa 2 h co-incubation with resveratrol (30 µM) or 
quercetin (30 µM) significantly attenuated HG and MGO-induced deficits in Ach- and EFS-
responses. 
CONCLUSIONS. Our study demonstrates that in mouse arteries, HG and MGO rather affect 
endothelium derived hyperpolarizing factor-mediated than nitric oxide (NO)-mediated 
relaxations. In corpora cavernosa HG and MGO interfere with NO release. Resveratrol and 
quercetin protect mouse corpora cavernosa from diabetic-induced damage to NO-mediated 
relaxant responses. This might rely on their antioxidant capacity. 
Keywords: resveratrol, quercetin, diabetes, erectile dysfunction 
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VI.2 Introduction 
Hyperglycemia and increased levels of methylglyoxal (MGO), a reactive metabolite produced 
during glycolysis, are two hallmarks of diabetes mellitus which can trigger the development 
of vascular complications in diabetes [1-5]. These vascular events are presumed to underlie 
the pathogenesis of diabetic-related erectile dysfunction (ED). Indeed, in different models of 
diabetes it has been demonstrated that neurogenic- and endothelium-mediated relaxation 
of isolated corpora cavernosa [6-11] or arteries [5, 12, 13] is impaired. Moreover, in vitro 
research showed that acute exposure of isolated arteries to high glucose or MGO affects 
endothelium-dependent relaxations in different vascular beds [1, 3, 14-16]. Oxidative stress 
may play a causative role in the damaging effect of hyperglycemia or MGO on the 
endothelium [1, 3, 5, 15, 16]. Therefore, antioxidant therapy might offer an option for 
treating diabetic complications, including ED. Resveratrol and quercetin are two naturally 
occurring polyphenols, mainly present in the skin of grapes and thus abundant in red wine. 
Both polyphenols are suggested to have beneficial cardiovascular properties, including a 
relaxant [17, 18] and antioxidant [17, 19, 20] capacity. Recently, our group reported a 
relaxant and antioxidant effect of resveratrol in isolated mouse corpora cavernosa [21]. 
Considering their antioxidant properties resveratrol and/or quercetin could potentially be of 
value in the treatment of diabetic ED. However, the antioxidant effect of these polyphenols 
in mouse mesenteric arteries and corpora cavernosa in diabetic conditions is as yet 
unexplored. Therefore, the aim of this study was to evaluate whether resveratrol and/or 
quercetin could protect mouse mesenteric artery and/or corpora cavernosa from high 
glucose and MGO-induced defects in endothelium- and neurogenic-mediated relaxations. 
VI.3 Materials and methods 
VI.3.1 Animals  
Adult (8-12 weeks) male Swiss mice were obtained from Janvier (Saint-Berthevin, France). 
Food and water was provided ad libitum and all animals were treated in accordance with the 
Guide for the Care and Use of Laboratory Animals published by the US National Institutes of 
Health. This study was approved by the local Ethical Committee for Animal experiments, 
Faculty of Medicine and Health Sciences, Ghent University, Belgium. 
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VI.3.2 Tissue preparation 
After cervical dislocation, thoracic aorta, mesenteric arteries (1st and 2nd order) and corpora 
cavernosa were carefully isolated and dissected free from surrounding structures. All tissues 
were kept in cold Krebs-Ringer bicarbonate (KRB) solution. Aorta and mesenteric arteries 
were cut into rings of about 3 mm in length and mounted in a wire myograph for isometric 
tension measurements. Of each mouse, one corpus cavernosum was mounted horizontally 
in a myograph with one end fixed to a transducer and the other to a micrometer. The tissue 
chambers were filled with 10 mL KRB solution at 37 °C (pH 7.4) equilibrated with 95 % O2–5 
% CO2. The preparations were allowed to equilibrate for 30 minutes in KRB solution that was 
frequently replaced. In order to obtain maximal, stable contractions and relaxations, 
mesenteric arteries were stretched to their optimal lumen diameter that gives a maximum 
response, as calculated on the basis of the passive wall tension-internal circumference 
relationship [22]. Aorta segments and corpora cavernosa were gradually stretched until a 
stable preload of 0.5 g (aorta) or 0.45 g (corpora cavernosa) was obtained. Subsequently, 
tissues were repeatedly activated using different protocols: (i) aorta with 120 mM K+ and 1 
µM phenylephrine (Phe) (ii) mesenteric arteries 3 times with 120 mM K+ and 10 µM Phe and 
(iii) corpora cavenosa two times with 5 µM Phe. The integrity of the endothelium was 
examined by precontracting the tissues with submaximal Phe concentrations (1 µM for 
aorta, 5 µM for corpora cavernosa and 10 µM for mesenteric arteries) and adding 
acetylcholine (Ach) (10 µM for arteries or 1 µM for corpora cavernosa). Only tissues that 
relaxed more than 50 % to Ach, were included in this study. 
VI.3.3 Experimental protocol 
Tissues were incubated for 2 h with: (i) control KRB solution containing 10 mM glucose or (ii) 
KRB solution containing 30 mM glucose (high glucose) and 120 µM MGO. Every 30 minutes 
the KRB solution in the organ baths was refreshed. After 2 h incubation, tissues were 
precontracted with Phe (1 – 10 µM). Firstly, the relaxant effect of resveratrol (1 – 100 µM) 
and quercetin (1 – 100 µM) was evaluated. Secondly, the protective effect of resveratrol and 
quercetin on endothelium-(in)dependent relaxations were evaluated. Relaxant responses to 
Ach (1 nM – 1 or 10 µM) and sodium nitroprusside (SNP) (1 nM – 1 µM), were examined 
after 2 h pretreatment with 30 mM glucose and 120 µM MGO in absence or presence of 
ascorbic acid (100 µM), tempol (100 µM), resveratrol (30 µM) or quercetin (10 or 30 µM). In 
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corpora cavernosa, neurogenic-mediated relaxations were also studied by applying electrical 
field stimulation (EFS; parameters: train duration 40 s; 1, 2, 4 and 8 Hz; pulse duration 5 ms 
and 80 V).  
VI.3.4 Drugs and chemicals 
The experiments were performed in a KRB solution of the following composition (mM): NaCl 
135, KCl 5, NaHCO3 20, glucose 10 (control) or 30 (high glucose), CaCl2 2.5, MgSO4 1.3, 
KH2PO4 1.2 and EDTA 0.026 in H2O. L-phenylephrine hydrochloride (Phe), acetylcholine 
chloride (Ach), sodium nitroprusside (SNP), Nω-Nitro-L-arginine methyl ester hydrochloride 
(L-NAME), indomethacin (indo), methylglyoxal solution (MGO), 4-hydroxy-tempo (Temp), L-
ascorbic acid (AA), resveratrol, quercetin and dimethylsulfoxide (DMSO) were obtained from 
Sigma (St. Louis, MO). Stock solutions were made in water except for indo (ethanol). The 
final concentrations of vehicle solution in the organ bath never exceeded 0.1 %. Stock 
solutions of 100 mM of resveratrol and quercetin were made in DMSO, but were further 
diluted in distilled water (10 mM) before adding to the organ baths.  
VI.3.5 Statistics 
The data are presented as mean values ± S.E.M. Relaxations are expressed as % decrease in 
precontractile tone. N is the number of individual strips/rings used. Sensitivity (pEC50) and 
maximum response (Emax) were calculated from the concentration-response curves to 
resveratrol, quercetin or acetylcholine. pEC50 was defined as the negative logarithm to base 
10 of the EC50 values and Emax was defined as the maximal relaxation. The data in our study 
was analysed using SPSS, version 22; IBM Corporation, Armonk, NY, USA. Statistical 
significance was evaluated using the Mann-Whitney U test. Two groups of data were 
considered significantly different when p<0.05. Graphs were created using Graphpad Prism, 
version 4.00, GraphPad Software, San Diego California USA.  
VI.4 Results 
VI.4.1 Relaxant capacity of resveratrol and quercetin in presence of high glucose and MGO 
Both resveratrol and quercetin (1 – 100 µM, 15 min) relaxed Phe-precontracted aortic and 
mesenteric rings concentration dependently (Fig. VI.1a and VI.1b). Maximal relaxation for 
resveratrol was 74.4 ± 5.1 % (aorta) and 101.8 ± 2.0 % (mesenteric arteries); pEC50 values 
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were 4.4 ± 0.1 and 4.9 ± 0.1 for aortic and mesenteric rings respectively. Maximal relaxation 
for quercetin was 59.0 ± 11.1 % (aorta) and 102.8 ± 4.3 % (mesenteric arteries); pEC50 values 
were 4.5 ± 0.1 and 5.4 ± 0.1 for aortic and mesenteric rings respectively. In contrast, only 
resveratrol evoked concentration dependent relaxations in corpora cavernosa (Emax: 50.6 ± 
9.6 % and pEC50: 4.9 ± 0.5) (Fig. VI.1c). Based on these results, following concentrations of 
resveratrol and quercetin were chosen for our subsequent experiments: 10 µM resveratrol 
and 3 µM quercetin for mesenteric arteries, 30 µM resveratrol and 30 µM quercetin for 
corpora cavernosa. 
 
 
Figure VI.1: (Vaso)relaxant effect of resveratrol or quercetin in presence of high glucose and methylglyoxal. 
(a) Aorta, (b) mesenteric artery and (c) corpora cavernosa. Tissues were incubated for 2 h with 30 mM glucose 
(HG) and 120 µM methylglyoxal (MGO) before constructing concentration-response (1-100 µM) curves to 
resveratrol (Res, 15 min) or quercetin (Quer, 15 min). Data are expressed as % decrease of Phe-induced tone; 
Mann-Whitney U test; #p<0.01 and *p<0.05 (vehicle control vs. Res) (n=5-6); ##p<0.01 and **p<0.05 (vehicle 
control vs. Quer) (n=5-6). 
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VI.4.2 High glucose and MGO impair Ach- and EFS-relaxations 
Endothelium-dependent relaxations where evaluated using Ach (1 nM – 1 or 10 µM), which 
induced concentration dependent relaxations in all tissues. To explore the role of 
endothelium derived hyperpolarizing factor (EDHF), Ach-curves were constructed in 
presence of the NO synthase inhibitor, L-NAME (0.1 mM, 20 min), and the cyclooxygenase 
blocker, indo (10 µM, 20 min). The presence of L-NAME and indo completely abolished Ach-
relaxations in aorta and corpora cavernosa, whereas these inhibitors did not affect Ach-
relaxations of mesenteric arteries (data not shown).  
After 2 h incubation with high glucose (30 mM) and MGO (120 µM), Ach-induced relaxations 
were significantly blunted in mesenteric arteries (Fig. VI.2a, VI.2b and VI.3a) and corpora 
cavernosa (Fig. VI.2c, VI.2d and VI.3b). EFS-relaxations of corpora cavernosa were 
significantly reduced by 2 h exposure to high glucose (30 mM) and MGO (120 µM) (Fig. VI.2e, 
VI.2f and VI.3c). 
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Figure VI.2: Effect of in vitro-diabetic conditions on acetylcholine and electrical field stimulated responses of 
mesenteric artery and corpora cavernosa. Original tracings showing the effect of 2 h incubation with high 
glucose (HG, 30 mM) and methylglyoxal (MGO, 120 µM) on (a-d) acetylcholine (Ach, -log M) and (e and f) 
electrical field stimulated (Hz) relaxations of mesenteric artery and corpora cavernosa after precontraction with 
phenylephrine (Phe; 10 µM for mesenteric arteries; 5 µM for corpora cavernosa). Response curve to Ach in 
mesenteric artery in (a) absence and (b) presence of HG and MGO; in corpora cavernosa in (c) absence and (d) 
presence of HG and MGO. EFS-relaxations in corpora cavernosa in (e) absence and (f) presence of HG and 
MGO. 
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Figure VI.3: Effect of in vitro-diabetic conditions on acetylcholine and electrical field stimulated responses of 
mesenteric artery and corpora cavernosa. Acetylcholine (Ach)-induced relaxations of (a) mesenteric artery and 
(b) corpora cavernosa after 2 h incubation with high glucose (HG, 30 mM) and methylglyoxal (MGO, 120 μM) 
after precontraction with Phe (10 μM for mesenteric arteries; 5 μM for corpora cavernosa). (c) Electrical field 
stimulated (EFS) relaxations of 5 μM Phe-precontracted mouse corpora cavernosa after 2 h incubation with 
high glucose (HG, 30 mM) and methylglyoxal (MGO, 120 μM). Data are expressed as % decrease of Phe-induced 
tone; Mann-Whitney U test; #p<0.01 and *p<0.05 (n=6-7).  
 
 
In contrast, the presence of 30 mM glucose and 120 µM MGO neither affected Ach-
relaxations of aorta (Fig VI.4a) nor SNP-relaxations of aorta, mesenteric arteries or corpora 
cavernosa (Fig. VI.4b, VI.4c and VI.4d). 
 
 
 
 
 
Chapter VI 
Protective effect of RWPs in diabetic conditions 
127 
 
 
 
Figure VI.4: Effect of in vitro-diabetic conditions on acetylcholine and sodium nitroprusside responses of 
aorta, mesenteric artery and corpora cavernosa. Acetylcholine (Ach)-induced relaxations of mouse (a) aorta 
and on sodium nitroprusside (SNP)-induced relaxations of (b) aorta, (c) mesenteric artery and (d) corpora 
cavernosa after 2 h incubation with high glucose (HG, 30 mM) and methylglyoxal (MGO, 120 µM) after 
precontraction with Phe (1 µM for aorta, 10 µM for mesenteric arteries and 5 µM for corpora cavernosa). Data 
are expressed as % decrease of Phe-induced tone; Mann-Whitney U test; (n=7-8 for Ach-curves) (n=4-6 for SNP-
curves). 
 
VI.4.3 Role of oxidative stress in glucose and MGO-impaired relaxations 
Mesenteric arteries and corpora cavernosa were pretreated for 2 h with 30 mM glucose and 
120 µM MGO in combination with the antioxidant AA (100 µM) or the superoxide anion 
scavenger Temp (100 µM). In mesenteric arteries both AA (Fig. VI.5a) and Temp (Fig. VI.6a) 
prevented glucose and MGO impairment of Ach-relaxations. Neither AA nor Temp altered 
sensitivity to Ach, whereas maximal Ach-responses were improved in presence of AA or 
Temp (Table 1). Similarly, in corpora cavernosa, both antioxidants counteracted the effect of 
glucose and MGO incubation on Ach- and EFS-responses (Fig. VI.5b and VI.5c, VI.6b and 
VI.6c). pEC50 values were unaltered by antioxidant treatment. Maximal Ach-responses were 
however improved in presence of AA or Temp (Table VI.1). 
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Figure VI.5: Ascorbic acid prevents high glucose and methylglyoxal-induced deficits in mesenteric artery and 
corpora cavernosa. Acetylcholine (Ach)-induced relaxations of (a) mesenteric artery and (b) corpora cavernosa 
after 2 h co-incubation with high glucose (HG, 30 mM) and methylglyoxal (MGO, 120 µM) in absence and 
presence of ascorbic acid (AA, 100 µM) after precontraction with Phe (10 µM for mesenteric arteries; 5 µM for 
corpora cavernosa). (c) Electrical field stimulated (EFS) relaxations of corpora cavernosa after 2 h incubation 
with high glucose (HG, 30 mM) and methylglyoxal (MGO, 120 µM) in absence and presence of ascorbic acid 
(AA, 100 µM). Data are expressed as % decrease of Phe-induced tone; Mann-Whitney U test; #p<0.01 and 
*p<0.05 (n=5-7). 
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Figure VI.6: Tempol prevents high glucose and methylglyoxal-induced deficits in mesenteric artery and 
corpora cavernosa. Acetylcholine (Ach)-induced relaxations of (a) mesenteric artery and (b) corpora cavernosa 
after 2 h incubation with high glucose (HG, 30 mM) and methylglyoxal (MGO, 120 µM) in absence and presence 
of tempol (Temp, 100 µM) after precontraction with Phe (10 µM for mesenteric arteries; 5 µM for corpora 
cavernosa). (c) Electrical field stimulated (EFS) relaxations of 5 µM Phe-precontracted mouse corpora 
cavernosa after 2 h incubation with high glucose (HG, 30 mM) and methylglyoxal (MGO, 120 µM) in absence 
and presence of tempol (Temp, 100 µM). Data are expressed as % decrease of Phe-induced tone; Mann-
Whitney U test; #p<0.01 and *p<0.05 (n=5-6). 
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Table VI.1. Effect of antioxidants and polyphenol treatment on acetylcholine-relaxations of mesenteric arteries 
and corpora cavernosa. 
 
Mesenteric arteries Corpora cavernosa 
pEC50 Emax (%) pEC50 Emax (%) 
HG + MGO 
HG + MGO + AA 
7.1 ± 0.4 
7.0 ± 0.2 
19.8 ± 2.6 
46.8 ± 4.8
#
 
7.8 ± 0.1 
7.8 ± 0.2 
35.8 ± 6.4 
83.5 ± 6.1
*
 
HG + MGO 
HG + MGO + Temp 
7.0 ± 0.3 
7.1 ± 0.1 
23.9 ± 5.04 
58.3 ± 4.4
#
 
7.7 ± 0.1 
7.9 ± 0.2 
38.7 ± 4.2 
74.3 ± 3.5
#
 
HG + MGO 
HG + MGO + Res 
6.3 ± 0.9 
6.7 ± 0.5 
23.2 ± 5.0 
34.8 ± 3.7 
7.7 ± 0.3 
7.6 ± 0.2 
47.6 ± 4.3 
83.8 ± 4.6
#
 
HG + MGO 
HG + MGO + Quer 
7.4 ± 1.0 
6.7 ± 0.2 
24.4 ± 4.4 
31.3 ± 6.3 
7.9 ± 0.3 
7.9 ± 0.02 
44.9 ± 3.5 
78.4 ± 13.3
#
 
pEC50, –log(EC50); Emax: maximal relaxation response; HG: high glucose (30 mM), MGO: methylglyoxal (120 
µM); AA: ascorbic acid (100 µM); Temp: tempol (100 µM); Res: resveratrol (10 µM for mesenteric arteries; 30 
µM for corpora cavernosa); Quer: quercetin (3 µM for mesenteric arteries; 30 µM for corpora cavernosa). Data 
are means ± SEM. *p<0.05; #p<0.01 (compared to HG + MGO group). 
 
VI.4.4 Effect of resveratrol and quercetin on glucose and MGO-impaired relaxations 
In mesenteric arteries, Ach-induced relaxations were explored after 2 h pretreatment with 
30 mM glucose and 120 µM MGO in combination with resveratrol (Res, 10 µM, 2 h) or 
quercetin (Quer, 3 µM, 2 h). Neither resveratrol (Fig. VI.7a) nor quercetin (Fig. VI.8a) 
prevented glucose and MGO impairment of Ach-relaxations as neither Emax nor pEC50 values 
were affected by resveratrol or quercetin treatment (Table VI.1). On the contrary, exposing 
the corpora cavernosa for 2 h to 30 mM glucose and 120 µM MGO in combination with 
resveratrol (30 µM, 2 h) or quercetin (30 µM, 2 h) significantly corrected blunted Ach- and 
EFS- relaxations (Fig. VI.7b and VI.7c, VI.8b and VI.8c). Emax values were significantly 
corrected by resveratrol as well as by quercetin treatment (Table VI.1). No effect of both 
polyphenols was found on the potency of Ach as pEC50 values were unchanged by 
resveratrol or quercetin addition (Table VI.1). 
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Figure VI.7: Effect of resveratrol on high glucose and methylglyoxal-induced deficits in mesenteric artery and 
corpora cavernosa. Acetylcholine (Ach)-induced relaxations of (a) mesenteric artery and (b) corpora cavernosa 
after 2 h incubation with high glucose (HG, 30 mM) and methylglyoxal (MGO, 120 µM) in absence and presence 
of resveratrol (Res, 10 µM for (a); 30 µM for (b)) after precontraction with Phe (10 µM for mesenteric arteries; 
5 µM for corpora cavernosa). (c) Electrical field stimulated (EFS) relaxations of 5 µM Phe-precontracted mouse 
corpora cavernosa after 2 h incubation with high glucose (HG, 30 mM) and methylglyoxal (MGO, 120 µM) in 
absence and presence of resveratrol (Res, 30 µM). Data are expressed as % decrease of Phe-induced tone; 
Mann-Whitney U test; #p<0.01 and *p<0.05 (n=5-7). 
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Figure VI.8: Effect of quercetin on high glucose and methylglyoxal-induced deficits in mesenteric artery and 
corpora cavernosa. Acetylcholine (Ach)-induced relaxations of (a) mesenteric artery and (b) corpora cavernosa 
after 2 h incubation with high glucose (HG, 30 mM) and methylglyoxal (MGO, 120 µM) in absence and presence 
of quercetin (Quer, 3 µM for (a); 30 µM for (b)) after precontraction with Phe (10 µM for mesenteric arteries; 5 
µM for corpora cavernosa). (c) Electrical field stimulated (EFS) relaxations of 5 µM Phe-precontracted mouse 
corpora cavernosa after 2 h incubation with high glucose (HG, 30 mM) and methylglyoxal (MGO, 120 µM) in 
absence and presence of quercetin (Quer, 30 µM). Data are expressed as % decrease of Phe-induced tone; 
Mann-Whitney U test; #p<0.01 and *p<0.05 (n=4-7). 
  
Chapter VI 
Protective effect of RWPs in diabetic conditions 
133 
 
VI.5 Discussion 
The present study was the first to demonstrate that co-incubation of mouse mesenteric 
arteries and corpora cavernosa with 30 mM glucose and 120 µM MGO causes deficits in 
endothelium- and neurogenic-mediated relaxations. In addition, resveratrol and quercetin 
were effective in preventing diabetic-induced deficits in corpora cavernosa. 
VI.5.1 Diabetic (neuro)vascular damage induced by in vitro high glucose and MGO treatment  
The concentrations of glucose and MGO used in our study were chosen based on literature. 
30 mM glucose is a level that is found or even exceeded in the blood of db/db mouse model 
of type 2 diabetes that is associated with severe endothelial dysfunction in the small 
mesenteric arteries [23]. In addition, in patients with poorly controlled diabetes, the MGO 
level in blood can raise up to 400 µM [24]. Moreover, exogenous MGO is not fully absorbed 
intracellularly [25]. Therefore the use of 30 mM glucose and 120 µM MGO in this study 
seems to be justified as these concentrations seem pathophysiologically relevant.  
The effect of either glucose or MGO on endothelium-dependent relaxations has been 
investigated in several studies [1, 3, 5, 14, 16], however no study has evaluated the joint 
effect of MGO and elevated glucose in mouse mesenteric arteries or corpora cavernosa. 
Since both glucose and MGO levels are increased in diabetes mellitus [4, 24], diabetic 
conditions are more precisely mimicked in vitro by co-incubating the tissues with both 
compounds. Our results are in line with previous studies showing a negative effect of high 
glucose or MGO on endothelium-dependent relaxations in mesenteric arteries of rats or 
mice [1, 14-16]. In addition, the impaired endothelium- and neurogenic-mediated 
relaxations observed in corpora cavernosa are in agreement with studies using other animal 
models for diabetes [7-11] or in diabetic men [6]. It thus seems that the in vitro 
glucose/MGO treatment used in this study indeed yields neurovascular damage as observed 
in vivo in diabetes mellitus. Confirming most of these studies, relaxant responses to SNP, an 
endothelium-independent nitric oxide (NO) donor, were unaltered by exposing the tissues to 
high glucose and MGO. Thus neither a diminished response at the level of the smooth 
muscle cells nor defects in the cyclic guanosine monophosphate pathway can explain the 
observed diabetic-induced deficits of Ach- and EFS-relaxations. Instead, these deficits will 
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thus rather result from decreased synthesis and/or increased quenching of endothelium- or 
neuronal-derived relaxing factors by high glucose and MGO. 
VI.5.2 Aorta versus mesenteric arteries 
No effect of diabetic conditions was found on Ach-relaxations in aorta, which is in contrast to 
Dhar et al. [3], who found a decreased Ach response in rat aorta after incubation with 25 
mM glucose. As in our study a trend in reduced Ach-relaxations of aorta could be observed, 
it is possible that the incubation time of glucose/MGO was too short to cause endothelial 
damage. With respect to the arteries used in this study, our results indicate that diabetic 
conditions affect endothelium-mediated relaxations in mesenteric arteries more rapidly than 
in aorta. This implies that the type of artery and/or the lumen diameter determines the 
effect of glucose/MGO on Ach-induced relaxations. Ach stimulates the release of 
endothelium derived relaxing factors: NO, prostacyclin and EDHF. Different vascular beds 
exhibit a marked heterogeneity in the relative contribution of these factors to endothelium-
dependent relaxations [26]. Indeed, inhibition of NO and prostacyclin production (using L-
NAME and indo respectively) did not affect Ach-relaxations in mesenteric arteries whereas 
the presence of these inhibitors completely abolished Ach-responses in aorta. This 
demonstrates that Ach-relaxations in mesenteric arteries are EDHF-mediated [12, 26] while 
in aorta these are NO-mediated. Thus, in mouse arteries high glucose and MGO seem to 
interfere more rapidly with EDHF- than with NO-dependent relaxations.  
VI.5.3 Corpora cavernosa 
Like in aorta, Ach- and EFS-relaxations of corpora cavernosa are NO-mediated (own 
observations and [10, 27]). However, unlike in aorta, these NO-mediated relaxations are 
inhibited by co-incubating the corpora cavernosa with 30 mM glucose and 120 µM MGO. So, 
besides the lumen diameter of the vessels, the type of tissue also contributes to the effect of 
diabetic conditions on relaxant responses to Ach or EFS. Since unaltered aortic Ach-
relaxations were observed in presence of high glucose and MGO, it can be assumed that (i) 
these diabetic conditions induce less damage in aorta or (ii) the aorta is more resistant to 
changes evoked by glucose/MGO. As previously mentioned, our results cannot rule out that 
longer exposure to high glucose/MGO could yield similar endothelial damage in aorta as 
seen in corpora cavernosa or mesenteric arteries. However, based on our results it seems 
Chapter VI 
Protective effect of RWPs in diabetic conditions 
135 
 
that both corpora cavernosa and mesenteric arteries are more prone to diabetic-induced 
endothelial and/or neurogenic changes compared to large arteries such as aorta.  
VI.5.4 Oxidative stress as underlying cause of in vitro-diabetic damage 
A hyperglycemia or MGO-dependent increase in reactive oxygen species (ROS) [1, 3, 5, 15, 
16] seems to be an important contributor to the pathogenesis of the diabetic-
(neuro)vascular complications. After all, antioxidant administration can limit oxidative 
damage and restore diabetes-induced defects in endothelial- and/or neurogenic responses 
of arteries [28-30] or corpora cavernosa [8-11]. Here we demonstrate that the antioxidant 
AA or the superoxide anion scavenger Temp markedly inhibit glucose/MGO-induced damage 
to endothelium- and neurogenic-mediated responses of mesenteric arteries and corpora 
cavernosa. Despite the large amount of evidence for high glucose or MGO-induced oxidative 
stress, the mechanisms whereby ROS formation is induced, are not fully understood. 
Recently it was reported that MGO-stimulated ROS production activates the endothelial 
plasma membrane transport protein, Na+/H+ exchanger (NHE1) [31]. Moreover high glucose-
induced vascular deficits are related to hyperactivity of NHE1 [32]. Activation of NHE1 may 
thus be a critical step for ROS-induced damage. Regardless of the mechanism by which 
glucose/MGO generate oxidative stress, our results indicate that ROS, including superoxide 
anion, interfere with the NO-pathway, in corpora cavernosa, or the EDHF-pathway, in 
mesenteric arteries, leading to impaired Ach- and EFS-relaxations. Although not addressed in 
this study, ROS interference with the NO-pathway involves either decreased NO synthesis or 
increased NO degradation. Increased oxidative stress leads to the oxidation of 
tetrahydrobiopterin (BH4), a cofactor that tightly regulates NO production, resulting in the 
uncoupling of endothelial NO synthase (eNOS) [33, 34]. In the presence of reduced 
concentrations of BH4, eNOS transfers electrons to molecular oxygen to produce superoxide 
rather than NO [33, 34]. In addition superoxide itself can react and consume NO, forming 
peroxynitrite and thus enhancing oxidative stress. Hence, NO-mediated relaxations are 
further impaired. On the contrary, less is known about the interference of oxidative stress 
with the EDHF-pathway. Impaired EDHF-responses due to increased oxidative stress does 
not result from altered K+ channel function [16]. ROS-induced altered interaction between 
cAMP and gap junctions communication might represent another explanation [16].  
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VI.5.5 Resveratrol and quercetin in diabetic conditions 
Numerous health benefits have been ascribed to the red wine polyphenols resveratrol and 
quercetin [17]. Even in diabetic rats these polyphenols restore impaired endothelium-
dependent relaxations of aorta [35-37] and improve erectile function [38-41]. In addition, 
studies have reported a direct anti-diabetic effect of resveratrol and quercetin as they were 
able to lower blood glucose levels in diabetic rats and mice [42, 43]. In this study resveratrol 
and quercetin administration prevented glucose/MGO-induced damage to endothelium- and 
neurogenic-induced relaxations in corpora cavernosa. This is in line with Murat et al. [44] 
who found that resveratrol protects and restores endothelium-dependent relaxation in 
hypercholesterolemic rabbit corpus cavernosum. On the contrary, in mesenteric arteries no 
protective effect of resveratrol or quercetin was found. Different explanations could clarify 
this tissue specific effect of both polyphenols. First, studies pointed out that resveratrol and 
quercetin stimulate endothelial NO production [17, 18, 20]. As endothelial- and neurogenic 
relaxant responses in corpora cavernosa are NO-mediated, enhanced endothelial or 
neuronal NO synthesis by the polyphenols could clarify the improved Ach-relaxations. In 
contrast this could not explain the inability of resveratrol and quercetin to protect 
mesenteric arteries from diabetic-damage to Ach-responses. We have shown that Ach-
induced relaxations in mesenteric arteries are EDHF mediated. Nonetheless, one could 
expect that if resveratrol and quercetin enhance endothelial NO production this could 
compensate for decreases in EDHF-responses, resulting in improved Ach-relaxations. 
However this was not the case. Moreover in a previous study [21] we found that resveratrol 
relaxes mouse corpora cavernosa independent of the endothelium or NO. In addition we 
also demonstrated that neither resveratrol nor quercetin stimulated Ach-relaxations of 
mouse corpora cavernosa as such [21]. Therefore improved NO production cannot explain 
why the protective effect of resveratrol and quercetin against glucose/MGO-induced 
damage is limited to the corpora cavernosa. 
Recently it was suggested that K+ channel activation could also be involved in resveratrol’s 
positive effects on the cardiovascular system [45], including in resveratrol’s relaxant effect 
on corpora cavernosa [46]. In our study there is no evidence to strengthen this idea, as we 
previously found that resveratrol relaxes mouse corpora cavernosa independent of K+ 
channel activation [20]. Furthermore this could not explain the protective effect of quercetin 
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on EFS- and Ach-relaxations in corpora cavernosa, since quercetin was not able to relax 
mouse corpora cavernosa.  
A second explanation for the positive effects of resveratrol and quercetin in corpora 
cavernosa and not in mesenteric arteries, could be found in the different amount of 
oxidative stress that is induced by the glucose/MGO treatment. Since in mesenteric arteries 
Ach-relaxations were almost completely abolished by high glucose and MGO, it is possible 
that the degree of generated oxidative stress is too high for resveratrol or quercetin to cope 
with. It is for instance suggested that the protective effects of resveratrol against oxidative 
injury are attributed to up-regulations of the endogenous cellular antioxidant system rather 
than to its direct ROS scavenging activity, as it is known that the direct antioxidant effect of 
resveratrol is rather low [17]. However both polyphenols are as efficacious as known 
antioxidants to attenuate diabetic-induced oxidative endothelial damage. In addition, in 
diabetic-mimicking conditions resveratrol has a direct relaxant effect as in the present study 
resveratrol relaxed corpora cavernosa concentration-dependently in presence of 
glucose/MGO. Taken together, these results thus suggest a potential therapeutic role for 
both polyphenols, but especially for resveratrol, in the treatment of diabetes- and oxidative 
stress-associated ED. 
VI.5.6 Limitations 
As this study represents a strictly pharmacological in vitro approach, it is hard to extrapolate 
our results to in vivo circumstances. Although some studies already pointed out that 
polyphenols in vivo have positive effects on vascular [17] or erectile function [38, 40, 41], 
further research in this field is definitely required. Furthermore, in our study only the acute 
effect of glucose/MGO and resveratrol and quercetin administration could be evaluated. 
Further research will have to confirm whether a similar positive effect on erectile function 
can be obtained after chronic treatment.  
VI.6 Conclusions 
This study demonstrates that high glucose in combination with MGO impairs endothelium- 
and neurogenic-mediated relaxations in mouse corpora cavernosa and mesenteric arteries 
which is prevented by antioxidants. In arteries, these diabetic conditions primarily affect the 
EDHF-pathway, while in corpora cavernosa high glucose and MGO interfere with NO release. 
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Furthermore it was shown that resveratrol and quercetin are effective in preventing high 
glucose and MGO deficits of endothelium- and neurogenic-mediated relaxations of mouse 
corpora cavernosa. Therefore our study further strengthens the strategy of using 
polyphenols, especially resveratrol, as possible alternative option in the treatment of 
diabetic ED. 
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Chapter VII Inhibition of cyclic GMP export by multidrug resistance protein 4: 
a new strategy to treat erectile dysfunction? 
VII.1 Abstract 
BACKGROUND. Intracellular cGMP concentrations are regulated by degradation enzymes 
(phosphodiesterases, PDEs) as well as by active transport across the plasma membrane by 
multidrug resistance protein (MRP) 4 and 5. 
AIM. This study evaluated the functional effect of MRP 4 inhibition and the role of MRP 4-
mediated cGMP export in mouse corpora cavernosa. 
METHODS. Isometric tension of mouse corpora cavernosa was measured after cumulative 
addition of MK-571, an inhibitor of MRP 4, or sildenafil, a PDE-5 inhibitor (PDE5i). In addition 
the effect of MRP 4 inhibition on cGMP-(in)dependent relaxations was studied. In vivo 
intracavernosal pressure (ICP) and mean arterial pressure (MAP) measurements were 
performed after intracavernosal injection (i.c.) of MK-571. The effect of MRP 4 inhibition on 
cGMP content was determined using an enzyme immunoassay kit. 
OUTCOMES. Measurement of the effect of MK-571 on cGMP content and relaxant responses 
of mouse corpora cavernosa to cGMP-(in)dependent vasodilating substances and 
determination of ICP/MAP after i.c. injection of MK-571. 
RESULTS. MK-571 and sildenafil both relaxed the corpora cavernosa concentration 
dependently with sildenafil being the most potent relaxing compound. Furthermore, MK-571 
enhanced relaxing responses to cGMP-dependent substances, such as sodium nitroprusside, 
sildenafil, acetylcholine and electrical field stimulation, the latter ones even under in vitro 
diabetic conditions. In contrast cGMP-independent relaxations were not altered by MRP 4 
inhibition. Intracavernosal administration of MK-571 significantly increased ICP, with 
minimal effect on MAP. cGMP analysis revealed that MRP 4 inhibition was accompanied with 
increased cGMP levels. 
CLINICAL TRANSLATION. MRP 4, at least when targeted locally in the penis or when 
combined with PDE5i, might be a valuable alternative strategy for the treatment of (diabetic) 
ED.  
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STRENGTHS & LIMITATIONS. This study is the first to demonstrate an in vitro direct relaxant 
and an in vivo pro-erectile effect of the MRP 4 inhibitor, MK-571, on mouse corpora 
cavernosa. However the functional effect of MRP 5-mediated export in mouse corpora 
cavernosa was not explored, which is suggested to play the predominant role in cGMP 
export. 
CONCLUSION. Inhibition of MRP 4 increases basal and stimulated levels of cGMP leading to 
corpora cavernosa relaxation and penile erection. Therefore it is suggested that, in addition 
to degradation of cGMP, export of cGMP by MRP 4 substantially contributes to regulating 
the cGMP levels in mouse corpora cavernosa. 
Keywords cyclic GMP, multidrug resistance protein, corpora cavernosa, relaxation, erectile 
dysfunction 
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VII.2 Introduction 
The intracellular signaling molecule cyclic guanosine monophosphate (cGMP) plays an 
important role in several cardiovascular processes, including in vascular relaxation. 
Intracellular levels of cGMP are the result of the balance between the rate of cGMP 
synthesis and the rate of cGMP elimination. In penile tissue, elevation of cGMP levels and 
subsequent relaxation of vascular and corporal smooth muscle cells is a key event for normal 
penile erection [1]. Therefore, most currently available treatment strategies for erectile 
dysfunction (ED) are targeted to increase intracellular levels of cGMP. Many studies focused 
on how degradation of cGMP could be prevented by phosphodiesterase inhibitors (PDEi). 
Due to the success of this research PDE5i are nowadays first choice in the treatment of ED. 
However, in addition to metabolic degradation of cGMP by PDE-5, cGMP can also be actively 
transported across the plasma membrane by members of the multidrug resistance protein 
(MRP) family [2-7]. MRPs are transmembrane proteins that use the energy produced by 
adenosine triphosphate (ATP) hydrolysis to transport a variety of substrates out of the cell. 
Yet, in contrast to the huge amount of research conducted on cGMP degradation no studies 
previously evaluated cGMP export in penile tissues. Two MRP family members, MRP 4 and 
MRP 5, have been shown to transport cGMP [2-8]. MRP 4 and/or MRP 5 expression was 
found in several tissues including vascular smooth muscle cells, endothelial cells [9-11] and 
interestingly also in corporal smooth muscle cells [12, 13]. In mouse aortic rings MRP 4-
mediated cGMP export has been demonstrated as an important regulator of cGMP-
mediated vascular relaxant responses [8]. Hence, MRP 4-mediated cGMP export could play a 
role in corporal relaxant responses as well and prevention of cGMP-transport out of the 
cavernosal smooth muscle cells might represent a new and alternative approach to elevate 
intracellular cGMP levels and thus to treat erectile dysfunction.  
 
VII.3 Aim 
The aim of this study was to examine the functional effect of MRP 4 inhibition as well as the 
role of MRP 4-mediated cGMP export in mouse corpora cavernosa. 
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VII.4 Methods 
VII.4.1 Animals  
Adult (8-12 weeks) male Swiss mice were obtained from Janvier (Saint-Berthevin, France). 
Food and water was provided ad libitum and all animals were treated in accordance with the 
Guide for the Care and Use of Laboratory Animals published by the US National Institutes of 
Health. This study was approved by the local Ethical Committee for animal experiments, 
Faculty of Medicine and Health Sciences, Ghent University, Belgium. 
VII.4.2 In vitro tension measurements 
Tissue preparation 
After cervical dislocation, corpora cavernosa were carefully dissected free from surrounding 
structures and mounted in organ bath myograph systems for isometric tension 
measurements. Corpora cavernosa were mounted horizontally in the myograph with one 
end fixed to a transducer and the other to a micrometer. The organ baths were filled with 10 
mL Krebs-Ringer bicarbonate (KRB) solution at 37 °C (pH 7.4) equilibrated with 95 % O2–5 % 
CO2. The tissues were allowed to equilibrate for 30 minutes in KRB solution that was 
frequently replaced. The corpora cavernosa were gradually stretched during 60 minutes until 
a stable preload of 0.45 g was obtained. Subsequently, the corpora cavernosa were 
contracted two times with 5 µM phenylephrine (Phe) and when a stable precontraction was 
reached the tissues were washed and allowed to relax to the resting tension. Next, the 
functionality of the endothelium within the corporal strips was examined by precontracting 
the corpora cavernosa with 5 µM Phe and adding 1 µM acetylcholine (Ach). Preparations 
that were not able to relax minimally 50 % of the maximum tension were excluded from the 
study. Thereafter, the corpora cavernosa were washed once again. When reaching a stable 
resting tension the experimental protocol was started.  
Experimental protocol  
Cumulative concentration-response curves to the MRP 4 inhibitor, MK-571, (1 nM – 100 µM) 
or to the PDE5i, sildenafil (1 nM – 100 µM), were constructed in cavernosal strips 
precontracted with Phe (5 µM). Similarly, the effect of MK-571 (1 nM – 100 µM) was studied 
in presence of 1H-[1,2,4]oxadiazolo[4,3-a]quinoxalin-1-one (ODQ). 
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In other experiments various cGMP–(in)dependent vasodilating substances were added at a 
stable tension to analyze the relaxing responses of the corpora cavernosa. In some 
experiments electrical field stimulation (EFS; parameters: train duration 40 s; 1, 2, 4 and 8 
Hz; pulse duration 5 ms and 80 V), was applied to study neurogenic-mediated relaxations. 
After constructing the first response curve, the corpora cavernosa were washed out and 
allowed to recover for 20-30 minutes. Next MK-571 (10 µM, 10 min) was added and 
responses to cGMP-(in)dependent vasodilating substances or EFS were studied again. In 
order to obtain comparable precontraction levels between control conditions and MK-571, 
the precontractile tone of the control corporal strips was adjusted by adding 3 µM Phe 
instead of 5 µM Phe. 
VII.3 In vivo study 
Mice were anesthetized with ketamine (100 mg/kg) and xylazine (10 mg/kg) and placed on a 
heated blanket to maintain their body temperature at 37°C. A PE-10 tube filled with 
heparinized saline (25 U/mL) was inserted into the carotid artery and connected to a 
pressure transducer to monitor the mean arterial pressure (MAP). A 30-gauge needle 
attached to another PE-10 tube was introduced into the right corpus cavernosum and also 
connected to a pressure transducer to measure the intracavernosal pressure (ICP). The ICP 
response to MK-571 (0.1 – 1 mg/kg) was investigated through intracavernosal (i.c.) 
administration via a separate cannula (30-gauge needle attached to PE-10 tube) inserted 
into the left corpus cavernosum (standardized injection volume of 5 µL). Between each 
injected dose the cannula was flushed several times with heparinized saline to remover 
residual agent. 
VII.4 cGMP analysis 
Corpora cavernosa from Swiss mice were isolated and dissected as described for the in vitro 
tension measurements. Subsequently, corpora cavernosa were weighed to determine the 
tissue wet weight. Next the two corpora cavernosa of each mouse were placed for 10 
minutes in 10 mL KRB solution at 37°C, bubbled with 95 % O2–5 % CO2. Thereafter, the 
control corpora cavernosa were treated with 5 µM Phe for 20 minutes. Other corpora 
cavernosa were treated with 5 µM Phe for 10 minutes and then MK-571 (10 µM or 100 µM) 
was added. Exactly 20 minutes after adding Phe (controls) or 10 minutes after adding MK-
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571, the corpora cavernosa were snap frozen in liquid nitrogen and stored at -80°C until 
further processing. cGMP was extracted and quantified using an enzyme immunoassay kit 
(Cayman Chemical cyclic GMP EIA kit, Michigan, USA). The frozen corpora cavernosa were 
pulverized by a Mikro-Dismembrator U (B. Braun Biotech International, Germany), 
homogenized in 6 % trichloroacetic acid (TCA) and centrifuged at 2000 g for 15 min at 4°C to 
collect the supernatant. The supernatant was washed three times with water-saturated 
ether to extract the TCA after which it was dried under nitrogen at 60°C. Dried extracts were 
dissolved in a 10 times volume of the assay buffer. Then, samples, controls and standards 
were acetylated and were added to the enzyme immunoassay plate to incubate for 18h at 
4°C. Optical density was measured with a 96-well plate reader (Biotrak II, Amersham 
Biosciences) at 405 nm. The concentration of cGMP was expressed as pmol/g tissue wet 
weight. 
Drugs and chemicals 
The experiments were performed in a KRB solution of the following composition (mM): NaCl 
135, KCl 5, NaHCO3 20, glucose 10 (control) or 30 (high glucose), CaCl2 2.5, MgSO4 1.3, 
KH2PO4 1.2 and EDTA 0.026 in H2O. L-phenylephrine hydrochloride (Phe), acetylcholine 
chloride (Ach), sodium nitroprusside (SNP), sildenafil citrate and methylglyoxal solution 
(MGO)  were obtained from Sigma (St. Louis, MO, USA); MK-571, 1H-[1,2,4]oxadiazolo[4,3-
a]quinoxalin-1-one (ODQ), forskolin and pinacidil monohydrate from Enzo Life Sciences 
(Lausen, Switzerland) and trichloroacetic acid (TCA) from Merck (Darmstadt, Germany). 
Stock solutions were made in water except for forskolin and pinacidil (DMSO) and ODQ 
(ethanol). The final concentrations of vehicle solution in the organ bath never exceeded 0.1 
%. All concentrations are expressed as final molar concentration in the organ bath. 
Statistical analysis 
The data are presented as mean values ± S.E.M. Relaxations are expressed as % decrease in 
precontractile tone. N is the number of individual strips used, or in case of the cGMP analysis 
n represents the number of animals used. Sensitivity (pEC50) and maximum response (Emax) 
were calculated from the concentration-response curves to MK-571 or sildenafil. pEC50 was 
defined as the negative logarithm to base 10 of the EC50 values and Emax was defined as the 
maximal relaxation. The data in our study was analyzed using SPSS, version 22; IBM 
Corporation, Armonk, NY, USA. Statistical significance was evaluated using the Mann-
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Whitney U test or Wilcoxon test when appropriate. Two groups of data were considered 
significantly different when p<0.05. 
VII.5 Results 
VII.5.1 In vitro experiments 
Relaxant effect of MK-571 on isolated mouse corpora cavernosa  
MK-571 and sildenafil evoked concentration-dependent relaxations in corpora cavernosa 
from Swiss mice (Fig. VII.1A and VII.1B). However, sildenafil was significantly more 
efficacious compared to MK-571 (Emax in presence of sildenafil: 85.95 ± 4.09 % vs in presence 
of MK-571: 67.02 ± 4.69 %, p<0.05). In addition the potency of sildenafil to relax the corpora 
cavernosa was significantly higher compared to MK-571 (pEC50 of sildenafil: 6.18 ± 0.30 vs 
MK-571: 5.07 ± 0.10, p<0.05). 
 
 
 
Figure VII.1 Relaxant effect of (A) MK-571 and (B) sildenafil on precontracted (5 µM Phe) corpora cavernosa 
from Swiss mice versus time controls. Data are expressed as % decrease of Phe-induced tone; Mann-Whitney 
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U test; #p<0.01 and *p<0.05 (n=6). 
 
 
 
Involvement of the cGMP-pathway in the relaxant effect of MK-571  
To explore the involvement of the sGC/cGMP pathway in the relaxant effect of MK-571 on 
mouse corpora cavernosa, MK-571-induced relaxations were studied in presence of the sGC 
inhibitor ODQ (10 µM, 10 min). The presence of ODQ did not alter the relaxant effect of MK-
571 in mouse corpora cavernosa (Fig. VII.2).  
 
Figure VII.2 Relaxant effect of MK-571 on precontracted (5 µM Phe) corpora cavernosa from Swiss mice in 
absence and presence of ODQ (10 µM, 10 min). Data are expressed as % decrease of Phe-induced tone; 
Mann-Whitney U test; (n=6 ). 
 
 
Effect of MK-571 on cGMP-dependent and cGMP-independent responses 
The effect of MK-571 on cGMP-dependent, cAMP-dependent and K+ channel-mediated 
responses was studied using SNP, sildenafil, forskolin, an adenylate cyclase activator, and 
pinacidil, a KATP channel opener, respectively. SNP- and sildenafil-induced relaxations of the 
mouse corpora cavernosa were significantly enhanced by preincubating the tissues with MK-
571 (10 µM, 10 min) (Fig. VII.3A and VII.3B). In contrast, MK-571 (10 µM, 10 min) did not 
affect the relaxant responses of the corpora cavernosa to forskolin or pinacidil (Fig. VII.3C 
and VII.3D). 
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Figure VII.3 Relaxant effect of (A) SNP, (B) sildenafil, (C) forskolin and (D) pinacidil on Swiss corpora cavernosa 
before and after addition of MK-571 (10 µM, 10 min). In control conditions corpora cavernosa were 
precontracted with 3 µM Phe, while after addition of MK-571 precontraction was ensured by adding 5 µM Phe. 
Data are expressed as % decrease of Phe-induced tone; Wilcoxon test; #p<0.01 and *p<0.05 (n=6-8). 
 
 
Effect of MK-571 on normal and diabetic damaged erectile function 
Neurogenic- and endothelial-mediated responses of mouse corpora cavernosa were studied 
by constructing EFS- and Ach-curves respectively. EFS and Ach evoked frequency- and 
concentration-dependent relaxations, which were significantly stronger after MK-571 
treatment (10 µM, 10 min) (Fig. VII.4A and VII.4B). 2 h treatment of corpora cavernosa with 
high concentrations of glucose (HG, 30 mM) in combination with methylglyoxal (MGO, 120 
µM) mimics diabetic damage to neurogenic– and endothelium-mediated corporal responses 
[14]. MK-571 (10 µM, 2h) significantly enhanced corporal relaxant responses to EFS and Ach 
even in diabetic conditions (Fig. VII.4C and VII.4D). 
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Figure VII.4 Relaxant effect of (A) electrical field stimulation (EFS) and (B) Ach on Swiss corpora cavernosa 
before and after addition of MK-571 (10 µM, 10 min). Data are expressed as % decrease of Phe-induced tone; 
Wilcoxon test; *p<0.05 (n=6-7). Relaxant effect of (C) EFS and (D) Ach on Swiss corpora cavernosa after 2 hours 
co-incubation with high concentrations of glucose (HG, 30 mM) and methylglyoxal (MGO, 120 µM) in absence 
and presence of MK-571 (10 µM, 10 min). Data are expressed as % decrease of Phe-induced tone; Mann-
Whitney U test; #p<0.01 and *p<0.05 (n=5-6). (A-D) In control conditions corpora cavernosa were 
precontracted with 3 µM Phe, while after addition of MK-571 was ensured by adding 5 µM Phe. 
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VII.5.2 In vivo experiments 
Intracavernosal injection of increasing amounts of MK-571 significantly increased ICP and 
ICP/MAP while decreasing MAP only minimally (3.74 mmHg ± 1.02 at 1 mg/kg) (Fig. VII.5 and 
VII.6) 
 
 
Figure VII.5 The intracavernosal pressure/mean arterial pressure (ICP/MAP) ratio (in %) after intracavernosal 
administration of MK-571 in Swiss mice; Wilcoxon test; *p<0.05 (n=6). 
 
 
 
Figure VII.6 Original tracings showing the change in intracavernosal pressure (ICP) as well as mean arterial 
pressure (MAP) after intracavernosal (I.C.) administration of MK-571 (1 mg/kg) in Swiss mice. 
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VII.5.3 cGMP analysis 
MK-571 (100 µM) significantly increased basal cGMP levels of the mouse corpora cavernosa 
by approximately 4.5 fold (Fig. VII.7). MK-571 (10 µM) also increased the level of cGMP in 
the corpora cavernosa by approximately 1.8 fold, however due to high variation of the 
results, this increase did not significantly differ from controls (Fig. VII.7). 
 
Figure VII.7 cGMP levels in corpora cavernosa from Swiss mice in basal conditions (control) and when 
incubated with MK-571 (10 or 100 µM, 10 min) in corpora cavernosa from Swiss mice. Data represent the 
means ± S.E.M; Mann-Whitney U test; #p<0.01 (n=5 (control), n=4 (MK-571 10 µM) and n=6 (MK-571 100 
µM)). 
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VII.6 Discussion 
This study evaluated for the first time the functional effect of inhibiting MRP 4-mediated 
transport in mouse corpora cavernosa using MK-571. MK-571 relaxes mouse corpora 
cavernosa concentration dependently and induces erection by increasing basal intracellular 
cGMP levels. In addition, MRP 4 inhibition enhances cGMP-dependent relaxations in normal 
as well as under in vitro diabetic conditions. 
For some years MRP 4 and MRP 5 have been identified as export pumps for cGMP. Thus 
MRP 4 and MRP 5 contribute, along with PDEs, to the regulation of intracellular cGMP levels 
[2-8]. Interestingly, MRP 4 and MRP 5 are also expressed in the smooth muscle cells of 
human corpora cavernosa [12, 13]. Hence, both MRP 4 and MRP 5 might be relevant in 
mediating cGMP export in corpora cavernosa. As the affinity of MRP 5 for cGMP is higher (Km 
= 2.1 µM [5]) than that of MRP 4 (Km = 9.7 µM [4]), MRP 5 is suggested to play a 
predominant role in cGMP export [12]. In the present study MRP-mediated transport was 
inhibited using MK-571, a known leukotriene receptor antagonist and potent inhibitor of 
MRP 4- but not MRP 5-mediated cGMP transport [5, 15, 16]. Therefore the results obtained 
in this study can only be interpreted in relation to MRP 4-mediated cGMP export. 
This study demonstrates for the first time that MK-571 relaxes mouse corpora cavernosa 
concentration dependently albeit somewhat less potent than sildenafil. The in vitro relaxant 
effect of MK-571 could furthermore be demonstrated in vivo since i.c. administration of MK-
571 raised ICP with a minimal effect on MAP. These results suggest that MK-571, at least 
when applicated locally, might have potential in treating ED. 
Although a direct relaxant effect of MK-571 was not earlier described, MK-571 
administration has been shown to reverse pulmonary hypertension in mice [10]. The 
protective effect of MRP 4 inhibition was accompanied with increased cGMP levels [10]. Our 
measurement of intracellular cGMP content in the corpora cavernosa also revealed 
significantly higher cGMP levels in tissues treated with 100 µM MK-571 compared to 
controls. Although 10 µM MK-571 induced about 50 % relaxation of mouse corpora 
cavernosa, surprisingly the increase in cGMP levels was not significantly different from 
controls after incubating the corpora cavernosa with 10 µM MK-571. Since mouse corpora 
cavernosa are very tough to homogenize, cGMP levels are not easily determined in these 
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tissues. Hence, the high variation in our results and the lack of significance in cGMP between 
controls and tissues incubated with 10 µM MK-571. However overall (a trend of) increased 
cGMP levels could be observed in MK-571 treated tissues, indicating that MK-571 relaxes 
mouse corpora cavernosa by enhancing basal cGMP levels. The relaxant effect of MK-571 
was furthermore evaluated in presence of the sGC inhibitor, ODQ. As sGC catalyzes the 
conversion of guanosine triphosphate (GTP) to cGMP, pharmacological inactivation of sGC 
will hamper subsequent cGMP production. The presence of ODQ did however not diminish 
the relaxing effect of MK-571 on the corpora cavernosa. Therefore it might be thought that 
MK-571 relaxes the corpora cavernosa independently of cGMP, which would be in contrast 
with the cGMP measurements. Yet, the results with ODQ should be interpreted more 
carefully. Although the use of ODQ inhibits cGMP production, some basal levels of cGMP are 
still maintained [17]. Export or degradation of basal cGMP levels is thus unaffected by 
pharmacological inhibition of sGC. Like MK-571, others reported that the relaxant effect of 
PDE5i under basal conditions in corpora cavernosa from different animals was not or only 
partially affected by ODQ treatment [18-20]. Moreover it has been shown that ODQ is an 
incomplete inhibitor of sGC as it does not fully inhibit aortic relaxation to a NO-donor when 
compared to aorta from sGC knockout mice [23]. Hence, as suggested by Lies et al. [21], the 
lack of effect of ODQ does not exclude the involvement of the cGMP-pathway. Therefore 
even when sGC activation is inhibited, MK-571 could still increase intracellular cGMP by 
preventing export of basal cGMP levels and thus relax mouse corpora cavernosa. 
Our study is the first to demonstrate an in vitro direct relaxant and an in vivo pro-erectile 
effect of MK-571 on mouse corpora cavernosa, however a hint that MRP 4 inhibition might 
be of great importance in the (vascular) relaxation process was provided by the experiments 
recently reported by Krawutschke et al. [8]. They demonstrated that MRP 4 inhibition by 
MK-571 significantly enhanced relaxations of aortic rings induced by the NO-donor S-nitroso-
L-glutathione (GS-NO). This effect was roughly comparable with that of PDE-5 inhibition. In 
line with Krawutschke et al. [8], MRP 4 inhibition significantly enhanced SNP responses to a 
comparable degree as PDE-5 inhibition (own unpublished results). Interestingly, MK-571 had 
a small, but significant, potentiating effect on sildenafil-induced relaxations. This observation 
suggest a great potential for MK-571 as combination therapy with sildenafil for the 
treatment of ED. Combination therapy of MK-571 with sildenafil might therefore improve 
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the efficacy of sildenafil in vivo. Moreover, since MRP 4 is widely distributed throughout the 
body [3], MRP 4 inhibition could evoke unwanted systemic side effects. Therefore, coupling 
MK-571 to a PDE5i might offer an elegant way to specifically target the corpora cavernosa in 
order to surpass these side effects.  
To explore whether the enhancing relaxant effect of MK-571 was specific to cGMP-
dependent relaxations, various other relaxing substances were tested. It has been reported 
that MRP 4 is able to export cAMP besides cGMP [2-5, 7, 10, 11, 22]. However pretreating 
the corpora cavernosa with MK-571 did not improve forskolin-induced relaxations. As MRP 4 
has a greater affinity for cGMP than for cAMP [5] this lack of effect is however not surprising. 
To further evaluate the cGMP-specificity of MK-571’s enhancing relaxant effect, the effect of 
MRP 4 inhibition was tested on KATP-mediated relaxations, using pinacidil. As no effect of 
MK-571 was observed on pinacidil-induced relaxations, these results indicate that in mouse 
corpora cavernosa MRP 4 inhibition seems to be specific for cGMP-mediated effects. 
Next, we wondered whether the positive effect of MRP 4 inhibition on cGMP-mediated 
responses, would still occur in pathologic conditions such as diabetes, a disease frequently 
associated with ED [23, 24]. Previously we demonstrated that diabetic damage to EFS- and 
Ach-mediated responses in mouse corpora cavernosa could be mimicked in vitro by 
incubating the corpora cavernosa for 2 h with high concentrations of glucose in combination 
with MGO [14]. Both in normal as well as under in vitro diabetic conditions MK-571 
significantly enhanced EFS- and Ach-mediated relaxations. This observation makes MRP 4-
mediated cGMP export a potential interesting target for the treatment of diabetic ED.  
As no specific inhibitor for the other MRP subtypes is available, this study could only 
investigate the effect of MRP 4 inhibition, which might play a minor role in cGMP export in 
corpora cavernosa [12]. It should be noticed that in hepatocytes oxidative stress induces 
MRP 4 expression [25]. Moreover, higher MRP 4 mRNA and protein levels were found in 
proliferative human coronary smooth muscle cells in vitro, compared to quiescent smooth 
muscle cells [11]. Similarly, MRP 4 was upregulated in pulmonary arteries from patients with 
idiopathic pulmonary arterial hypertension as well as in mice exposed to hypoxic conditions 
[10]. These studies indicate that MRP 4 expression in smooth muscle cells is increased under 
pathologic conditions. Hence the pronounced positive effects of MRP 4 inhibition on the 
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functioning of mouse corpora cavernosa seen in this study, might even be greater in in vivo 
pathological conditions associated with ED. 
VII.7 Conclusion 
This study demonstrated that in mouse corpora cavernosa two distinct pathways exist to 
regulate intracellular cGMP levels: (i) cGMP degradation and (ii) cGMP export. Although it 
has been suggested that MRP 4 plays a minor role in cGMP export [12], inhibition of MRP 4 
potently relaxed mouse corpora cavernosa and enhanced cGMP-dependent relaxations 
especially in diabetic conditions. Moreover MRP 4 inhibition elicited a pro-erectile effect in 
vivo. These results suggest that MRP 4, at least when targeted locally in the penis or when 
combined with a PDE5i, might be a valuable alternative strategy for the treatment of 
(diabetic) ED.  
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Chapter VIII Discussion and future perspectives 
VIII.1 Modulation of vascular tone by perivascular adipose tissue 
Blood flow to the organs and tissues is continuously adapted depending on their metabolic 
and functional needs. By changing the tone of the vascular smooth muscle cells, blood 
vessels alter their diameter and as a consequence blood flow to the organs and tissues is 
regulated. The regulation of blood flow has always been an important research topic, 
however the focus of vascular research has changed over the years. The earliest functional 
studies analyzed the effects of agents on vascular smooth muscle tone and identified 
receptor subtypes. With the discovery in the 1980s of nitric oxide (NO) as an endothelium-
derived relaxing factor (EDRF) and its crucial role for normal vascular function, vascular 
research was reoriented. From then on it became clear that the endothelium is an important 
paracrine tissue that controls the homeostasis of the underlying vascular smooth muscle 
cells by producing and releasing several substances that control vascular tone [1]. Nowadays 
endothelial dysfunction is considered as a pivotal factor in the pathogenesis of several 
vascular diseases such as hypertension, atherosclerosis and erectile dysfunction which are 
often associated with obesity and diabetes [2-5]. The past decades, besides the endothelium 
and the nerve endings, perivascular adipose tissue gained attention as neighboring tissue 
that can control vascular smooth muscle tone through the release of vasoactive factors 
(adipo(cyto)kines). It has been shown that PVAT exerts a vasorelaxing (‘anticontractile’) 
effect due to the release of the ‘adipocyte-derived relaxing factor(s)’ (ADRF(s)) [6-10]. 
Dysfunctional PVAT (i.e. dysregulated adipocytokine release and structural changes in 
adipose tissue mass) has been observed in various disease states such as obesity and 
hypertension [11-15]. As a consequence besides the endothelium, PVAT is now considered 
as an important contributor for the development of obesity-related vascular complications 
[16-19]. Thus, interference with or prevention of adipose tissue dysfunction might offer a 
therapeutic option to treat or alleviate vascular complications as seen in for instance obese 
patients. 
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VIII.1.1 Can the relaxing influence of PVAT be positively or negatively modulated by 
resveratrol treatment and/or testosterone depletion? 
Previously we have shown that acute hypoxia enhances the anticontractile effect of PVAT 
surrounding mouse aorta [20]. Since the relaxing influence of PVAT can be altered under 
acute hypoxia, our interest was driven to seek other circumstances that may modify the 
relaxing effect of PVAT. As both resveratrol and testosterone are known to influence adipose 
tissue function, the first part of this project studied the vasorelaxing effect of PVAT and 
evaluated whether this effect could be modulated by resveratrol or orchidectomy. First of all 
our study confirmed the importance of PVAT as paracrine regulator of vascular tone. The 
presence of PVAT clearly attenuated the contractile responses of the aortic segments to 
norepinephrine (NOR), confirming the beneficial anticontractile (vasorelaxing) effect of PVAT 
under physiological circumstances [6-10]. Moreover this anticontractile effect was 
independent of NO and cyclooxygenase (COX), suggesting potential involvement of ADRF(s) 
as indicated in literature [8]. Next we assessed the influence of acute addition of resveratrol 
on the vasorelaxing effect of PVAT. Resveratrol is a naturally occurring polyphenol found in 
the skin of grapes and thus highly abundant in red wine. For some years resveratrol has been 
broadly studied and diverse physiological actions have been ascribed including antioxidant, 
anti-inflammatory and anti-carcinogenic effects [21, 22]. In addition resveratrol was shown 
to exert anti-obesity effects through mechanisms involving down-regulation of adipogenesis 
and inflammatory processes [23]. Moreover resveratrol has been demonstrated to mimic 
the positive effects of calorie restriction in obese humans. These include improvement of 
insulin resistance, decreased levels of blood glucose, triglycerides and cytokines as well as 
decreased intrahepatic lipid content, and decreased systolic blood pressure [24, 25]. 
Furthermore several in vitro studies indicated that resveratrol alters the adipocytokine 
secretion profile of adipocytes towards a less inflamed one [24, 26-32]. Therefore it could be 
expected that resveratrol potentiates the vasorelaxing influence of PVAT. However, since in 
our study no enhanced ‘anticontractile’ effect of PVAT could be observed in the presence of 
resveratrol, our results could not confirm the beneficial potential of resveratrol addition on 
adipose tissue functioning as suggested by others. Instead, a lower anticontractile effect of 
PVAT was seen in the presence of resveratrol. In addition the beneficial relaxing effect of 
resveratrol was lost in presence of PVAT. These effects could be explained by a probably dual 
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action of resveratrol: (i) a direct relaxant effect and (ii) an attenuation of vasodilatory 
adipo(cyto)kine production or secretion.  
However, despite our ‘negative’ results concerning resveratrol addition, the results of this 
study do not allow us to draw firm conclusions with respect to resveratrol as potential 
therapeutic option in case of dysfunctional adipose tissue and subsequent vascular diseases. 
Several factors hamper addressing this question and should therefore be kept in mind.  
First, experiments described in chapter IV were performed in normal, healthy conditions. As 
such, no dysfunctional PVAT was present that could be counteracted by resveratrol 
treatment. This could be important since resveratrol has been shown to alter 
adipo(cyto)kine secretion only in dysfunctional adipose tissue [24, 26-32]. In search of a 
method to render PVAT dysfunctional, we focused on the effect of orchidectomy on PVAT 
functioning since low levels of testosterone increase the risk of obesity, cardiovascular 
diseases, and even mortality in men [33, 34] through the increase of body adipose tissue 
mass deposition [35, 36]. In addition, testosterone depletion increases vasoreactivity of the 
arteries [37] and testosterone is thought to influence adipocytokine secretion [38-40]. 
Considering these facts, it was expected that testosterone depletion, using orchidectomy, 
would affect the normal functioning of PVAT leading to a decreased vasorelaxing effect of 
PVAT. Despite the orchidectomy that was successfully performed (indicated by atrophy of 
seminal vesicles), 4 weeks of testosterone depletion surprisingly did not alter the 
anticontractile effect of PVAT surrounding mouse aorta. The failure of orchidectomy to alter 
PVAT functioning in our experiments might be explained by a second point that needs to be 
kept in mind when investigating the paracrine role of PVAT, namely the vascular bed. 
Vascular beds are surrounded by PVAT that varies with anatomical location and which can 
be characterized either as white adipose tissue (WAT) or brown adipose tissue (BAT). While 
both types of PVAT share functions common with adipose tissue, such as the paracrine 
effects, some specific differences are present. For example, thoracic PVAT is distinct from 
mesenteric PVAT, as thoracic PVAT resembles BAT. All of the experiments described to 
evaluate the effect of resveratrol and orchidectomy on the vasorelaxing effect of PVAT, were 
performed on segments from the thoracic aorta, which is known to be surrounded by BAT 
[41]. However, unlike white PVAT, surrounding mesenteric arteries [6, 42], brown PVAT 
appears to be resistant to dysregulated adipocyte biology of obesity and subsequent 
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inflammation [43]. This surprising regional difference in susceptibility to adipose tissue 
dysfunction is an interesting field for future research since it is currently unclear whether 
there are any differences regarding the paracrine (pro- or anti-contractile) effects between 
thoracic brown PVAT and mesenteric white PVAT, both under normal as well as under 
pathological conditions.  
Since white PVAT surrounding mesenteric arteries, might be a more accurate model to 
investigate adipose tissue dysfunction as seen in obesity, a first attempt was made to 
explore whether the functional properties of PVAT vary among vascular beds with distinct 
PVAT types. Therefore additional experiments were set-up in which mouse mesenteric 
arteries with and without PVAT were investigated. In line with others [10, 44, 45], the 
presence of PVAT attenuated the contractile responses of mesenteric arteries to 
phenylephrine (PHE), indicating that the anticontractile effect of PVAT exists even in 
mesenteric arteries (Figure IX.1 in supplementary data). Next, several attempts were made 
to create an in vitro model for dysfunctional adipose tissue surrounding mesenteric arteries. 
Since oxidative stress has been found to underlie the functional changes in adipose tissue 
during obesity [12, 44-47], different protocols were used that are known to induce oxidative 
stress. Treating the mesenteric arteries with and without PVAT with palmitic acid (PA) or 
high concentration of glucose in combination with methylglyoxal both resulted in a loss of 
anticontractile effect of PVAT surrounding the mesenteric arteries. Unfortunately these 
promising results could no longer be reproduced systematically due to unexplained 
problems. As a consequence we were not able to investigate the effect of acute resveratrol 
addition on the functioning of PVAT surrounding mesenteric arteries under obese-like 
circumstances. The development of a solid in vitro method for adipose tissue dysfunction 
would therefore be of great value. It was reported that the anticontractile effect of PVAT in 
rat mesenteric arteries was lost after chronic experimental hypoxia [44, 48]. Therefore 
chronic hypoxia induction might offer an option to induce adipose dysfunction in our 
experimental set-up as well. These experiments along with future research should help to 
clarify whether the different PVAT depots (brown vs white) affect the overall paracrine 
effect of PVAT in normal as well as under pathological conditions. 
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Taken together, our first study suggests that acute resveratrol addition attenuates the 
vasorelaxing effect of PVAT. In contrast our results could not provide evidence for a 
modulatory role for orchidectomy on the functioning of PVAT. 
VIII.2 New strategies to treat erectile dysfunction 
The importance of the NO/cGMP as a key pathway for normal penile erection is well 
established [49]. Dysfunction of the NO/cGMP signaling pathway is believed to contribute to 
erectile dysfunction (ED) [49]. Currently different treatment options for ED are available, 
PDE- 5 inhibitors such as sildenafil, vardenafil and tadalafil being the first choice [50]. These 
PDE-5 inhibitors prevent the normal hydrolysis of cGMP by PDE5 and thereby cGMP 
accumulation is promoted, which facilitates penile smooth muscle relaxation. Therefore, 
PDE-5 inhibitors can reverse, to a certain degree, deficiencies in the NO/cGMP pathway. 
PDE-5 inhibitors have a known clinical efficacy in the treatment of ED with various etiologies 
and a broad range of severity [51-53]. However, the limitation in the efficacy of these agents 
is that a minimum or 'critical amount' of NO is necessary for these drugs to work. Nerves 
that are severely damaged will not be able the synthesize NO. In addition in conditions such 
as diabetes mellitus or in case of severe vascular disease, there is a decreased expression or 
activity of neuronal nitric oxide synthase (nNOS) or endothelial nitric oxide synthase (eNOS), 
impaired NO release, or (reactive oxygen species (ROS)-induced) decreased bioavailability of 
NO which all hamper the production of sufficient amounts of cGMP [54]. If these alterations 
are severe, they cannot be compensated by PDE 5 inhibition. As a result 30-35 % of the 
patients suffering from ED fail to respond to PDE-5 inhibitors [54, 55]. Therefore the search 
for new and better alternatives is necessary and ongoing. Therapeutic strategies favoring NO 
synthesis, release or bioavailability may improve erectile function or at least enhance the 
efficacy of PDE-5 inhibitors when applied in combination. 
VIII.2.1 Do resveratrol and/or quercetin exert positive effects on corpora cavernosa? How do 
they work? 
The first candidates that we studied as potential new therapeutic option to treat ED, were 
the red wine polyphenols, resveratrol and quercetin. Both polyphenols are widely 
distributed in various plants, vegetables and fruit and are known for a variety of biological 
effects including anti-cancer, anti-inflammatory, and vascular protective effects such as a 
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vasodilatory and an antioxidant capacity [21, 22, 56, 57]. Therefore these compounds could 
also be of value for treating erectile dysfunction, however the effect of resveratrol or 
quercetin on erectile (dys)function is poorly understood. Thus the second and third study of 
this project evaluated whether resveratrol quercetin could also exert their beneficial 
vascular and antioxidant effects in erectile tissue. Our study showed that resveratrol, but not 
quercetin, relaxed mouse corpora cavernosa. Although we could not demonstrate a direct 
relaxant effect of quercetin on mouse corpora cavernosa, others found that quercetin was 
able to relax isolated human corpora cavernosa [58]. Several mechanisms have been 
proposed by which resveratrol relaxes arteries or corpora cavernosa from different species. 
These include both endothelium (NO/cGMP)-dependent and endothelium-independent 
mechanisms [59-64]. However in our study the involvement of NO in the relaxant effect of 
resveratrol on mouse corpora cavernosa could not be confirmed since treatment with the 
NOS inhibitor, L-NAME, did not decrease the relaxant effect of resveratrol on the corpora 
cavernosa. Moreover the contribution of cGMP in resveratrol’s relaxant effect on mouse 
corpora cavernosa was further evaluated by focusing on soluble guanylyl cyclase (sGC), the 
enzyme that generates cGMP. Pharmacological inhibition of sGC using ODQ, did however 
not decrease the relaxant effect of resveratrol in mouse corpora cavernosa. In addition the 
role of sGC/cGMP in resveratrol-induced relaxations was determined more accurately using 
genetically modified mice. Despite the existence of two isoforms for each subunit of sGC, 
only the sGCα1β1 and sGCα2β1 heterodimers are catalytically active and found in vivo [65]. A 
deletion in the catalytic domain of the α1 subunit selectively inactivates the sGCα1β1 isoform 
[66]. Even in the corpora cavernosa from these sGCα1
-/- mice, resveratrol induced 
concentration-dependent relaxations similar to those in the wild-type control mice. 
Although sGCα1β1 is the predominant form in most tissues, including in the vascular and 
penile smooth muscle cells, residual activity of the sGCα2β1 isoform should not be 
underestimated [67]. Hence, genetically modified knock-in mice (sGCβ1
ki/ki) were developed 
in which mutation of the histidine 105 residue of sGCβ1 to phenylalanine results in the 
expression of heme-free NO-insensitive sGC which affects both heterodimeric isoforms [68]. 
The results of the resveratrol-induced relaxations in these sGCβ1
ki/ki mice are presented in a 
supplementary figure (Figure IX.2). However, no involvement of the sGCα2β1 isoform could 
be observed. Taken together, all these results indicate that the relaxant effect of resveratrol 
on mouse corpora cavernosa occurs independently of NO/sGC/cGMP.  
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This conclusion is somehow surprising since the limited research on the effect of resveratrol 
on corporal tissue has provided evidence that resveratrol can elevate cGMP levels in corpora 
cavernosa smooth muscle cells through a NO-dependent pathway [69]. In addition, it has 
been reported that resveratrol normalizes the impaired endothelium-dependent relaxations 
of corpora cavernosa from hypercholesterolemic rabbits [70, 71]. Why our data show no 
involvement of the NO/cGMP pathway in corporal relaxation to resveratrol in mice, while 
other studies have clearly demonstrated the contribution of this pathway in the protective 
effect of resveratrol on corporal tissue could have several reasons. First, species differences 
could be an explanation. Second, our study focused on the acute effect of resveratrol on 
corpora cavernosa from ‘healthy’ mice, whereas the improvement of endothelium-
dependent relaxations by resveratrol was observed in ‘sick’ animals as rabbits were 
hypercholesterolemic [70, 71]. Therefore it is possible that in resting conditions resveratrol 
does not induce corporal relaxations through activation of the NO/cGMP pathway or that in 
resting conditions this pathway and downstream effector mechanisms are not direct targets 
for the acute effects of resveratrol.  
Next, several attempts were made to elucidate the exact underlying mechanism of 
resveratrol’s relaxant effect in mouse corpora cavernosa. In addition to activation of the NO-
pathway, multiple modes of action have been identified for resveratrol. Unfortunately the 
use of several inhibitors of different potential molecular targets of resveratrol failed to prove 
the involvement of K+ channels, COX metabolites, heme oxygenase, adenosine receptors, 
the cAMP pathway or adenosine monophosphate-activated protein kinase (AMPK). The 
results investigating the involvement of AMPK in the relaxant effect of resveratrol on mouse 
corpora cavernosa are represented in Figure IX.3. Recently a study demonstrated that the 
resveratrol-induced relaxations in mouse corpora cavernosa is partly dependent on H2S 
formation and acts independent of eNOS pathway [72]. However only a small part of the 
relaxant effect of resveratrol seemed to be mediated by H2S, suggesting that (an)other 
mechanism(s) must be involved as well. It thus seems that the exact mechanism(s) by which 
resveratrol relaxes corpora cavernosa is hard to characterize. The pleiotropic actions of 
resveratrol and its potential to activate distinct pathways, might explain why the relaxant 
effect of resveratrol on the corpora cavernosa could never be completely abolished. Maybe 
a cocktail of several inhibitors of different molecular pathways should be used.  
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Overall this study found a positive relaxant effect of resveratrol, but not quercetin, on 
mouse corpora cavernosa. However as yet the underlying mechanism remains elusive. 
VIII.2.2 Do resveratrol and/or quercetin exert positive effects on corpora cavernosa under in 
vitro-diabetic conditions? 
In a next step, we wanted to evaluate the effect of the red wine polyphenols on the 
contractility of the corpora cavernosa and arteries in conditions that are known to be 
associated with vascular and/or erectile dysfunction. Several reports already indicated that 
in diabetic or hypercholesterolemic animals resveratrol and quercetin restore impaired 
endothelium-dependent relaxations of different arteries and/or corpora cavernosa [70, 71, 
73-76]. There is growing evidence demonstrating the role of oxidative stress in the 
pathophysiological mechanism of several vascular diseases including erectile dysfunction 
[54]. Hence, several protocols were set-up to create an oxidative stress-like environment in 
order to evaluate the potential positive effects of resveratrol and quercetin on the arteries 
and corpora cavernosa from mice in diseased conditions.  
The first series of experiments were performed using palmitic acid, which is one of the most 
abundant saturated fatty acids in plasma. In addition, saturated fatty acids are found in 
elevated concentrations in obesity/diabetes [77]. It is well-documented that high levels of 
free fatty acid (FFA), including PA, cause oxidative stress [78-82] which is thought to underlie 
the impairment of endothelium-mediated relaxations after PA incubation [83, 84]. In our 
study PA significantly attenuated neurogenic mediated relaxations which might reflect the 
oxidative stress-induced damage. Of the polyphenols, only resveratrol was able to prevent 
PA-induced neurogenic damage. However, due to the small size of the corpora cavernosa, 
we were not able to perform direct oxidative stress measurement, therefore no clear 
conclusions could be made concerning the antioxidant capacity of resveratrol in this set-up. 
In addition, if PA induced oxidative stress, than it could be expected that the endothelium 
would be primarily affected considering its crucial role for normal vascular/corporal 
functioning. However in this study PA did not induce endothelial damage since endothelium-
mediated relaxations were not reduced. Moreover, the small restoring effect of tempol, a 
known antioxidant, and quercetin, which is thought to be a more potent antioxidant than 
resveratrol [85, 86], suggests that oxidative stress does not completely explain the PA-
induced damage in our experimental set-up. Therefore another process must be involved as 
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well. Recently it has been suggested that in neuronal cells, PA inhibits normal autophagy 
[87], an important cellular process that removes damaged organelles or cellular constituents 
and provides energy under starvation conditions or repairs damage under stressed 
conditions. Interestingly resveratrol was shown to promote autophagy [88, 89] and thus this 
might explain why resveratrol protected the corpora cavernosa from PA-induced damage to 
the electrical field stimulation (EFS)-mediated relaxations. 
Since PA damaged the contractility of the corpora cavernosa only to a minimal extent, a 
more effective way to mimick oxidative stress-like damage was sought. Therefore diabetic 
conditions were mimicked in vitro using the combination of high glucose and methyglyoxal 
(MGO), since both compounds are found in high concentrations in the plasma of diabetic 
patients. Moreover, both hyperglycemia and increased levels of MGO are thought to 
contribute to the development of the vascular complications seen in diabetes [90]. Our data 
with glucose/MGO indeed indicated that these acute diabetic conditions affect the 
endothelial and neurogenic mediated-relaxant responses of small arteries and the corpora 
cavernosa. In vivo this could eventually be translated into microvascular damage and erectile 
dysfunction. Tempol, ascorbic acid, resveratrol and quercetin were able to prevent 
glucose/MGO-induced damage to the corpora cavernosa. Whereas only tempol and ascorbic 
acid prevented the diabetic damage in the mesenteric arteries. It was suggested that the 
degree of oxidative stress in the mesenteric arteries might be too high for both polyphenols 
to counteract, leading to their inability to protect these arteries from in vitro diabetic–
induced damage. 
In summary, in addition to a positive relaxant effect of resveratrol on mouse corpora 
cavernosa, the studies using PA and glucose/MGO revealed that both resveratrol and 
quercetin are able to protect mouse corpora cavernosa from obesity or diabetes-like 
damage to neurogenic and/or endothelium-mediated relaxant responses. These in vitro 
results suggest a potential role of both polyphenols for improving erectile function in 
diseased conditions. However, the study using glucose/MGO, investigated the effect of acute 
diabetes induction and acute polyphenol treatment in vitro and therefore the results cannot 
be simply extrapolated to chronic treatment or to an in vivo situation. Future experiments 
should confirm whether the same positive effects of resveratrol and quercetin in vitro also 
occur in vivo using for instance diabetic-induced mice. Until now we were unable to 
Chapter VIII 
Discussion and future perspectives 
174 
 
establish a stable in vivo-model for diabetes and thus to study these compound in an in vivo 
set-up. However, some reports already demonstrated that chronic treatment of diabetic or 
hypercholesterolemic animals with resveratrol and quercetin alone or in combination with 
PDE-5 inhibitors significantly improved erectile function [69, 91-93]. Since we and others 
investigated the ability of resveratrol and quercetin to prevent diabetic-induced impairment 
of erectile function, the question still remains whether these polyphenols could be useful as 
therapeutic option for ED. This should be addressed in future experiments studying the 
effects of resveratrol and quercetin once erectile dysfunction is already established.  
Moreover, we and others demonstrated the positive effects of resveratrol and quercetin in 
the cardiovascular system using preclinical studies. The next logical step would be to 
determine whether the observed beneficial effects are transferable to humans. However, 
evidence regarding the safety, optimal dosage and positive effects of polyphenols in humans 
is rather scarce. Only few studies demonstrated the cardioprotective activity of resveratrol 
and quercetin in humans through effects related to the improvement of inflammatory 
markers, glucose metabolism, endothelial function and the ability the lower blood pressure 
[94, 95]. As mentioned in the introduction, the therapeutic usage of resveratrol and 
quercetin is somewhat hampered by their low bioavailability. Therefore future research 
should focus on methods that are able to increase the bioavailability, delay the metabolism 
of the polyphenols or target their delivery. Currently, self-nano-emulsifying drug delivery 
systems (SNEDDS) and liposome- or nanotechnology based resveratrol/quercetin 
formulations are being developed to improve aqueous solubility and stability and to enhance 
targetability and the rate and extent of absorption of the polyphenols [96-100]. In addition 
both compounds could be used as blueprints to design and synthesize novel more potent 
drugs. For example, a newly developed resveratrol analog, HS-1793, does not contain the 
unstable double bond found in resveratrol and the positions of two of the three hydroxyl 
groups in the aromatic ring of HS-1793 are also different. It is found that HS-1793 is 
metabolically more stable and exerts cardioprotective effects [101]. Furthermore, since 
metabolites of resveratrol and quercetin were found to exert some biological effects as well 
[102-107], it would be interesting and physiologically more relevant to study the effects of 
resveratrol and quercetin glucuronides and sulfates on erectile function.  
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VIII.2.3 Does inhibition of cGMP export elicit positive relaxant responses in mouse corpora 
cavernosa? 
It is a well-established fact that increasing cGMP is a cardinal event for normal penile 
erection. Therefore current therapies to treat ED are often targeted towards increasing 
these cGMP levels. Indeed, PDE-5 inhibitors, which inhibit cGMP degradation, represent an 
effective way to overcome ED. However, as previously mentioned, the urge for alternatives 
is necessary. In search for new therapeutic options to treat ED, the last part of this project 
focused on how cGMP levels could be increased in corpora cavernosa by inhibiting multidrug 
resistance protein (MRP)-mediated cGMP export. Recently it has become clear that in 
addition to degradation by PDE, export of cGMP out of the smooth muscle cells by MRP 4 
and MRP 5 also determines the intracellular levels of cGMP [108-114]. Since both MRP 4 and 
MRP 5 expression were found in corporal smooth muscle cells [115, 116], they might 
represent an alternative way to increase cGMP content and thus to treat ED. Due to the lack 
of specific inhibitors for the different subtypes of MRPs we could only investigate the effect 
of MRP 4 inhibition using the leukotriene receptor inhibitor MK-571. Although MK-571 is a 
known leukotriene receptor inhibitor, several studies indicated that MK-571 potently inhibits 
MRP 4 mediated transport as well [117, 118]. MRP 4 has previously been reported as a 
potential target for therapeutic intervention of pulmonary arterial hypertension [119] and 
other cardiovascular diseases [120]. In addition the importance of cGMP export in the 
regulation of vascular relaxation was recently illustrated [112], suggesting that MRP 4 
inhibition could be of value in corporal relaxant responses as well. However the functional 
effect of MRP 4 inhibition and the cGMP-dependency of this effect in corpora cavernosa was 
never explored. The results in our study on cGMP export, indeed showed for the first time 
that MK-571 potently relaxed corpora cavernosa through an increase of basal cGMP levels. 
This effect was less pronounced to that of sildenafil, suggesting the existence of both a 
degradation and a cGMP export pathway in the corpora cavernosa. Moreover, MK-571 
enhanced cGMP-mediated relaxations even in diabetic mimicking conditions, suggesting that 
MRP 4 might be a valuable alternative target for treating (diabetic-related) ED. Although this 
study identified positive effects of MRP 4 inhibition on isolated cavernosal tissue, it is hard to 
extrapolate these in vitro findings to normal physiologic response of intact erectile tissue 
considering the absence of arterial flow, venous outflow, autonomic innervation and other 
homeostatic factors that might interfere with the cavernosal tone. As the in vivo 
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experiments performed in this study already revealed that intracavernosal administration of 
MK-571 exerts pro-erectile effects, future in vivo experiments evaluating for instance oral 
administration should confirm the overall in vivo relevance of MRP 4 inhibition on erectile 
function in normal as well as in pathological conditions.  
VIII.2.4 General future considerations 
Based on our in vitro work, resveratrol, quercetin and MRP 4 inhibition are suggested to be 
useful for improving erectile function. So what concentration should be obtained in man to 
benefit from these positive effects? Several aspects hamper to answer this question. First, 
extrapolating the in vitro concentrations of for instance resveratrol used in this study that 
yielded beneficial effects on the erectile tissue (ranging from 10 – 100 µM) would mean that 
plasma concentration in man should reach about 2 250 – 22 500 ng/mL. As previously 
mentioned, due to the low bioavailability, these concentrations are however far above 
achievable considering that plasma levels of unchanged resveratrol only peaked to 539 
ng/mL (or 2.4 µM) after oral intake of 5 g of resveratrol. However due to possible species 
differences, the in vitro concentrations used in mouse tissues cannot be extrapolated as 
such to humans. Confirmation of the positive results of resveratrol, quercetin and MRP 4 
inhibition found on mouse erectile tissues, is therefore necessary in human tissue. Second, in 
vitro concentrations of compounds needed to cause a direct relaxant effect in corpora 
cavernosa might be higher than their concentrations needed to exert an in vivo effect. For 
instance free plasma concentrations in man peak at 300 ng/mL, 400 ng/mL and 20 ng/mL 
after a single oral dose of sildenafil (100 mg), tadalafil (20 mg) and vardenafil (20 mg) 
respectively [121]. These concentrations are notably lower than the concentrations of these 
PDE-5 inhibitors causing direct relaxation of corpora cavernosa in vitro [122]. Thus, taken 
together although our studies could clearly indicate positive effects of resveratrol, quercetin 
and MRP 4 inhibition on the corpora cavernosa, in order to consider these compounds as 
potential therapeutic option to treat erectile dysfunction and to determine their effective 
dose, confirmation of these in vitro results is necessary in (i) human tissue and (ii) in vivo.  
Resveratrol, quercetin and MRP4 inhibition showed positive effects on the erectile tissue, 
however, a major limitation of basically any compound that is under consideration as 
alternative for treating ED, is the unwanted systemic (side)effects. Indeed the perfect 
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therapy for treating ED is one that is specifically targeted towards the corpora cavernosa, 
not causing systemic (adverse) effects. At present such a compound is still an illusion. Even 
though the first-line therapy for ED, PDE-5 inhibitors, are widely used and have shown their 
efficacy in treating ED, there are several well-documented adverse effects associated with 
their use such as headache, facial flushing, nasal congestion, and dyspepsia [123]. These side 
effects are a result of their systemic dispersal following ingestion, and the target enzyme 
(PDE-5) being expressed in a variety of other tissues besides the corpora. Similarly the 
relaxant effect of resveratrol, quercetin and MK-571, that were studied in this thesis, was 
not restricted to the corpora cavernosa since all compounds possessed potent relaxant 
capacity in aorta. The results of the relaxant effect of MK-571 on mouse aorta are 
represented in Figure IX.5 in the supplementary data. Therefore it is not unlikely that a 
systemic hypotension effect would occur in vivo which would limit the use of resveratrol, 
quercetin or MRP 4 inhibition as alternative strategy for treating ED. However it should be 
noted that several PDE-5 inhibitors like sildenafil, vardenafil and taladafil also potently relax 
isolated aorta rings [124], yet their cardiovascular effects are usually minor [123]. Future 
research should clarify whether resveratrol, quercetin and MRP 4 inhibition cause, despite 
their in vitro vasorelaxant effect, similar minimal systemic effects. However, as systemic 
(side) effects might occur, other administration routes such as local application to the penis 
might represent a minimally invasive option to surpass potential systemic blood pressure 
lowering (side)effects. Recently, a new topical application and delivery method has been 
developed by which nanoparticles encapsulating erectogenic agents are applied as a gel to 
the glans and penile shaft [125]. This method has also been proven effective for the topical 
application of NO-releasing nanoparticles in a rat model of radical prostatectomy [126]. A 
topical application of nanoparticles containing erectogenic agents could avoid variation in 
absorption profiles, first-pass metabolism, and systemic effects, and might thus be an 
elegant and excellent alternative for oral medication in the future. Another way to overcome 
possible side effects might be to combine current PDE-5 inhibitors to the tested compound 
in this thesis. In chapter VII it was shown that MK-571 improved sildenafil-induced 
relaxations in corpora cavernosa, at least in vitro. Therefore coupling or combining MK-571 
to sildenafil might be an option to specifically target the corpora cavernosa and thus limit 
systemic effects. Future research should reveal whether similar potentiating effects occur in 
vivo and whether these also account for resveratrol and quercetin.  
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In conclusion, our studies exploring new therapeutic options for the treatment of ED, 
demonstrated (i) an unraveled relaxant effect of resveratrol on mouse corpora cavernosa, 
even in diabetic mimicking conditions; (ii) an antioxidant effect of resveratrol and quercetin 
that protects mouse corpora cavenosa from diabetic-induced damage and (iii) a relaxant 
effect, enhancement of cGMP-mediated relaxations of mouse corpora cavernosa and pro-
erectile effect of MRP 4 inhibition. Taken together, these results suggest that resveratrol, 
quercetin and MRP 4 inhibition might improve erectile function and be of value in the 
treatment and/or prevention of (diabetic-induced) ED. However, the in vivo relevance of 
resveratrol, quercetin and cGMP export still needs to be explored.  
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IX.1 Supplementary data of the effect of PVAT in mesenteric arteries 
Figure IX.1 shows that phenylephrine (PHE, 1 nM – 10 µM) elicited concentration-dependent contractions in 
mesenteric arteries without ((-)PVAT) and with ((+)PVAT) adherent adipose tissue. The presence of PVAT 
significantly attenuated contraction responses to PHE. Data are expressed as mN contraction; Mann-Whitney U 
test; *p<0.05; #p<0.01; n=6-7. 
.
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IX.2 Supplementary data of the effect of resveratrol on corpora cavernosa from sGCβ1 
knock-in mice 
 
Figure IX.2 indicates the effect of resveratrol (10-100 µM, 15 min) and corpora cavernosa from sGCβ1
ki/ki  
mice 
after precontraction with norepinephrine 5 µM. Resveratrol-induced corporal relaxations in sGCβ1
ki/ki  
mice did 
not differ from those obtained in wild type controls. Data are expressed as % relaxation of the NOR-induced 
tone; Mann-Whitney U test; n=8. 
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IX.3 Supplementary data of the involvement of adenosine monophosphate-activated 
protein kinase in the relaxant effect of resveratrol on mouse corpora cavernosa 
 
Figure IX.3 shows the relaxant effect of resveratrol on precontracted (5 µM norepinephrine (NOR)) corpora 
cavernosa from Swiss mice in absence and presence of the adenosine monophosphate-activated protein kinase 
inhibitor, compound C (10 µM). Data are expressed as % decrease of NOR-induced tone; Mann-Whitney U test; 
(n=9). 
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IX.4 Supplementary data of the effect of MK-571 on mouse aorta 
 
Figure IX.4 shows the relaxant effect of MK-571 on precontracted (5 µM Phe) aorta from Swiss mice versus 
time controls. Data are expressed as % decrease of Phe-induced tone; Mann-Whitney U test; #p<0.01 and 
*p<0.05; (n=4). 
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Summary 
Blood flow to the organs and tissues is determined by a balance between relaxation and 
contraction of the smooth muscle cells in the walls of the blood vessels. Any disturbance of 
this balance, will result in impaired blood flow regulation which can lead to pathological 
conditions, such as hypertension and erectile dysfunction. Vasoactive factors released from 
neighboring cells (i.e. paracrine modulators) including the perivascular adipose tissue play a 
substantial role in the regulation of blood flow. Under physiological conditions the adipose 
tissue secretes vasodilatory and vasoconstrictory adipokines, which are described in chapter 
III, and elicit a net beneficial relaxing effect.  
In chapter IV, possible alterations in the vasorelaxing effect of perivascular adipose tissue 
(PVAT) were investigated using an in vitro set-up based on isometric tension measurements 
in arteries mounted in a wire myograph. Resveratrol, a polyphenol present in the skin of 
grape and highly abundant in red wine, is a compound with known relaxant, antioxidant and 
anti-inflammatory properties and exerts beneficial effects on adipogenesis as well as on 
adipose tissue function. We demonstrated that resveratrol decreases the relaxing influence 
of PVAT surrounding mouse thoracic aorta and that in presence of PVAT the positive effects 
of resveratrol are neutralized. This study could not provide evidence for resveratrol as 
potential candidate to alleviate complications associated with adipose tissue dysfunction. In 
addition testosterone depletion, known to affect adipose tissue distribution and functioning, 
did not alter the vasorelaxing effect of PVAT.  
Like vascular function, erectile function depends on a delicate balance between smooth 
muscle contraction and relaxation. Nitric oxide (NO) with subsequent intracellular 
accumulation of cGMP, is generally accepted to be the main activator of arterial and 
corporal smooth muscle relaxation. The efficacy of phosphodiesterase-5 (PDE-5) inhibitors 
for the treatment of erectile dysfunction clearly demonstrate the importance of the 
NO/cGMP pathway for normal penile erection. However, some limitations and drawbacks in 
the use of PDE-5 inhibitors, necessitate research on other potential strategies and/or 
targets. Since the red wine polyphenols, resveratrol and quercetin have shown their 
beneficial effects in the cardiovascular system, the potential benefits for erectile function 
were explored using in vitro tension measurements. In chapter V it was demonstrated that 
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resveratrol, but not quercetin, relaxed mouse corpora cavernosa, however the underlying 
mechanism(s) remain(s) elusive. Furthermore, resveratrol and to a lower extent quercetin, 
prevented obesity-like induced damage to neurogenic-mediated relaxant responses of the 
corpora cavernosa. These data suggest a beneficial effect of resveratrol on erectile 
(dys)function. 
To gain further insight whether resveratrol and quercetin could be beneficial in the 
treatment of diabetic-associated erectile dysfunction, an in vitro model was created to 
mimick the diabetic circumstances which lead to vascular and erectile dysfunction. In 
chapter VI it was found that treatment of mesenteric arteries and corpora cavernosa with 
high concentrations of glucose in combination with methylglyoxal, a reactive glucose 
metabolite, induced damage to endothelium- and neurogenic-dependent relaxations. 
Oxidative stress was suggested as underlying mechanism for these diabetic deficits. In the 
corpora cavernosa these defects were prevented by both resveratrol and quercetin. The 
results suggest a protective effect of both polyphenols on mouse corpora cavernosa against 
diabetic-induced damage. 
Besides PDE’s also multidrug resistance protein (MRP) 4 and MRP 5, that export cGMP out of 
the smooth muscle cells, determine intracellular cGMP levels. Chapter VII explored the 
functional effect of inhibiting MRP 4 in mouse corpora cavernosa in vitro to evaluate it as 
potential alternative target for the treatment of erectile dysfunction. Inhibition of MRP 4 
relaxed mouse corpora cavernosa by increasing cGMP levels and exerted pro-erectile effects 
in vivo. In addition, MRP 4 inhibition enhanced cGMP-dependent relaxations, suggesting that 
inhibition of cGMP export might be a valid alternative strategy to treat erectile dysfunction. 
In conclusion, this work demonstrates that the vasorelaxing influence of adipose tissue is not 
altered by testosterone depletion, while it was decreased by resveratrol administration. 
With respect to the erectile function studies, resveratrol, quercetin and MRP 4 inhibition 
exerted positive effects on the contractility of the mouse corpora cavernosa including a 
relaxant and/or antioxidant effect. Therefore it is suggested that resveratrol, quercetin and 
MRP 4 inhibition might improve erectile function and be of value in the treatment and/or 
prevention of (diabetic-induced) ED, alone or in combination with current therapies.  
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Samenvatting 
De doorbloeding van de organen en weefsels wordt in belangrijke mate bepaald door de 
balans tussen relaxatie en contractie van de gladde spiercellen in de wand van de 
bloedvaten. Een verstoring van deze balans leidt tot een ontregelde doorbloeding, wat op 
zich de ontwikkeling van verscheidene pathologische aandoeningen zoals hypertensie en 
erectiestoornissen in de hand kan werken. Vasoactieve substanties vrijgesteld uit naburige 
weefsels, ook wel paracriene modulatoren genoemd, zoals uit het vetweefsel dat de arteriën 
omringt (het perivasculair vetweefsel), spelen hierbij een belangrijke rol. Onder fysiologische 
omstandigheden stelt het vetweefsel vasodilaterende en vasocontraherende adipokines vrij 
(beschreven in hoofdstuk III) en oefent het vetweefsel hierdoor een netto positief 
relaxerend effect uit op de bloedvaten. 
In hoofdstuk IV werd onderzocht welke omstandigheden het vasorelaxerend effect van het 
perivasculair vetweefsel kan versterken of aantasten. Hiervoor werd gebruik gemaakt van 
een in vitro techniek die gebaseerd is op het meten van isometrische spanningsverschillen in 
arteriën opgespannen in een draadmyograaf. Resveratrol, een polyfenol die voorkomt in de 
schil van druiven en dus teruggevonden wordt in rode wijn, is een component met gekende 
relaxerende, antioxidante en anti-inflammatoire eigenschappen, alsook met mogelijke 
gunstige effecten op de vorming en de functie van het vetweefsel. We toonden aan dat 
resveratrol het relaxerend effect van het vetweefsel rond de thoracale muis aorta verzwakt. 
Verder zorgde de aanwezigheid van het perivasculair vetweefsel ervoor dat de positieve 
effecten van resveratrol niet tot uiting kwamen. Deze studie kon niet bewijzen dat 
resveratrol complicaties die te wijten zijn aan stoornissen in de secretiefunctie van het 
vetweefsel zou kunnen verbeteren. Daarnaast had een tekort aan testosteron, wat de 
ophoping en de functie van het vetweefsel negatief te beïnvloedt, geen effect op het 
vasorelaxerend vermogen van het perivasculair vetweefsel. 
Net zoals bij het functioneren van de arteriën, is het goed functioneren van het erectiele 
weefsel afhankelijk van een delicate balans tussen gladde spiercel contractie en relaxatie. 
Algemeen wordt aanvaard dat stikstofmonoxide (NO) met erop volgend een intracellulaire 
ophoping van het cGMP, de belangrijkste activator is van arteriële en corporale gladde 
spiercel relaxatie. De doeltreffendheid en het succes van fosfodiësterase-5 (PDE-5) 
inhibitoren bij de behandeling van erectiestoornissen illustreren duidelijk het belang van de 
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NO/cGMP signaaltransductie cascade voor zowel inductie als aanhouden van een erectie. 
Omwille van sommige beperkingen of neveneffecten, is een behandeling met PDE-5 
inhibitoren niet altijd aangewezen, wat verder wetenschappelijk onderzoek naar nieuwe 
potentiële strategieën en/of doelwitten noodzakelijk maakt. Aangezien de rode wijn 
polyfenolen resveratrol en quercetin verscheidene positieve effecten uitoefenen in het 
cardiovasculair systeem, werden hun mogelijke gunstige effecten voor de erectiele functie 
nagegaan gebruikmakend van in vitro spanningsmetingen. In hoofdstuk V, werd aangetoond 
dat resveratrol, maar niet quercetin, relaxatie veroorzaakte van corpora cavernosa van 
muizen. Het onderliggende mechanisme van dit relaxerend effect blijft echter ongekend. 
Daarenboven, kon resveratrol, en in mindere mate quercetin, de op obesitas-lijkende schade 
aan zenuw-afhankelijke relaxaties van de muis corpora cavernosa voorkomen. Deze 
resultaten suggereren dat resveratrol een positief effect kan uitoefenen op erectiele 
(dys)functie. 
Om verder inzicht te verwerven of resveratrol en quercetin nuttig kunnen zijn bij de 
behandeling van diabetes-geassocieerde erectiestoornissen, werd een in vitro model 
gecreëerd waarbij de diabetes omstandigheden, die leiden tot vasculaire en 
erectiestoornissen, nagebootst werden. In hoofdstuk VI zagen we dat de behandeling van 
muis mesenterische arteriën en corpora cavernosa met hoge concentraties aan glucose in 
combinatie met methyglyoxal, een reactief glucose metaboliet, schade aan endotheel- en 
zenuw-afhankelijke relaxaties teweegbracht. Oxidatieve stress werd gevonden als 
onderliggend mechanisme van deze diabetische defecten. In de corpora cavernosa konden 
zowel resveratrol als quercetin deze schade voorkomen. Uit deze data blijkt dat beide 
polyfenolen de corpora cavernosa kunnen beschermen tegen schade veroorzaakt door 
diabetes. 
Naast PDE’s bepalen ook multidrug resistente eiwitten (MRP) 4 en 5 de intracellulaire 
hoeveelheid van cGMP, aangezien deze het intracellulair cGMP uit de gladde spiercellen 
kunnen transporteren. Hoofdstuk VII ging in vitro na wat het functioneel effect was van de 
belemmering van MRP 4 in de muis corpora cavernosa en evalueerde of MRP 4 een mogelijk 
alternatief doelwit zou kunnen zijn voor de behandeling van erectiestoornissen. Inhibitie van 
MRP 4 relaxeerde de muis corpora cavernosa door een stijging in cGMP te veroorzaken en 
lokte in vivo erectie uit. Daarenboven werden cGMP-afhankelijke relaxaties versterkt door 
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remming van MRP 4, hetgeen doet vermoeden dat het verhinderen van cGMP export 
inderdaad een mogelijk alternatieve strategie kan zijn bij de behandeling van 
erectiestoornissen. 
Samenvattend, toont dit werk aan dat de relaxerende invloed van vetweefsel onveranderd 
blijft door een tekort aan testosteron, terwijl resveratrol het relaxerend effect van 
vetweefsel afremt. Voor wat betreft de studies over de erectiele functie werd aangetoond 
dat resveratrol, quercetin en inhibitie van MRP 4 positieve effecten hebben op de 
contractiliteit van de muis corpora cavernosa via een relaxerend en/of antioxidant effect. 
Bijgevolg wijst dit erop dat resveratrol, quercetin en MRP 4 inhibitie de erectiele functie 
mogelijks zouden kunnen verbeteren en dat ze waardevol zouden kunnen zijn in de 
behandeling en/of preventie van (diabetes-geassocieerde) erectiestoornissen, in 
monotherapie of in combinatie met huidige therapieën. 
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